GOOD MORNING,
EVERYONE. WELCOME TO THE 64TH
MEETING OF THE NATIONAL ADVISORY
COUNCIL FOR BIO MEDICAL
ENGINEERING. I'M DAVID GEORGE,
THE ASSOCIATE DIRECTOR AND
EXECUTIVE MEMBER OF THIS
COMMITTE. THIS IS OPEN TO THE
PUBLIC EXCEPT FOR PENDING GRANTS
THIS AFTERNOON. THE OPENING
SESSION IS BEING LIVE-BROADCAST
ON THE NIH VIDEOCAST AND
RECORDED FOR ARCHIVES. THE
COMMUNITY AND PRESENT ERS ARE
PRESENTING THE CONFERENCE. WE
WELCOME ALL. THANK YOU TO ALL
WHO ARE WATCHING ON THE
VIDEOCAST. MEMBERS OF THE PUBLIC
WHO RUSH TO EXPRESS VIEWS
REGARDING ANY ITEMS DISCUSSED
DURING THIS MEETING MAY DO SO IN
WRITING WITHIN THE NEXT TEN DAYS
BY EMAILING ME AT INFO
INFO @ NIBIB.NIH.GOV. PLEASE PUT
NIBIB COUNSEL IN THE SUBJECT
LINE OF THE EMAIL. ALTHOUGH
EVERYONE IS NOW WELL-VERSE ED IN
VIDEO CONFERENCING IN RECENT
YEARS I WILL REMIND EVERYONE TO
PLEASE MUTE YOURSELF WHEN NOT
SPEAKING. FOR COLLEAGUES AND
GUESTS WHO ARE PRESENTING
REMEMBER TO PRESENT FROM THE
FILE ON YOUR COMPUTER'S HARD
DRIVE RATHER THAN NETWORK DRIVE.
BE LAUGHING LOGGED OFF VPN WHEN
PRESENTING AND SHUT DOWN
UNNECESSARY SOFTWARE. THE CHAT
BOX IN ZOOM IS ENABLED TO CHAS
WITH OUR HOST, MR. RYAN DAVA. HE
IS MANAGING OUR VIDEO CONFERENCE
TODAY. FOR TECHNICAL PROBLEMS
DURING THE MEETING REACH OUT TO
RYAN DIRECTLY IN THAT EMAIL.
SO RYAN, IT IS -- YES, THANK
YOU, RYAN. I DIDN'T HAVE THE
CHAT TURNED ON. THANK YOU, RYAN.
I'D LIKE TO NOTE WE HAVE A
QUORUM FOR TODAY'S MEETING. WE
ARE ANTICIPATING DR. JOYCE WONG
TO JOIN US A LITTLE LATER. DR.
GILDA BERABINO WILL BE UNABLE TO
JOIN US TODAY. I WOULD LIKE TO
THANK THE NIBIB COMMITTEE
MANAGEMENT OFFICER PAM
GLIBBINGMAN AND SPECIALIST
ALICIA HOPKINS FOR ORGANIZING
HELP. I WOULD LIKE TO RECOGNIZE
RYAN DAVA, OUR NIBIB COLLEAGUE
AND VIDEOCAST COLLEAGUE FOR
WORKING IN ALL THE VIDEO
ARRANGEMENTS. I WOULD ALSO LIKE
TO THANK DR. CATHY SALAIDA, THE
ASSOCIATE DIRECTOR FOR RESEARCH
ADMINISTRATION FOR NIBIB FOR ALL
HER HELP. HER DETAIL WITH NIBIB
HAS CONCLUDED. WE REALLY
PROSECUTE HER WILL-- APPRECIATE
ANECDOTAL TO HELP OUT. THE WORK
FOR THE ASSOCIATE DIRECTOR IS
ONGOING. I WE HOPE TO MAKE AN
ANNOUNCEMENT BY THE NEXT COUNCIL
MEETING. I ALSO NEED TO POINT
OUT THESE PROCEEDINGS ARE
GOVERNED BY THE FEDERAL --
EXCUSE ME, FEDERAL ADVISORY
COMMITTEE ACT, FACA, THE
GOVERNMENT AND SUNSHINE ACT.
THAT MEANS THIS MEETING IS A N
ANNOUNCED TO THE PUBLIC IN THE
F
FEDERAL REGISTER AND HAS AN OPEN
PORTION, WE ARE IN NOW AND
CLOSED PORTION THIS AFTERNOON
FOR DISCUSSION OF INDIVIDUAL
APPLICATIONS. WE ANTICIPATE
ADJOURNING THE OPEN SESSION AT
ABOUT 2:00 P.M. TODAY. IN TERMS
OF FUTURE COUNCIL DATE, I WOULD
LIKE TO TAKE A MOMENT TO DRAW
YOUR ATTENTION THAT THE FUTURE
COUNCIL MEETING DATES ARE LISTED
AT THE BOTTOM OF THE AGENDA.
COUNCILMEMBERS, THEY WERE ALSO
FOUND IN THE NIBIB COUNCIL TAB
OF THE ELECTRONIC COUNCIL BOOK.
REVIEW THE DATES, WHEN YOU HAVE
A CHANCE. LET US KNOW WHEN YOU
SEE A CONFLICT FOR ANY OF THESE
DATES. OUR NEXT MEETING WILL BE
MAY 15TH, 2024. THIS WILL BE AN
IN-PERSON MEETING ON THE NIH
CAMPUS. IT WILL BE IN THE PORTER
BUILDING. OR BUILDING 35, FOR
THOSE OF YOU IN THE KNOW. SO WE
ARE LOOKING FORWARD TO
EXPERIENCING COUNCIL ON CAMPUS.
LOOKING INTO -- AHEAD INTO NEXT
YEAR WE NOTE THAT THE CURRENT
DATE FOR THE MAY 2025 MEETING
OV
OVERLAPS WITH THE ARM MEETING SO
LOOKING AT MAY 2025 SO
COUNCILMEMBERS, PLEASE STAND BY.
WE WILL BE IN COMMUNICATION AND
LET YOU KNOW WHEN WE HAVE FOUND
AN IN-PERSON LOCATION FOR THAT
MEETING AND UPDATE YOU
ACCORDINGLY, THANK YOU. FINALLY
I WOULD LIKE TO MOVE INTO
CONSIDERATION OF THE MINUTES AND
COUNCIL OPERATING PROCEDURES. IN
PREPARATION FOR VOTING I ASK THE
COUNCILMEMBER S IF YOU WOULD
PLEASE UNMUTE YOURSELF SO YOU
CAN CAST A VOICE VOTE. THE DRAFT
MINUTES WERE MADE AVAILABLE TO
YOU ABOUT TWO WEEKS AGO IN THE
ECB. ARE THERE ANY COMMENTS OR
MODIFICATIONS YOU WOULD LIKE TO
MAKE TO THE MINUTE S? HEARING
NONE,LY ENTERTAIN A MOTION TO
APPROVE.
>> MOTION TO APPROVE.
>> A SECOND?
>> SECOND IT.
>> ALL IN FAVOR SAY AYE. ALL
OPPOSED NAY. THE MOTION PASSES,
THANK YOU. SIMILARLY FOR THE
COUNCIL OPERATING PROCEDURES,
EVERY JANUARY WE REAFFIRM
COUNCIL PROCEDURES. THE DRAFT
OPERATING PROCEDURES WERE MADE
AVAILABLE TWO WEEKS AGO IN THE
ECB. WE PROPOSED NOTE CHANGES TO
THE OPERATING PROCEDURES THIS
YEAR. ARE THERE ANY COMMENTS OR
MODIFICATIONS YOU WOULD LIKE TO
MAKE TO THE OPERATING
PROCEDURES? MOTION TO APPROVE?
AND IS THERE A SECOND?
>> SECOND.
>> ALL IN FAVOR AYE. ALL
OPPOSED NAY. ALL RIGHT, THANK
YOU. WITH THOSE INTRODUCTIONS IN
ADMINISTRATIVE REMARKS WE WILL
TURN THE PROCEEDINGS OVER TO
NIBIB DIRECTOR DR. BRUCE
TROMBERG, THANK YOU.
>> BRUCE TROMBERG: THANK YOU,
DAVE. MAYBE WE CAN TAKE THE
SLIDE DOWN AND GO INTO OUR
PRETEND LIKE WE ARE ALL IN THE
SAME ROOM. I GUESS WE KNOW NOW
THAT IT IS NOT JUST OUR
IMAGINATIONS. WE HAVE
EXPERIENCED THIS NOW A FEW
TIMES. SO IT IS REALLY SHOULD BE
A LITTLE EASIER PERHAPS OR MAYBE
HARDER GOING BACK TO ZOOM AFTER
WE HAVE DONE THAT. I HAVE TO
ACKNOWLEDGE IT WAS A WISE
DECISION, THANK YOU TO PAM AND
ALICIA AND DAVE FOR ADVOCATING.
SOMEHOW THEY FORESAW THE AMAZING
STORM SYSTEM THAT HIT ALL OF US.
WE STILL HAVE SEVERAL INCHES OF
SNOW ON THE GROUND HERE.
ALTHOUGH ALLEGEDLY IT IS
DISAPPEARING MAYBE TODAY,
PERHAPS TOMORROW. WE ARE
HOPEFUL. SO I THINK IT WAS A
GOOD MOVE. MAYBE A NEW
TRADITION. AT LEAST FOR THE
SHORT-TERM. THANK YOU, DAVE, FOR
TAKING OVER THE REIGNS. BEFORE I
START ANY COMMENTS OR ANYTHING
FROM COUNCIL? I'M TRYING TO MAKE
THIS AS CLOSE TO IN-PERSON AS
POSSIBLE. I APPRECIATE ALL OF
YOU FOR JOINING. PROBABLY DEEP
DOWN INSIDE MANY OF YOU FEEL
LIKE THIS IS ACTUALLY NOT TOO
BAD, ROLLING INTO THE ZOOM
MEETING, AS WELL LOWER BARRIER
TO GETTING ON PLANES, HOTELS AND
THINGS LIKE THAT. ALL RIGHT.
NOTHING IN THE CHAT. THIS IS
ALLOWING ME TO WASTE A LITTLE
BIT OF TIME WHILE I FIND MY
PRESENTATION. SO I WILL JUMP
RIGHT INTO IT. I THINK -- LET ME
GO INTO PRESENTATION MODE.
HOPEFULLY EVERYBODY CAN SEE
THAT. THIS ACTUALLY MARKS-YEAH,
THANK YOU, DAVE. MY P FIRST
PRESENTATION AS DIRECTOR WAS
THREE YEARS AGO IN 2019, SO KIND
OF MARKS A FIVE -- FIVE YEARS IS
SORT OF THE MINIMUM PERIOD OF
TIME THAT MOST DIRECTORS SERVE.
IT IS THE MANDATORY
CONGRESSIONAL REQUIREMENT FOR
REVIEW OF DIRECTORS. SO I'VE
JUST GONE THROUGH THAT. IT'S
BEEN A GREAT PROCESS. LET ME GET
STARTED AGAIN BY THANKING ONCE
AGAIN BUILDING ON DAVE'S
COMMENTS, PAM AND ALICIA FOR
THEIR WONDERFUL JOB WITH COUNCIL
ORGANIZATION. OUR SLIDE TIME,
ASHA, KHALIL AND ALICE, THANK
YOU FOR GIVING ME THE SUBSTRATE
FOR PUTTING THIS TOGETHER AND
WORKING WITH ALL OF OUR PROGRAM
DIRECTORS AND OUR TEAM TO
GENERATE THE IDEAS AND CONCEPTS
FOR OUR INITIAL ROUND OF SLIDES.
OUR SENIOR LEADERSHIP, JILL,
DAVE AND RICHARD, MONU, CHRIS
AND KATHY, WHOM DAVE MENTIONED.
KATHY HAS FINISHED HER DETAIL.
WE CURRENTLY HAVE A SEARCH GOING
ON. AS DAVE MENTIONED WE HOPE TO
BE ABLE TO ANNOUNCE A PERMANENT
HIRING VERY SOON. KATHY HAS BEEN
INSTRMENTAL IN PUTTING THIS
COUNCIL TOGETHER, AS WELL AS
PREVIOUS ONCE. WE ARE VERY
GRATEFUL FOR OF HER EFFORTS. I
WOULD LIKE TO START WITH THE
LEAD STORY, WHICH PROBABLY ALL
OF YOU PROBABLY ARE OF COURSE
AWARE OF NOW, QUITE ACUTELY. I
JUST WANT TO EMPHASIZE A FEW
POINTS. MONICA WAS APPOINTED IN
NOVEMBER, FINALLY, AFTER SENATE
APPROVAL. SENATE SUBCOMMITTEE
INTERROGATION OR QUESTIONING
THAT WENT ON WITH THE FIRST
QUESTION THAT CAME OUT OF THE
HELP COMMITTEE, WHICH IS THE
SUBCOMMITTEE THAT PUTS HER
THROUGH THAT PROCESS OF ASKING
DETAILED QUESTIONS. WAS HOW TO
RESTORE THE TRUST IN SCIENCE AND
WITH THE NIH. I WAS ACTUALLY
QUITE SHOCKED AT. IF YOU HAVE
TIME YOU SHOULD TAKE A LOOK AT
THAT VIDEO ON C-SPAN. MONICA IS
THE 17TH NIH DIRECTOR, THE FIRST
SURGEON AND SECOND WOMAN TO HOLD
THE POSITION. SHE HAS ABOUT 30,
35-YEAR CAREER AS SURGEON. SHE
WAS MEMBER OF THE BRIGHAM AND
DANA FARBER. PRIOR, I THINK MOST
OF YOU KNOW, SHE WAS THE NCI
DIRECTOR. MONICA SPECIALIZED IN
GI CANCERS AND HAD A VERY
VIBRANT RESEARCH PROGRAM IN THAT
AREA. WHAT MANY OF YOU MAY NOT
KNOW IS THAT MONICA AS AN
UNDERGRADUATE MAJORED IN
CHEMICAL ENGINEERING AT
PRINCETON. SHE ACTUALLY DID HER
SENIOR RESEARCH ON TRANSFER
ACROSS SEMI PERMEABLE MEMBRANES.
SHE LOVES MASS TRANSPORT. HER
FAVORITE EQUATION IS THE BERNULI
EQUATION.
WE ARE LUCKY TO HAVE MONICA. I
WOULD LIKE TO SPEND A FEW
MOMENTS SUMMARIZING -- EVERYONE
HAS BEEN ASKING HER, WHAT IS
YOUR PRIORITIES FOR NIH? WHAT IS
GOING ON. HERE IT IS, STRAIGHT
FROM MONICA. SHE'S ACTUALLY PUT
ALL THE IC DIRECTORS THROUGH A
SPRINT OVER THE LAST SIX WEEKS
BECAUSE, AS SHE TOLD US, AFTER
SHE WAS APPOINTED, THE EVOLUTION
AND DECLARATION OF WHAT SHE
BELIEVES IS MOST IMPORTANT IS
NOT JUST SOMETHING THAT SHE WILL
SORT OF SWOOP IN AND DECLARE BUT
SOMETHING SHE REALLY WANTS TO
BUILD CONSENSUS ABOUT WITH HER
COLLEAGUES. THE LEADERSHIP AT
NIH. HERE'S GUIDING PRINCIPLES
SHE'S RECENTLY ARTICULATED AND
HAS BEEN WORKING ON FOR SEVERAL
WEEKS. THIS IS FROM MONICA: OUR
WORK IS NOT FINISHED WHEN WE
DELIVER SCIENTIFIC DISCOVERIES
BUT FINISHED WHEN ALL ARE LIVING
LONG AND HEALTHY LIVES. NIH
RESEARCH ENCOMPASSES LABORATORY,
CLINIC AND COMMUNITY. PATIENTS
ARE PARTNERS IN DISCOVERY. TO
TACKLE THE MOST PERSISTENT AND
COMPLEX PROBLEMS, NIH AIMS TO
BRING MORE MEMBERS OF THE PUBLIC
INTO THE RESEARCH ENTERPRISE
PARTNERS. INCOME, AGE, RACE,
GEOGRAPHIC, DISABILITY STATUS
SHOULD NOT BE BARRIERS FOR A
PARTICIPATING IN RESEARCH OR
BENEFIT ING FROM THE RESEARCH
ADVANCES. SO YOU WILL HEAR HER
VOICE AS SURGEON AND ENGINEER
COMING THROUGH IN A LOT OF THESE
STATEMENTS. YOU KNOW, REALLY
UNDERSCORING OUR WORK IS NOT
FINISHED WITH THE DISCOVERIES
BUT FINISHED WHEN THE PRACTICAL
APPLICATION ARE MOVING ALONG
HEALTHY LIVES. PROGRESS IS
ACCELERATED WHEN METHODS SUCH AS
NEW ANALYTICS APPLIED TO
EVERYONE. WHEN NEW DISCOVERIES
ARE RAPIDLY AND EQUITABLY
ADOPTED IN CLINICAL CARE. NIH IS
COMMITTED TO HAR NASZING POWER
OF AIML TO ADVANCE ACROSS
DIVERSE FIELDS, DISEASES AND
SCIENTIFIC COMMUNITIES SO I
THINK THIS RESONATES WITH OUR
COMMUNITY, ADVANCED SCIENTIFIC
METHODS, NEW ANALYTICS AND
TECHNOLOGIES. I WORKED HARD TO
GET THAT WORD TECHNOLOGY IN
THERE, IN HER LEXICON. I'M SO
HAPPY TO SEE IT. ARE UNLOCKING
POSSIBILITIES TO HARNESS DATA IN
WAYS THAT ACHIEVE FASTER AND
MORE DEFINITIVE RESULTS. NIH HAS
LAUNCHED AND WILL CONTINUE TO
LAUNCH INNOVATIVE AND AMBITIOUS
FUSION OF BIOMEDICINE AND AL. ON
THE BUDGET, WHICH EVERYONE IS
CONCERNED ABOUT HERE ARE MONDAY
DA'S COMMENTS: WE REMAIN HOPEFUL
WE WILL NOT BE SUBJECT TO
DRASTIC CUTS. HOWEVER EVEN A
FLAT BUDGET WILL HAVE A
SIGNIFICANT IMPACT. GREAT IDEAS
AND POTENTIAL FOR NEW
DISCOVERIES OBVIOUSLY WILL BE
LOST. THERE IS A REAL CONCERN WE
WILL LOSE A GENERATION OF EARLY
CAREER INVESTIGATORS. THE IRP,
THE INTRAMURAL PROGRAM IS
SENSITIVE TO BUDGET CUTS SO SHE
UNDERSCORES HOW PARTNERSHIP IS
CRUCIAL GOING FORWARD. AGAIN, I
THINK THAT RESONATES WITH OUR
COMMUNITY. WE ARE NATURAL
PARTNERSHIP BUILDERS, THRIVE AND
LOOK TO BRING EFFORTS INTO
APPLICATION AREAS ACROSS THE
NIH. MONICA LOOKS AT THE NIH
COLLECTIVELY AS AN AGENCY AND
REALLY WANTS TO SORT OF BRING
PEOPLE TOGETHER AS CLOSELY AS
POSSIBLE IN COLLABORATION AND
WORKING ON THESE KIND OF
ARTICULATED GOALS. SO SINCE
MONICA BROUGHT UP THE BUDGET,
THAT IS A GOOD SEGUE FOR ME TO
GO INTO A BUDGET UPDATE. I THINK
AGAIN ALL OF YOU PROBABLY HAVE
BEEN FOLLOWING THIS. WE ARE NOW,
THANKFULLY, OPERATING UNDER
CONTINUING RESOLUTION GOING
THROUGH MARCH 8TH. IT IS AT THE
SAME FY '23 APPROPRIATION LEVEL.
IMPORTANTLY, THE TOP-LINE
SPENDING AGREEMENT FOR FY-24 WAS
REACHED JANUARY 8TH. SO THAT
NON-DEFENSE DISCRETIONARY
PORTION OF THE BUDGET, $773
MILLION IS FLAT FROM FY23. THAT
IS A REALLY GOOD PIECE OF NEWS.
WHAT WE DON'T KNOW IS WHAT THE
INDIVIDUAL APPROPRIATION BILLS
WILL LOOK LIKE. THEY ARE UNDER
DEVELOPMENT. HENCE THE
CONTINUING RESOLUTION BECAUSE
CONTINUE WAS IN ABSOLUTELY NO
POSITION TO REALLY DEVELOP THOSE
INDIVIDUAL APPROPRIATION BILLS
BEFORE THE PREVIOUS DEADLINES.
SO WHAT IS THE PRACTICAL IMPACT
AT NIBIB? OUR INTERIM PAYLINE
FOR PARENT RO1 ANNOUNCEMENTS IS
14TH PERCENTILE, 19 FOR NEW
INVESTIGATORS. MOST AWARDS ARE
PAID AT REDUCED LEVELS PENDING
FINAL FY24 APPROPRIATION. SO,
YOU KNOW, THIS IS ALL -- WE HAVE
KIND OF -- WE HAVE BEEN
PREPARING FOR THIS IN OUR
DISCUSSIONS WITH YOU GUYS.
CERTAINLY INTERNALLY
EXTENSIVELY. A FLAT BUDGET IS
SORT OF OUR BEST-CASE SCENARIO.
THERE MAY VERY WELL BE CUTS IN
THIS NON-DEFENSE DISCRETIONARY
AS THE INDIVIDUAL APPROPRIATION
BILLS. THERE'S LOTS OF JOCKEYING
FOR THESE INDIVIDUAL
APPROPRIATION BILLS TO KEEP THEM
AS FLAT AS POSSIBLE ACROSS --
AND NOT HAVE CUTS ESPECIALLY TO
HHS. WE WILL SEE WHAT THE
OUTCOME IS FOR THAT. I THINK,
YOU KNOW, IT IS PRETTY -- WE ARE
CONFIDENT YOU CAN EXPECT THAT
THERE WILL BE CONTINUED
CONSERVATIVE REDUCTION FOR
AWARDS AND RESOURCES AS YOUNG AS
POSSIBLE AS YOUNG INVESTIGATORS.
AS MONICA POINTED OUT THEY OFTEN
BEAR BRUNT IN BUDGET CUTS. SO
THE SCIENCE POLICY AND
COMMUNICATIONS, IF YOU REMEMBER
IN -- IN JANUARY 2023 BEGAN
PUTTING TOGETHER A 2022 YEAR IN
REVIEW. THEY HAVE DONE ANOTHER
FANTASTIC JOB WITH THIS. IT IS
ACCESSIBLE ON OUR WEBSITE, THE
2023 YEAR IN REVIEW. AND IN NEWS
HIGHLIGHTS AND PROGRAM UPDATES,
QUITE POPULAR WITH NEARLY 40,000
VIEWS OF ALL THE RELEASE, ALL
THAT INFORMATION. YOU CAN SEE A
MAJOR, MAJOR THEME HERE IS
ULTRASOUND. ULTRASOUND WITH AI,
WEARABLE ULTRASOUND, ULTRASOUND
USING TO DELIVER OXYGEN, TO
INCREASE PROFUSION. PRINTING
THROUGH TISSUE WITH 3D
ULTRASOUND. ULTRASOUND SELFIES.
LOT OF GREAT STORIES AND
CONGRATULATIONS TO THE
ULTRASOUND COMMUNITY FOR
GENERATING SUCH BEAUTIFUL WORK.
OF COURSE OTHER THINGS ARE NOTE
BUD THAT JUMPED OUT SO I WANTED
TO REINFORCE THAT THEME. ALSO IN
SCIENCE HIGHLIGHTS AND PRESS
RELEASES, WE HAVE HAD 50,000
VIEWS THERE. THEMATICALLY WHAT
IS VERY, VERY INTERESTING IS
REALLY IN THE -- MONICA'S VERY
FIRST COMMENTS .
THE DISCOVERIES, TECHNOLOGIES
AND APPLICATION TO IMPROVE
HEALTH AND OUTCOMES FOR
PATIENTS. LOTS OF INTEREST IN
OUR RADAX TECH FETAL MONITORING
CHALLENGE. THE RT ROING WEBSITE,
MAKEMYTESTCOUNTY FOR RAPID
ANTIGEN AND PROGRAM WHICH I WILL
UPDATE IN THE SLIDES, WHICH
OFFERS THE OPPORTUNITY TO GET
TEST AND TREATMENT COMPLETELY IN
YOUR HOME. LOTS OF INTEREST IN
THAT. MANY PEOPLE HAVE
SUBSCRIBED. IF YOU LOOK AT THE
TESTTOTREAT.ORG AND CHECK OUT
THAT WEBSITE. SO WE HAVE HAD
SEVERAL NEW NIBIB STAFF JOIN US.
I'D LIKE TO TAKE A MOMENT TO
INTRODUCE THEM. YOU WILL BE
INTERACTING WITH THEM OR HAVE
ALREADY INTERACTED. I WILL JUST
SAY BRIEF WORDS ABOUT EACH. ON
THE LEFT, ROB-/* ROBBERRY, HIS
STORY IS DIFFERENT. HE STARTED
IN APPLIED SCIENCE. JANUARY 2ND
OF THIS YEAR HE CAME FROM
HARVARD MEDICAL SCHOOL , THE
DIRECTOR OF BRAIN AND SPINAL
CORD LAB FOR BRAIN IMAGING AT
MGMH. HE HAS MORE THAN 20 YEARS
IN TECHNICAL DEVELOPMENT OF MRI
AND APPLICATIONS. WHEN HE WAS AT
HARVARD, ASSISTANT PROFESSOR OF
RADIOLOGY AND AFFILIATED FACULTY
IN THE HARVARD MIT SLASH HST AT
MIT. AND HELD THAT POSITION
SINCE 2016. THIS IS FUN. THIS IS
IN THE DEMOCRACY 2 OFFICE. HE
SAW HIS SIGNATURE HANGING ON NA
POS
-- HANGING ON THAT POSTER WHEN
HE WAS THE AWARDEE. THAT IS
NEAT. ROB SAID HE IS A PRODUCT
OF THIS. CERTAINLY CRITICAL
COMPONENT, HE BRINGS THAT
PERSPECTIVE TO HIS WORK AS
PROGRAM DIRECTOR SO WE ARE SO
GLAD TO HAVE HIM. MARIE DE SALVE
DESALT, WHO I HAVE MENTIONED
BASED AS A DATA SCHOLAR TWO
YEARS HERE AT NIBIB, HE STARTED
OFFICIALLY AS A PROGRAM
DIRECTOR, WE ARE PLEASED TO SAY,
IN SEPTEMBER OF 2023. HIS
PORTFOLIOS IN ART OFFICIAL
INTELLIGENCE IN DEVELOPMENTAL
TECHNOLOGIES. HE IS A LEADING
EXPERT -- I CAN ATTEST BECAUSE
OF MANY CONVERSATIONS WE HAVE
HAD IN QUANTITATIVE FUNCTIONAL
IMAGE OF HUMAN LUNG USING PROTON
MRI. PRIOR TO BECOMING A DATA
SCHOLAR AT NIBIB HE WAS
ASSISTANT PROFESSOR AT
BIOENGINEERING AT UC SAN DIEGO.
HIS TWO YEARS AS DATA SCHOLAR,
WHICH IS A WONDERFUL, WONDERFUL
PROGRAM THAT OUR OFFICE OF DATA
SCIENCE RUNS PLAY ED A KEY ROLE
IN ESTABLISHING IN THE ON GOING
SUCCESS OF MIDRIC, MEDICAL
IMAGING DATA RESOURCE CENTER,
ONE OF OUR SIGNATURE PROGRAMS
THAT CUTS ACROSS MANY DOMAINS IN
IMAGING THAT WE SUPPORT. THAT
WAS BETWEEN 2020 AND 2022. SO WE
ARE GLAD TO HAVE HIM JOINING US
NOW. I THINK DATA SCHOLAR IS THE
WORD. TO GET CONNECTION TO THE
NEXT PERSON JOINING, PROFESSOR E
WONG, A DATA SCHOLAR IN DHIT.
SHE JOINED US IN DECEMBER OF
2023 ON SABBATICAL LEAVE FROM
ACADEMIA. SHE IS AN ASSOCIATE
PROFESSOR AND FORMER GRADUATE
PROGRAM DIRECTOR AT DEPARTMENT
OF MATHEMATICS AND STATISTICS AT
THE UNIVERSITY OF MARYLAND,
BALTIMORE COUNTY. SHE SERVED
SINCE 2015 AND EXPERT IN
CLINICAL DESIGN AND NOVEL
STATISTICAL APPROACHES IN PUBLIC
HEALTH AND APPLICATIONS. AT
NIBIB WE ARE EXCITED TO SAY SHE
IS WORKING WITH DR. ANDREW WHITE
IN BHIT ON ANALYZING THE
OVER-THE-COUNTER TESTING DATA
GENERATED QUITE SIGNIFICANTLY
FROM OUR RADAX PROGRAMS. WE ARE
EXCITED TO START WITH THAT.
FINALLY THERE IS ONE ADDITIONAL
PROGRAM SPECIALIST. ADRIANA
ALICO JOINED NIBIB IN
OCTOBER 2023 AS A SCIENTIFIC
INNOVATIVE PROGRAM SPECIALIST IN
THE OFFICE OF THE DIRECTOR.
SHE'S SUPPORTING ON GOING RADAX
IN POSTPARTUM AND FETAL
MONITORING AND DESIGNING AND
MANAGING OTHER OPEN INNOVATIVE
PROGRAMS IN CLOSE COLLABORATION
WITH DR. TAYLOR GILLILAND.
PREVIOUSLY ADRIANA, SHE'S HAD
INTERESTING BACKGROUND SERVED AS
CONTRACTOR IN WAR FAR TREATMENT
DIVISION OF ARMY MEDICAL
MATERIAL DEVELOPMENT ACTIVITY.
SHE HELPED MANAGE AWARDS TO
MEDICAL DEVICE COMPANIES, DEPLOY
NOVEL AND MEDICAL EQUIPMENT TO
THE WARFIGHTER AND RECEIVED HER
BACHELORS IN BIOMEDICAL
ENGINEERING FROM TULANE.
ADRIANA, WE ARE REALLY GLAD TO
HAVE YOU. YOU BRING AMAZING
EXPERTISE THAT IS RELEVANT AND
NEW DIMENSION TO SOME OF THE
THINGS WE DO AT NIBIB. I WOULD
LIKE TO ALSO SAY A FEW WORDS OF
THANKS TO DEPARTING STAFF. PETER
KIRSHNER, MANY OF YOU KNOW FOR
TWO DECADES, A LITTLE OVER TWO
DECADES HE MADE ENORMOUS
CONTRIBUTIONS TO NIBIB, ADVISING
ON MEDICAL TOPICS, PROMOTING THE
UTILIZATION OF RELIABLE DATA FOR
GUIDING APPLICATIONS OF
DIAGNOSTIC TECHNOLOGIES. REALLY
UNDERSTANDING AND ESTIMATING THE
TRUE IMPACT OF IMAGING SCIENCE
ADVANCES ON HEALTH CARE. PETER
SERVED IN MANY ROLES WHILE IN
NIBIB INCLUDING ACTING DIRECTOR
OF THE INTRAMURAL PROGRAMS IN
2003-206 SO INSTRMENTAL IN
GETTING THEM OFF THE GROUND. THE
CO -DIRECTOR OF THE NIBIB CDRH.
THE FDA CDRH LABORATORY FOR
ASSESSMENT OF MEDICAL IMAGING
SYSTEMS FROM 2005-2008. HE ALSO
HELPED CREATE THAT. SO WE ARE
VERY GRATEFUL TO PETER FOR HIS
WORK. HE ALSO HAS BACK GROUND, I
SHOULD NOTE, AS A STAFF MEMBER
AT OAKRIDGE NATIONAL LABORATORY.
WE WERE VERY FORTUNATE TO HAVE
HIS COLLABORATING INTERACTIONS
AT OAKRIDGE AND DOT DURING THE
POSITION WITH NIBIB. WE ARE ALSO
THANKFUL TO RUDY MC ANDREW, WHO
SERVED AS A SENIOR GRANTS
MANAGEMENT SPECIALIST WITH
OFFICE OF GRANTS MANAGEMENT FOR
THE PAST EIGHT YEARS. IN HER
ROLE SHE SERVED AS THE GRANTS
MANAGEMENT LIAISON FOR OUR
MEDTECH BLUEPRINT PROGRAM AND
NATIONAL INSTITUTE OF AGING
ALZHEIMER'S SUPPLEMENT PROGRAM.
YOU HAVE HEARD A LOT ABOUT BOTH
THESE PROGRAMS. INCREDIBLY
IMPACTFUL PROGRAMS. WE ARE
THANKFUL TO RUDY FOR NAVIGATING
US THROUGH THAT. SO
CONGRATULATIONS TO BEV RUS
SHAVASTARI, PROGRAM DIRECTOR,
INFO MAT IKS. RECEIVED AN
ACHIEVEMENT AWARD FROM
ENGINEERING MEDICINE AND BIOLOGY
SOCIETY. I THINK THE CITATION
REALLY SUMS IT UP WITH BERUSE
FOR OUTSTANDING LEADERSHIP AND
PIONEERING EFFORTS IN THE FIELD
OF BIOMEDICAL FIELD AND
REMARKABLE LEADER SHIP FOR YOUNG
INVESTIGATORS. SO WE
CONGRATULATE BERUSE FOR THAT
AWARD AND SPOT-ON CITATION THAT
DESCRIBES HIS IMPACT ON OUR
COMMUNITY. SO I WILL CONCLUDE
THIS SECTION OF THE DIRECTOR'S
REPORT ON A SAD NOTE. WE LOST A
DEAR COLLEGE, IGMA. TOO YOUNG.
ING WAS A STAFF SCIENTIST IN THE
TRACER AND CORE FACILITY AT
NIBIB. HE CAME HERE IN 1993 AS A
VISITING SCHOLAR AND JOINTED THE
PET DEPARTMENT IN THE CLINICAL
CENTER IN 1999 AND MOVED TO
NIBIB AS WE WERE LAUNCHING THE
INTRAMURAL PROGRAM IN 2004. HE
WAS A WIDELY RESPECTED EXPERT IN
MASS SPEC AND SEPARATION
TECHNOLOGIES. MUCH SOUGHT AFTER
GAEND ROUSE COLLABORATOR ON
SMALL METAL LITES, MATERIAL
CHARACTERIZATION. HE AUTHORED OR
CO -AUTHORED OVER 100 SCIENTIFIC
PUBLICATIONS, HAD TWO U.S. PAT
TENTS AND KNOWN FOR HIS PROFOUND
SINCERITY, CHEERFULNESS,
EAGERNESS TO HELP. WE SEND OUR
CONDOLENCES TO HIS FAMILY AND
COLLEAGUES AND TAKE A MOMENT TO
REMEMBER YING. WE LOST HIM AT
THE END OF THE YEAR LAST YEAR.
SO I WOULD LIKE TO MOVE INTO
FUNDING OPPORTUNITIES AND
ACTUALLY DRAW YOUR ATTENTION TO
OUR VISION STATEMENT ON OUR
WEBSITE, IF YOU HAVEN'T SEEN IT
ALREADY. AND A CONSEQUENCE OF MY
LAST PRESENTATION WITH YOUR
FEEDBACK AND SUPPORT. OUR VISION
TECHNOLOGIES TO SHAPE THE FUTURE
OF HEALTH SAKE COMPONENT OF
ROLLOUT OF THE PLAN, IN THE
PROCESS OF DOING IN SMALL WAYS
RIGHT NOW. HOPEFULLY IN MAY AND
IN THE NEXT COUNCIL MEETING WE
WILL HAVE COMPLETED THAT
ROLLOUT. YOU WILL SEE SIGNS OF
THAT ON OUR WEBSITE IN THE
COMING MONTHS. THE FIRST KIND OF
BIG STORY -- AND YOU HAVE BEEN
FOLLOWING THIS FOR QUITE
SOMETIME, IS RELEASE OF THE RFA
ON ENHANCING ENGINEERING OR THE
BETA PROGRAM AT HISTORICALLY
BLACK PROGRAMS, HBCUs. SO THIS
IS A CAPACITY BUILDING PROGRAM.
ALBERT AAVILAR HAS TALKED AND
PRESENTED. A TWO-PHASE UH-3
PROGRAM. WE HAVE HAD LOTS OF
INTEREST. ALBERT HAS TALKED TO
MANY, MANY POTENTIAL APPLICANTS.
DUE DATES -- AND WE ARE LOOKING
FORWARD TO HOPEFULLY RECEIVING
EXCELLENT APPLICATIONS, ARE
JANUARY 29TH THIS YEAR,
SEPTEMBER 30TH THIS YEAR AND
SEPTEMBER 30TH NEXT YEAR. SO
THAT IS THE NEAR-TERM PLAN FOR
OUR CENTERS, OUR BEV ITA, THE
OTHER BIGGEST CENTER PROGRAM
THAT WILL BE EXCLUSIVELY
SUPPORTED CAPACITY-BUILDING AND
GROWTH TRAINING OPPORTUNITIES AT
HBCUs. MANY OF YOU HAVE HEARD
BEFORE THE HEEL, HELPING END
ADDICTION LONG-TERM. A NIH
INITIATIVE. FOCUSED NOT ONLY ON
OPIOID USE DISORDER BUT ALSO
UNDERSTANDING AND DEVELOPING
APPROACHES TO MITIGATE PAIN. WE
CALL THAT THE HEAL PAIN
INITIATIVE. THIS IS A RECENT
BRANCHOUT. ITS OPERATING WITH A
NEW EXECUTIVE COMMITTEE. I'M A
MEMBER OF THAT. A NEW STEERING
COMMITTEE, DR. MARIAH BITMAN,
ONE OF OUR PROGRAM DIRECTORS AT
NIBIB IS ONE OF THE MEMBERS OF
THE STEERING COMMITTEE. WE HAVE
RECENTLY SIGNED ON TO AN
INITIATIVE AT RFA THAT I THINK
IS ALL LINED WITH OUR
COMMUNITY'S WORK THAT EMPHASIZES
THE DISCOVERY, DEVELOPMENT AND
VALIDATION OF REAL-WORLD DIGITAL
T
END-POINTS USING DEVICES. THIS
IS TO MONITOR PAIN, RESPONSE TO
INTERVENTIONS AND IMPACT ON
QUALITY OF LIFE. THESE
END-POINTS ARE DEFINED IN THE
RFA AS BIOSIGNATURES THAT CAN BE
OBTAIN ED FROM FUNCTIONAL AND
PHYSIOLOGICAL ASSESSMENTS
CAPTURED BY REMOTE OR WEARABLE
ADVICES. VERY MUCH ALIGNED WITH
WHAT OUR COMMUNITY DOES IN
EVENTS. ADDRESSES AN IMPORTANT
NEED TO DEVELOP APPROACHES THAT
CAN QUANTIFY OBJECTIVELY LEVELS
OF PAIN IN INDIVIDUAL, WHICH IS
A PERSISTENT ISSUE, PERSISTENT
PROBLEM AND CHALLENGE IN
TREATING PAIN. WE'VE PRESENTED
AND GOTTEN INVOLVED IN IMAGING
APPROACHES. NOW WITH EXPANSION
OF THE HEAL PAIN INITIATIVE I
THINK WE WILL HAVE AN IMPACT IN
OTHER AREAS AS WELL. ANOTHER --
NOW THIS IS A NOTICE OF SPECIAL
INTEREST, OR A NOSI, QUANTUM
BIOIMPLEMENTATIONS. WE HAVE BEEN
HAVING THESE CONVERSATIONS AND I
THINK THERE IS EXCITEMENT AND
MOMENTUM BUILDING UP. NOTABLY,
OF COURSE OURS. BUT TRADITIONAL
PARTNERS, NEI, HLBI, NIGS, WHICH
SUPPORTS LOT OF THESE, END CAPS
AND NCI. CONTACT OFROUZ
ANDERSON. WE HOPE TO SEE IT
EXPAND AS WE ARE STARTING TO SEE
MORE AND MORE QUANTUM-SENSES
TECHNOLOGIES, EVERYTHING FROM
IMAGING TO MATERIALS AND
BIOMATER
BIOMATERIALS. AFROUZ IS LEADING
THE COUNCIL IN FINLAND
PARTNERSHIP. YOU WILL SEE SOME
COME FROM NIH EVERY ONCE IN A
WHILE THAT POINT OUT SPECIFIC
AREAS OF INTEREST BOTH TO NIH
COMMUNITY AS WELL AS
INTERNATIONAL COLLABORATORS. IN
THIS ONE CORE AREAS THAT OUR
COMMUNITY WORKS IN, PLATONICS,
ARTIFICIAL INTELLIGENCE,
BIOECONOMY, MATERIALS, DIGITAL
PRECISION CANCER MEDICINE ARE OF
GREAT INTEREST TO OUR COLLEAGUES
IN FINLAND. SORT OF BROADLY THE
WAY THIS WORKS, IF YOU PUT AN
APPLICATION TOGETHER WITH A
COLLEAGUE FROM FINLAND AND IT
RECEIVES FUNDING, OUR SIDE NIH
WILL FUND THE APPROPRIATE FINISH
AGENCY, THE RESEARCH COUNCIL OF
FINLAND WOULD FUND THE FINISH
INVESTIGATOR. NO MONEY FROM THE
NIH WOULD GO TO FINLAND OR VICE
VERSA, BUT IT IS DESIGNED TO
ENCOURAGE THESE MULTI NATIONAL
TYPES OF COLLABORATIONS. ANOTHER
EXAMPLE OF -- AND PROBABLY THE
MOST HIGHLY EVOLVED EXAMPLE OF
THIS TYPE IS COLLABORATIVE
RESEARCH AND COMPUTATIONAL
MIRROR SCIENCE, CONTACT SHI TWAN
IF YOU ARE INTERESTED. THIS
INVOLVES POTENTIAL PARTNERSHIPS
WITH SPAIN, JAPAN, ISRAEL,
FRANCE AND GERMANY. ALSO WITH
THE DEPARTMENT OF ENERGY. SO
THIS IS A NEW ISSUANCE. THE NEXT
APPLICATION DUE DATE HERE IS
MARCH 7TH OF 2024. IT IS A
REALLY WONDERFUL OPPORTUNITY TO
ESTABLISH INTERNATIONAL
COLLABORATIONS. SO PLEASE BUILD
ON COLLABORATIONS YOU MAY HAVE
AND GET SPECIFIC, DEDICATED
FUNDING SUPPORT. FINALLY TO SORT
OF CONCLUDE THIS PORTION OF MY
PRESENTATION, WE ARE HIRING TWO
MORE PROGRAM DIRECTOR POSITIONS.
THESE HAVE BEEN OPEN FOR A
WHILE. WE ARE HOPING TO INCREASE
THE VISIBILITY AND EXPLAIN A
LITTLE BETTER ABOUT WHAT THESE
PROGRAM DIRECTOR POSITIONS ARE.
SOMETIMES THE GOVERNMENT'S
METHOD OF ADVERTISEMENT IS NOT
NECESSARILY TARGETED TO THE
RIGHT COMMUNITIES. SO ONE OF
THEM IS IN IMAGE-GUIDED
INTERVENTIONS. OBVIOUSLY ONE OF
THE FASTEST GROWING AREAS IN
MEDICINE. YOU CAN'T REALLY DO
INTERVENTIONS SUCCESS FULLY
WITHOUT BEING ABLE TO VISUALIZE
THEM. IMAGE-GUIDED APPROACHES
ARE -- TAKE ADVANTAGE OF
ADVANCES IN TECHNOLOGIES THAT
OUR COMMUNITY IS REALLY ON THE
CUTTING EDGE OF DEVELOPING. GUIN
LOU IS DIRECTOR IN DIVISION OF
APPLIED SCIENCES AND TECHNOLOGY.
PLEASE CONTACT HER IF YOU KNOW
OF PEOPLE WHO MAY BE INTERESTED.
YOU HAVE HEARD FROM MY DIRECTION
OF PROGRAM DIRECTORS AND DATA
SCHOLARS THE KIND OF
INDIVIDUALS, YOU KNOW, IN OUR
COMMUNITY WHO MAY BE INTERESTED
IN THESE TYPES OF POSITIONS. THE
SECOND ONE IS A PROGRAM DIRECTOR
IN POINT OF CARE TECHNOLOGIES
AND DIGITAL HEALTH. AGAIN
CONTACT OUR DIVISION DIRECTOR
BERUSE FOR INFORMATION ABOUT
THIS. YOU ARE ALL VERY FAMILIAR
WITH WHAT WE HAVE DONE IN POINT
OF CARE. I WILL CONTINUE TO TALK
IN AN UPDATE. THIS IS A CRITICAL
POSITION. WE ARE HOPEFUL WE CAN
BE SUCCESSFUL WHEN CREATING SOME
EXPERTS HERE. SO NOW I WOULD
LIKE TO UPDATE A LITTLE ON SOME
OF OUR PROGRAMS THAT HAVE HAD
UNIQUE SUCCESSES AND THAT ARE
INTERESTING, EMERGING STORIES.
YOU HAVE PROBABLY BEEN FOLLOWING
THE THREAT OF MANY OF THESE
STORIES. YOU HAVE HEARD ANDREW
WHITE, OUR PROGRAM DIRECTOR,
TALK ABOUT THE HOME TEST TREAT
PROGRAM. HE'S GIVEN BOTH KIND OF
THE INITIAL PILOT AND EXPANSION
PHASE UPDATES. THE PILOT PHASE
WAS LAUNCH ED A YEAR AGO. THE
IDEA BEING YOU CAN TEST AT HOME
IF YOU ARE A POSITIVE TEST. IN
2023 THIS WAS JUST FOR COVID. IF
YOU HAD A POSITIVE WITH THE
RAPID ANTIGEN TEST, YOU COULD
THROUGH THIS PROGRAM ACTUALLY
GET PAXLOVID. WE EXPANDED BEYOND
A SMALL AREA IN PENNSYLVANIA TO
ATLANTA AND HOUSTON THAT WAS A
PILOT EXPANSION. ALL THE WHILE
WORKING ON MULTIPLEX TESTS, FOR
COVID AND FLU. JUST AT THE END
OF LAST YEAR, TIMED IT SO THAT
WE WERE ABLE TO SORT OF CATCH
THE WAVE OF COVID PANDA FLU
EXPANDING AS WELL AS THE
TECHNOLOGIES. THAT'S RECEIVED
FAIR AMOUNT OF PUBLICITY AND
ACCOUNTED FOR A LOT OF THOSE
PAGE VIEWS. YOU HAVE SEEN SOME
OF THIS PERHAPS IN THE POPULAR
PRESS. SO JUST TO UPDATE FROM
THAT DECEMBER OF 2023 LAUNCH OF
THE PROGRAM, IT IS A COVID AND
FLU NATIONWIDE PROGRAM. IT IS
TESTTOTREAT.ORG. YOU CAN SEE
THAT WEBSITE. WHAT IS UNIQUE
ABOUT THIS, AT ITS CORE THE
TECHNOLOGY IS THE LUCERA PCRU
AND ISONUC TEST APPROVED FOR
HOME USE. THIS IS AVAILABLE FOR
ELIGIBLE PARTICIPANTS IN THIS
PROGRAM. OUR RADAX ITAP PLAY ED
A CRITICAL ROLE IN GETTING THAT
VALIDA
VALIDATED. LUCERA, SOME OF YOU
MAY RECALL, WAS PURCHASED OUT OF
BANKRUPTCY BY PFIZER. PFIZER
ALSO MAKES PAXLOVID. SO IT IS
SORT OF NESTED MARKET THAT THEY
ARE LOOKING FOR BOTH THE
DIAGNOSTIC TESTING AS WELL AS
THERAPY. WE WILL SEE THAT THEME
CONTINUE TO EMERGE IN BOTH THE
DIAGNOSTICS AND THERAPEUTICS
INDUSTRIES. SO THIS IS NOW A
PARTNERSHIP BETWEEN US AND
SEVERAL OTHER ORGANIZATIONS --
WELL, FROM THE VERY BEGINNING.
WE HAVE WORKED WITH ASPER, CDC
AND EMED IS THE TELEHEALTH OR
PROVIDER THAT MANAGES THE
CONFIRMATION OF TEST RESULTS AS
WELL AS PRESCRIPTIONS
INTERACTING WITH ONLINE
PHARMACIES. SO THIS IS MADE
POSSIBLE BY TWO FUNDAMENTAL
ELEMENTS FROM OUR RADAX TECH
PROGRAM. THE ITAP PROGRAM,
ACCELERATED AUTHORIZATIONS OF
MULTI -PLEX AS WELL AS DIGITAL
MARS AND MAKEMYTEST COUNT
REPORTING SYSTEM. HERE WE ARE
TODAY. A QUICK UPDATE. NEARLY
50,000 PEOPLE HAVE ENROLLED.
THAT IS VERY, VERY CLOSE TO OUR
TARGET, WHICH IS POWERED TO HELP
ADDRESS SOME RESEARCH QUESTIONS.
THE TELEHEALTH VISITS HAVE
EXCEEDED OUR TARGET. THERE ARE
OVER 5,000 OF THOSE. ALSO
ANTI -VIRAL PRESCRIPTIONS THAT
HAVE BEEN DELIVERED, OVER 4,000
AGAIN EXCEEDING OUR TARGET THERE
ARE RESEARCH QUESTIONS EMBEDDED
IN UMAS, ONE OF THE KEY
PERFORMING SITES IN POCTURN IS
TAKING THE LEAD ON ADDRESSING
THOSE QUESTIONS. THEY ARE
BROADLY ABOUT PROGRAM USE,
EFFICACY, IMPACT, SUSTAINABILITY
IN POPULATIONS THAT HAVE LIMITED
ACCESS TO HEALTH CARE. THAT IS
THE FOCUS OF THIS PROGRAM. IT IS
PROVIDE THESE RESOURCES TO
INDIVIDUALS WHO HAVE LIMITED
ACCESS. ANOTHER MAJOR EFFORT
THAT I WANT TO UPDATE YOU ON --
AND YOU HAVE HEARD ME TALK ABOUT
AND REFER AND ALLUDE TO IT
SEVERAL TIMES IN PREVIOUS
COUNCIL MEETINGS IS THIS NASUM
REPORT ON DIGITAL TWINS. THE
NASUM REPORT IS NOW OUT. IT
ACTUALLY CAME OUT MID-DECEMBER
LAST YEAR. NIBIB CO -SPONSORED
IT. IT IS A CONSENSUS STUDY
REPORT. THERE'S LOTS OF EXCITING
INFORMATION IN THIS. I WANTED TO
GIVE YOU A LITTLE BREAKING NEWS.
CONTACT GRACE PANG WHO HAS
CHAMPIONED AND CONTINUES TO
CHAMPION IT ACROSS MANY AREAS OF
MODELLING COMPUTATION WITHIN THE
NIH. ONE OF THE IMPORTANT THINGS
THIS REPORT HAS DONE IS DEVELOP
THE DEFINITION THAT BUILDS ON
PREVIOUS ONES, BUT IT IS A VERY
ACCESSIBLE DEFINITION. I THINK
IF YOU ARE NOT INVOLVED IN
DIGITAL TWIN WORK, I THINK IT IS
A LITTLE OFFPUTTING. I THINK IT
IS MAYBE HARD TO UNDERSTAND WHAT
IS A DIGITAL TWIN UNLESS OF
COURSE YOU DO ENGINEERING. AND
DIGITAL TWINS HAVE REALLY BECOME
STANDARD IN ENGINEERING
CONSTRUCTION AND FABRICATION.
BUT IN HEALTH IT IS HARD TO
UNDERSTAND. THIS STANDARDIZED
DEFINITION IS I THINK EXTREMELY
USEFUL. MANY PEOPLE CAN CONNECT
WITH THIS. AND ALSO SORT OF
IMAGINE HOW THE WORK THEY ARE
DOING IN MODEL-BASED WHATEVER IT
IS, IMAGING OR MATERIALS,
DEVICES AND SO FORTH, COULD
STRONGLY BE CONNECTED TO DIGITAL
TWINS AND PERHAPS EVEN BE QUITE
RELEVANT AND MAYBE UTILIZED
RESOURCES DEVELOPED FOR DIGITAL
TWINS. THEY GIVE SEVERAL
EXAMPLES IN THE REPORT. I WILL
JUST SORT OF PULL OUT A CANCER
PATIENT EXAMPLE THAT IS
HIGHLIGHTED. YOU CAN SEE WHAT
I'M TALKING ABOUT THERE. IT
REQUIRES A VIRTUAL
REPRESENTATION. THOSE WOULD BE
MECHANISTIC AND EMPIRICAL MODELS
REPRESENTING TUMOR GROWTH AND SO
FORTH AND REQUIRE A PHYSICAL
COUNTERPART. COULD BE PATIENT
DATA FROM IMAGING, BLOOD TESTS
AND OTHER CRITICAL ASSESSMENTS
AND BIDIRECTIONAL INTERACTION SO
UPDATES THE VIRTUAL
REPRESENTATION TO REFLECT
CHARACTERISTICS OF THE
INDIVIDUAL PATIENT. INFORMS
CLINICAL DECISION, TREATMENTS
AND CLINICAL ASSESSMENTS. THOSE
COULD BE CLINICAL DECISION
SUPPORT OR ACTUAL CLINICAL
DECISIONS THAT ARE BANKABLE THAT
QUESTIONS WILL ACT ON. THESE NEW
CLINICAL ASSESSMENTS WOULD
INFORM AND THEN SUBSEQUENTLY
UPDATE THE DIGITAL TWIN. SO I
THINK A PRACTICAL AND RELATABLE
EXAMPLE ALL OF US CAN IDENTIFY
WITH. THERE IS A NOSI OUT FROM
NCI IN THE DIVISION OF DIGITAL
TWINS. IT IS CALLED THE DIGITAL
TWINS IN RADIATION ONCOLOGY. YOU
SHOULD TAKE A LOOK AT THAT. I
THINK NCI WILL BE RELEASING MORE
NOSI AND OTHER IC PERHAPS IN THE
NEAR FUTURE. GRACE IS LEADING
THE INTERAGENCY MODELLING AND
ANALYSIS GROURNGP, IMAC, WHICH
ROAD MAPPING. I THINK YOU WILL
SEE CONTINUED GROWTH AS PEOPLE
GET MORE AND MORE INVOLVED. THIS
REALLY DOVE TAILS BECAUSE OF THE
IMPORTANCE OF ARTIFICIAL
INTELLIGENCE IN DIGITAL TWINS
INTO SOMETHING I HAVE MENTIONED
IN PREVIOUS COUNCIL MEETINGSN.
JANUARY OF 2023, OSTP RELEASED A
REPORT ON STRENGTHENING AND DMOK
ADVERT
ADVERTISE -- DEMOCK ADVERTISING
THE DIVISION. THERE WAS A
INFRASTRUCTURE TO BROAD EN
RESOURCES THAT ARE ESSENTIAL SO
WHAT IN PRACTICAL TERMS IS THAT?
IT IS A NATIONAL AI RESEARCH
RESOURCE, OR NAIR. PHYSICALLY
THIS WOULD BE PHYSICALLY A
MATRIX ORGANIZATION BUT IT IS
ESTIMATED -- YOU KNOW, DON'T
HAVE A FULLY DEFINITIVE VIEW BUT
ACTIVELY ENGAGED IN THIS
PROCESS. IT IS ESTIMATED TO BE A
$2.6 BILLION, SIX-YEAR
INVESTMENT IN INFRASTRUCTURE FOR
ARTIFICIAL INTELLIGENCE. WHAT IS
VERY IMPORTANT IS THAT, YOU
KNOW, WE ARE NOT JUST -- IT WILL
BE LED BY NSF. BUT WE ARE NOT
BYSTANDERS. WE ARE ACTIVELY
PARTICIPATING IN NAIR AND IN
PARTICULAR A PILOT PROGRAM IN
2024 TO DEPLOY RESOURCES TO
EARLY NEAR USERS AND MIDRIC
SPECIFICALLY HAS BEEN SELECTED
AS A PILOT PROGRAM RESOURCE FOR
NAIR. RESOURCES, ACTIVITIES,
STRUCTURE AND PEOPLE INVOLVED IN
MIDRIC WILL BE INCREASINGLY
ENGAGED. I THINK WE HAVE A
UNIQUE OPPORTUNITY TO TAKE
LEADERSHIP ROLE AND NOT JUST
RELY ON THE NAIR INITIATIVE LED
BY THE PHYSICAL SCIENCE AND
COMPUTATIONAL COMMUNITY BUT THE
BIOMEDICAL COMMUNITY WILL BE
ABLE TO CONTRIBUTE STRONGLY,
THANKS TO OUR COLLEAGUES, BRAD,
CHRIS AND RUIZ, WHO HAVE REALLY
CHAMPIONED THIS ENGAGEMENT AND
PILOT PROJECT PROGRAM.
NOT ONLY THE NAIR IS ANOTHER
ENTITY THAT'S EMERGED TO TRY TO
CREATE UNIQUE RESOURCES AND
TOOLS THAT ARE WIDELY ACCESSIBLE
IN ARTIFICIAL INTELLIGENCE BUT
ARPAH, YOU MAY HAVE HEARD OF
THEIR BIOMEDICAL FABRIC TOOL
BOX. THERE WAS A NATIONAL CALL
FOR THIS. INFRASTRUCTURE FOR
DATA INGESTION, CURE RADIAT CURN
SHGS /* /* CURATION FOR AI
HEALTH CARE. I'M PLEASED TO SAY
OUR TEAM MIDRIC HAS BEEN FUNDED
BY ARPAH BY PERFORMERS, AN ARPA
PARTNERSHIP , A CONCRETE
PARTNERSHIP THAT WILL EXTEND OUR
MIDRIC ACTIVITIES, FOCUSED
AROUND COVID INTO CANCER. SO IT
EXTENDS ALL OF THE FUNCTIONAL
TOOLS IN OUR TOOL BOX INTO OTHER
AREAS. MANY OF THESE ARE A
RESULT OF OUR REALLY CRITICAL
AIML BIAS TOOL SINCE MIDRIC WAS
LAUNCHED. I ENCOURAGE YOU TO ALL
LOOK AT THE ESTIMATOR, SCAN THE
QR CODE, IF YOU HAVEN'T ALREADY.
THESE WILL BECOME FOUNDATIONAL,
THE IDENTIFICATION OF VARIOUS
SOURCES AND WAYS TO MITIGATE
THEM I THINK ARE GOING TO BECOME
FOUNDATIONAL IN TOOL BOXES
DEVELOPED FOR BOTH NAIR, ARPAH
AND MANY OTHER INITIATIVES IN AI
AROUND THE WORLD. SO SWITCHING
GEARS A LITTLE BIT WE HAVE
TALKED ABOUT RADAX AND IMPACT ON
NIBIB PROGRAMS. WE HAVE A NUMBER
OF EXAMPLES OF THAT IMPLICATION
GOING ON AT NIBIB WITH MULTIPLEX
TEST COMBINATION COVID AND FLU,
DEVELOPMENT OF IMPOX AND
MULTI SEX SEXUALLY TRANSMITTED
DISEASE TESTS. OUR EFFORTS TO DO
POINT OF CARE, HEPC TESTING AND
H.I.V. VIRAL LOAD. YOU HAVE
HEARD OF RADAX MATERNAL HEALTH
AND FETAL MONITORING
TECHNOLOGIES. FOR THE LAST
COUPLE OF YEARS WE HAVE BEEN
TALKING ABOUT HOW RADAX
PRINCIPLES HAVE BEEN EXTENDED TO
NEUROTECHNOLOGIES. WHAT IS
REALLY EXCITING ABOUT THE
NEUROTECHNOLOGY EXTENSION IS
THERE IS A BROAD GROUP OF
STAKEHOLDERS ACROSS NIH WITHIN
BLUEPRINT THAT HAVE ADOPTED
THESE TECHNOLOGIES AND REALLY
CRITICALLY ENGAGED IN ADVANCING
RADAXIFICATION, NOT JUST NIBIB
BUT ACROSS THE NIH. THIS EFFORT
HAS BEEN LED BY MULTIPLE ICs AND
A REALLY TALENTED GROUP OF
PROGRAM DIRECTORS ACROSS MANY
IIC
NOTABLY WITHIN NIBIB. WE HAVE
THE CHAMPIONING OF THE PROGRAM.
MICAH'S PLAYED INSTRMENTAL ROLE
IN GETTING THIS PROGRAM
LAUNCHED, MANAGING IT QUITE
STRATEGICALLY. SO I HAVE ASKED,
BECAUSE YOU ARE PROBABLY TIRED
OF HEARING MY VOICE, I HAVE
ASKED MIKE TO JUMP IN. HE HAS
EXTRAORDINARY EXPERTISE AND
VISION WITH THIS PROGRAM. MAYBE
MIKE ARE YOU READY TO JUMP ON
THE LINE AND -- GREAT. SO I WILL
RUN THE SLIDES. I HAVE A FEW.
YOU HAVE A TREAT. YOU CAN LISTEN
TO MIKE TALK ABOUT THE EVOLUTION
AND PURPOSE AND WHERE WE ARE
WITH THIS PROGRAM RIGHT NOW.
>> ABSOLUTELY. THANKS, BRUCE.
ABOUT TWO AND A THIRD WE
PRESENTED CONCEPT CLEARANCE TO
COUNCIL, LAYING OUT THE VISION
OF HOW THE PROGRAM IS STRUCK
CHU
STRUCTURED, WHERE IT STARTS AND
ENDS. WE WILL SHOW HOW THING S
HAVE BEEN REFINE ED IN THAT
TIME. THE PROGRAM STARTED AFTER
SUCCESSFUL CONCLUSION OF RO1s
AND APPLIED RESEARCH THAT NIH
NORMALLY FUNDS. ALL THE GREAT
WORK WE DO IN OUR NORMAL PAY
LINE. SO AFTER -- INVESTIGATOR
HAS DEMONSTRATED GOOD PROOF OF
CONCEPT WE KNOW IF WE INTERVENE
WE CAN DIAGNOSE OR TREAT
SOMETHING BUT DON'T KNOW HOW TO
GET TO MARKET. DON'T KNOW HOW TO
GET TO A PERSON HUMAN STUDY.
THAT SOUR ENTRY POINT. WE TAKE
THOSE PROJECTS THAT COME IN
THROUGH SOLICITATION. IF THEY
ARE AT SUCH EARLY STAGE, THEY
DON'T KNOW THE QUESTIONS OTHER
THAN BEING HERE TO WORK, THEY
HAVE DONE OTHER BASIC RESEARCH,
BPI OR OTHER NORMAL MECHANISMS
AND TAKE INTO WHAT WE CALL
SEEDLING, WHERE WE HELP THEM
SOLVE INITIAL PROBLEMS. ONCE
READY TAKE THEM INTO DEVELOPMENT
PROJECT, LARGER SCALE, SORT OF
RO1 IN SCALE AND GET READY FOR
PERSON HUMAN STUDY, THE GREEN
AND ORANGE BOXES. ON RIGHT YOU
WILL SEE TRANSLATOR BOX. THAT IS
LATER HUMAN STUDIES,
DEMONSTRATING INITIAL TRIAL FOR
SAFETY AND EFFECTIVENESS. IN
ADDITION TO GIVING THE
INVESTIGATORS CAPITAL WE GIVE
THEM RESOURCES, THINGS THEY NEED
TO BE SUCCESSFUL. WE DON'T JUST
GIVE MONEY BUT SOMETIMES
SOMEBODY HOPPING OUT OF ACADEMIC
LAB OR SMALL STARTUP, THEY DON'T
KNOW WHAT RESOURCES TO GET OR
HOW TO FIND OR NEGOTIATE,
BUSINESS AGREEMENTS. SO OUR
PROGRAM STARTS AT THAT POST
PROOF OF CONCEPT AND ENDS AFTER
THAT FEASIBILITY STUDY. LET ME
TELL YOU A LITTLE MORE ABOUT
THAT HUB PROCESS IN GREEN AND
ORANGE BOXES. NEXT. SO WE TAKE A
FUNNEL PROCESS, YOU SHOULD BE
FAMILY WITH THIS. WE ARE CALLING
IT A DOLPHIN TANK BECAUSE
DOLPHINS ARE KIND AND HELPFUL.
IT GOES THROUGH A NORMAL FUNNEL.
WE HAVE A PREPROPOSAL WHERE WE
GET WHERE WE TRY TO IDENTIFY
WHICH PROJECTS GET WITHIN
MISSION. WHICH MIGHT BE
SUCCESSFUL BUT WE DON'T KNOW
ENOUGH TO SO WE INVITE THEM TO
SUBMIT FULL PROPOSAL, THEN
ANOTHER REVIEW , A DEEP DIVE.
THEN NEXT WE ROUTE THEM THROUGH
ONE OF TWO PATHWAYS. DEVELOPMENT
PROJECT, WHICH I SAY IS A LARGER
EFFORT, OR SEEDLING. THE
SEEDLING, THEY DON'T HAVE THAT
PROOF OF CONCEPT ISSUE. THAT'S
BEEN RESOLVED BUT HAVE WEAKNESS
IN SOMEBODY RESOLVABLE WITH
SIX-MONTH, MINIMAL EFFORT FOR
THINGS DONE ON PAPER.
EFFECTIVELY LIKE COME UP WITH
REGULATORY PLAN, MORE DETAILS ON
THE PROJECT. WE ARE MISSING A
TEAM MEMBER, MISSING THE
CLINICAL EXPERTISE OR ADVOCATE
OR THIS KIND OF ENGINEERING
EXPERTISE. REFINE THE SCOPE OF
WORK. REALLY JUST DIAL IN WHAT
IS ACTUALLY TO BE DONE. THE LAST
ONE IS PROGRAM FOR ENHANCING
DIVERSE PERSPECTIVES. WE TAKE A
SIMILAR APPROACH TO BRAIN
INITIATIVE, PILOTING AND
SPEARHEADING ACROSS NIH TO MAKE
SURE PROJECTS COME IN AND FUNDED
BY NIH INCORPORATE DIVERSE
PERSPECTIVES FROM A COMMUNITY OF
INNOVATORS, END USERS AND
PATIENTS. SEEING HOW TO HELP
THOSE WEAKNESSES THAT CAN BE
DONE ON PAPER IN SIX MONTHS WITH
SOME MENTORSHIP. NEXT PLEASE.
NOW FOR DEVELOPMENT PROJECTS WE
HAVE TWO HUBS. U54 COPPER
AGREEMENTS. ONE THROUGH MASS
GENERAL CALLED SENATE. THEY HAVE
AN EN ENTITY CALLED SENTA AND
ONE FROM JOHNS HOPKINS CALLED
NEURO TECH HARBOR AND MONEY
PASSES TO THE INNOVATOR, WILL
RECEIVE UP TO $5,000 TO
INNOVATOR AS WELL AS IN-KIND
RESOURCE, PPD, ACTUALLY MEDICAL
PROVIDING RESOURCE. SO
PRE-CLINICAL STUDY, THE DESIGN
RESOURCE, REGULATORY SUPPORT, ET
CETERA, ET CETERA. NEXT PLEASE.
FOR THE SEEDLINGS THEY ARE RUN
ONLY OUT OF NEURO TECH HARBOR
OUT OF HOWARD UNIVERSITY. THEY
ARE MANAGING AND TRAIN ING THIS
COHORT OF BUDDING INNOVATORS AND
GIVING THEM UP TO $50,000 OF
FUNDS DIRECTLY WAS WELL AS AT
LEAST $50,000 OF IN KIND
SUPPORT. EVERYONE GETS A MENTOR,
TRANSLATING TO MEDICAL TECH,
USUALLY THE SAME FIELD OR SAME
TECHNOLOGY. AS WELL AS
REGULATORY CON SUPPORT WITH PPD
AND ENTREPRENEURIAL TRAINING. SO
EVERYONE GETS SOMETHING, IF THEY
ARE FUNDED. YOU KNOW, OUR JOB IS
TO TEE UP THE SEEDLINGS IF THEY
ARE READY IN THE NEXT ROUND.
NEXT SLIDE, PLEASE. WE HAVE MADE
AWARDS. MADE 36 PROJECTS OVER
THE LAST COUPLE YEARS ADDING UP
TO OVER 14 MILLION DIRECTLY TO
INNOVATORS. NOT INCLUSIVE OF THE
MEDICAL RESOURCES, ET CETERA.
THESE ARE FUNDED BY SEVEN
RESOURCE, AS WELL AS BRAIN
INITIATIVE. HILL PARTNERSHIP IS
PARTNERING IN SOME CAPACITIES.
WE HAVE A LOVELY SCIENCE
HIGHLIGHT ON THE WEBSITE.
ENCOURAGE YOU FOLLOW THAT LINK
AND READ MORE ABOUT PROJECTS WE
HAVE FUNDED. SEE THAT PROGRESS
BRE
PROGRESSION. I WOULD LIKE TO
HIGHLIGHT THIS. JULIA RECENTLY
MOVED TO UNIVERSITY AT ARIZONA
THIS MONTH. FOR NONADDICTIVE
TREATMENT FOR PAIN, LOW
INTENSITY ULTRASOUND TARGETING
THE DORSAL ROOT GANGLIA. WE
FUNDED HER IN THE PROJECT. MOST
FUNDED IN NOVEMBER SO DON'T HAVE
A LOT OF PROGRESS TO SHOW SO
WANT TO TALK ABOUT THIS WE
FUNDED FURTHER AGO IN PILOT.
STARTED WITH THIS SCHEMATIC
SKETCH GENERAL IDEAS AND FEW
PRECLINICAL STUDIES IN MICE
USING OFF-THE-SHELF TECHNOLOGY .
THE WAY WE TEND TO EVALUATE IN
THE PROGRAM IS WITH THIS GATES
WHEEL, THIS CIRCULAR DIAGRAM IN
THE MIDDLE THAT HAS FOUR AXISES
IN ORANGE, REGULATORY, MARKETING
GREEN, CLINICAL AND INSIDE
TRACK. GO FROM BASIC NEEDS
ASSESMENT, IDEA, PROOF OF
CONCEPT TO CLINICAL TRIALS AT
6:00, VALIDATION AND ULTIMATELY
STANDARD OF CARE AT 11:00 THERE.
THIS IS THE ASSESSMENT WHEN SHE
CAME IN WITH THE INITIAL
PROPOSAL INTO THE PILOT PROGRAM,
EQUIVALENT TO WHAT WE WOULD FUND
IN A SEEDLING. OVER THE LAST
COUPLE YEARS WE GAVE HER AN
INVESTMENT. SHE DEVELOPED,
WORKED WITH MENTOR AND SUBMITTED
FULL PROPOSAL AT WHICH POINT SHE
WAS GAUGED TO THE DIAGRAM IN
RIGHT, FAR MORE FILLED IN. A
SIGNIFICANT ADVANCE OF
TECHNOLOGY. MUCH CLEAR PICTURE
OF REGULATORY. STILL A LOT OF
GAPS. A HUGE ADVANCEMENTS IN THE
MARKETING PLAN. HUGE ADVANCES IN
CLINICAL THAT DEMONSTRATION WITH
LARGE ANIMAL MODEL. VIDEOS OF
THESE PIGS I SWEAR JUST -- AFTER
THE TREATMENT THEY LOOKED LIKE
THEY ARE DANCING. IT IS
HILARIOUS. IN THIS PROJECT SHE
GAVE THIS LOVELY QUOTE HERE
ABOUT HOW VALUABLE PROGRAM WAS
TO SUPPORT GUIDANCE, MENTOR,
PROJECT MANAGERS AND HELPING TO
BRING TECHNOLOGY TO PATIENTS
FASTER. THAN IF GRANTS BUT HAD
GOTTEN NORMAL ADVANCEMENT FROM
PARTIES. WE ARE LOOKING FOR
MORE. WE HAVE A SOLICITATION IN
FEBRUARY, EARLY FEBRUARY. I EN
KI
ENCOURAGE YOU TO CLICK AND
REFRESH THIS LINK. LOOKING AT
CENTERS, ALL THE WAY FROM
ADDICTION FROM ALCOHOL,
SUBSTANCE, ALZHEIMER'S RELATED
DMEN DEMENTIA AND FULL PANOPLY.
WE ARE EXCITED AND INTEND TO
FUND. WE WOULD LIKE YOU SUBMIT
PROPOSALS NOW YOU HAVE PROJECTS
OF THE TYPE OF PROJECTS. ALSO
HAVE THE CLINICAL PROGRAM THAT
HAS A SEAT DATE IN FEBRUARY AS
WELL. I WILL PASS IT BACK TO
BRUCE. IF YOU HAVE QUESTION, I
WILL ANSWER AT THE END, THANK
YOU.
>> THANK YOU, MIKE. WHAT MIKE
IMPLIED BUT MAYBE DIDN'T SAY
EXPLICITLY, ONE OF THE BRILLIANT
FUTURES IS WE ARE KIND OF LIKE
THE POINT GUARD, IF YOU LIKE
BASKETBALL METAPHORS, BECAUSE WE
WORK WITH OUR COLLEAGUES TO SORT
OF INSPIRE TAKING SHOTS ON GOAL.
IN OTHER WORDS, THEY ARE
SPENDING THE MONEY TO SUPPORT
THE TECHNOLOGIES. WE WORK
COLLABORATIVELY WITH THEM TO
EVALUATE, BRING IN RESOURCES
THAT CAN VALIDATE AND MOVE THEM
ALONG. FOR EXAMPLE, THIS ONE IS
FUNDED BY NIDA, NINDA. WE ARE
NOT EXPLICITLY FUNDING THE
DEVELOPMENT. PROVIDING A LOT OF
IN-KIND SUPPORT. THAT IS THE
NATURE AND CHARACTERISTIC. I
THINK A WONDERFUL MODEL FOR HOW
SMALL ICs CAN ARE HAVE AN
OUTSIZED IMPACT ACROSS HIH AND
BIOMEDICAL COMMUNITY. SO LET ME
MOVE INTO TRAINING AND
DISSEMINATION UPDATES. WE ARE
OBVIOUSLY VERY ACTIVE SO I HAVE
A FEW HIGHLIGHTS FOR YOU. ONE
BIG PIECE OF NEWS, YOU HAVE
PROBABLY FOLLOWED THE BSIP
PROGRAM, BIOMEDICAL SUMMER
INTERNSHIP, PIONEERED BY BOB,
SINCE THE BEGINNING OF NIBIBI.
STARTED TO SUPPORT ONLY SUMMER
INTERNSHIPS FOR BIOMEDICAL
ENGINEERING BECAUSE THERE WASN'T
MUCH IN EARLY 2000s AND DESIGNED
TO BUILD UP THAT POPULATION.
WITH MONU'S ARRIVAL AND CREATION
OF BETA CENTER AND AFTER TEN
EXTENSIVE DISCUSSIONS WITH BOB
WE HAVE BROUGHT THE PROGRAM
UNDER THE AEGIS OF DATA CENTER.
WE HAVE TWO TRACKS. THERE IS
MORE OF THE CLASSIC, WHICH
INVOLVES BME STUDENTS. IN FACT,
ENGINEERING AND COMPUTATIONAL
SCIENCE STUDENTS WHO HAVE HAD
SIGNIFICANT RESEARCH EXPERIENCE,
A FEW YEARS IN BIOMEDICAL
APPLICATIONS OF TECHNOLOGIES. SO
THAT PROGRAM IS REALLY DESIGN
SORT OF CAPTURE STUDENTS MOVING
TINT FOURTH YEAR AND ON A FAST
TRACK. ONE OF THE OTHER THINGS
WE ARE QUITE INTERESTED IN IS
HAVING STEM STUDENTS THAT DON'T
HAVE EXPERIENCE AND MAYBE NEVER
HAD OPPORTUNITY TO GET RESEARCH
EXPERIENCE AND MAYBE THEY ARE
NOT RESEARCH INTENSIVE. THIS
PROGRAM OPENS IT UP. THIS IS
WHAT WE CALL BISIM STEM,
COMPLEMENTARY TO BME AND WILL
EFFECTIVELY DOUBLE THE SIZE OF
THE PROGRAM. IT IS ACCESSIBLE
THROUGH DATA CENTER AND CONTACT
MONU. IF YOU HAVE STUDENTS WHO
ARE INTERESTED, WE THINK THIS IS
AN EXCITING WAY TO BRING PEOPLE
INTO THE FIELD WHO MAY NOT
NORMALLY OTHERWISE HAVE THOSE
OPPORTUNITIES, IN ADDITION TO
SUPPORTING KIND OF OUR
TRADITIONALTRADIT
TRADITIONAL CONSTITUENCY. FOR
THE FIRST TIME WE WERE ABLE TO
GIVE AWARDS AND ANNOUNCE WINNERS
AT THE -- AT A PLENARY SESSION,
THE NIBIB POLLEN PL EF /* /* --
PLENARY. THEY GOT TO COME UP AND
HAVE THE PRESENTATION. THESE ARE
AWARDEES AVAILABLE FOR THE
CONCEPT TRAINING. WE HAVE
STUDENTS GOING INTO THAT. IT IS
PLAYING MORE ENGAGED ROLE. NOT
ONLY GIVE AWARDS BUT GIVE
RESOURCES TO PROMOTE INNOVATIVE,
ENTREPRENEURSHIP AND MORE. WE
HAVE A NEW DEBUT TO ANNOUNCE.
EACH YEAR WE HAVE BEEN ABLE TO
INCREASE. THIS YEAR IS NO
EXCEPTION. OUR TOTAL PRIZE PURSE
COMING UP TOWARD THIS YEAR'S
CHALLENGE IS $160,000 NOW. I
REFLECTS ADDITION OF A NEW PRIZE
IN 2024 FROM NIDDK. THAT IS THE
KIDNEY TECHNOLOGY DEVELOPMENT
PRIZE. SO WE HOPE THAT A LOT OF
YOU WILL BE INTER TESINTERESTED
APPLYING. THIS IS A NATIONAL
NEED TO DETECT KIDNEY DISEASE
APPROACHES AT EARLIER AND
EARLIER STAGES. I THINK THIS IS
A WONDERFUL OPPORTUNITY. DAVE
SOIS
OUR CHAMPION AND ENCOURAGE
PEOPLE TO REACH OUT AND CONTACT
HIM. WHEN YOU DO THE MATH, WITH
ALL THE PRIZES THAT WE'RE ARGUED
A SHGS /* /* -- WE'RE ARGUED
WARDING THERE IS A GOOD CHANCE
SO I ENCOURAGE PEOPLE TO GET
YOUR STUDENTS GOING. WE HAD A
REPORT NUMBER OF APPLICATIONS
LAST YEAR. HOPEFULLY THAT TREND
WILL CONTINUE. JUST A QUICK
REPORTING ON A COUPLE OF
WORKSHOPS. A REALLY GROUND
BREAKING SYNTHETIC BIOLOGY FOR
AGE AGING. I'M FOLLOWING
CLOSELY. YOU SEE THE ARROW. OF
COURSE WE ARE VERY, VERY
INTERESTED AND VERSING THIS
DIFFERENTIATION OR REVERSING
AGING. I THINK THIS HOLDS SOME
OF THE KEY. THERE WILL BE A LOT
OF ACTIVITY AND DISCUSSION AT
THIS WORKSHOP. CONTACT TUBA FEHR
FOR MORE INFORMATION.
UNFORTUNATELY WE DON'T HAVE A
VIDEO CAST BUT WE HAVE BOTH DAYS
OF THE ANNUAL CONSORTIUM
MEETING. SCAN THOSE CODES,
THANKS TO VERMONT, TUBA, NICOLE
FOR ORGANIZING AND OF COURSE TO
DAVE FOR CHAMPIONING THIS AREA
AND CREATING OPPORTUNITIES FOR
ALL OF OUR COMMUNITY IN
BIOMANUFACTURING. I WILL LINGER
ON THE VIDEO CAST. PLEASE BE
SURE TO SCAN THOSE CODES. THEY
ARE A VALUABLE RECORD WITH
INCREDIBLE INFORMATION AND TALKS
YOU CAN ACCESS. ANOTHER MAJOR
CONFERENCE THAT IS HAPPENING
WHERE WE HAVE VIDEO CASTS AND
OWE CAN SEE THE QR CODES OF DAY
ONE AND TWO, WAS THE POPTURN
CONFERENCE AND TECHNOLOGY SHOW
CASE. NOT JUST A CONFERENCE WITH
REN STATIONS AND TALKS. ACTUALLY
HA
WITH PRESENTATIONS. AN ENORMOUS
RESPONSE WITH MANY PEOPLE COMING
TO NATUR TO SEE AND ENGAGE. I
POINT OUT THIS PHOTO IN LOWER
LEFT-HAND CORNER, THERE ARE
FOLKS YOU MAY RECOGNIZE IN THAT.
THERE IS OF COURSE ME AND
TIFFANY, YOUR NIBIB
REPRESENTATIVES THERE. TIFFANY
IS THE LEADER AND CHAMPION OF
THIS CONFERENCE. TIFFANY HAS
MANAGED TO PUT TOGETHER AN
AMAZING, AMAZING COUPLE OF DAYS
WITH OUTSTANDING TOPICS AND
PANELS IN CONVERSATION. BUT YOU
WILL SEE A COUPLE OF NEW FACES.
THE NIBIB DIRECTOR GAVE THE TALK
AT THE CONFERENCE. WE WERE
GRATEFUL AND REINFORCED THE
EARLY FORMING POINTS THAT I
SHOWED AT THE BEGINNING OF MY
TALK SO WE ALL GOT TO HEAR FROM
HER. I THINK HER DEDICATION TO
COMING TO THAT SESSION I THINK
IS A STRONG REFLECTION OF HER
ENTHUSIASM AND WHAT WE HAVE BEEN
ABLE TO ACCOMPLISH AND HOPES FOR
IN FUTURE. YOU SEE REBECCA
RICHARDS CORDHAM ON THE RIGHT.
REBECCA IS ONE OF TWO NEW
CENTERS IN POPTURN AND THE
COMPETITION FOCUSSING ON POINT
OF CARE TECHNOLOGIES IN CANCER.
ABSOLUTELY CRITICAL AREA,
EXPANDING OUR PARTNERSHIP WITH
COLLEAGUES ACROSS THE NIH FOR
DEVELOPING CANCER-BASED
TECHNOLOGIES. WE ARE EXCITED TO
HAVE HER JOIN. A CLASSIC PHOTO,
GLAD TO SEE THEM BOTH. ANOTHER
PROGRAM THAT WE HAVE LAUNCHED,
YOU HAVE HEARD US TALK ABOUT THE
BEAMS CHALLENGE. SO I'M GOING TO
ANNOUNCE THE WINNERS OF THIS. IT
IS BIO MEDICAL ENGINEERING
ADAPTED FOR MIDDLE SCHOOLERS. IF
YOU WILL RECALL, IT WAS A CROWD
SOURCING EFFORT TO GET NEW
CURRICULUM MOST APPROPRIATELY
TARGETED TO MIDDLE SCHOOLERS AND
BEGIN TO GET GREATER EXPOSURE OF
BIOMEDICAL ENGINEERING AND
TECHNOLOGY TO THAT POPULATION.
THIS WAS LED BY JESS NEED IN OUR
COMMUNICATIONS OFFICE. HERE ARE
THE WINNERS. THE FIRST,
NANOPARTICLES FOR DRUG DELIVERY.
THIS INTRODUCES CONCEPTS
INCLUDING EXAMPLE PRESENTATIONS,
CASE STUDIES, LAB ACTIVITIES
DESIGNED TO BE AFFORDABLE AND
SIMPLE. THIS IS A BIOENGINEERING
GRAD OF JOHNS HOPKINS AND HAS
PASSION FOR EDUCATION AND
TRAINING. THE NEXT IS IN GENETIC
TELEPHONE. A STORY-DRIVEN
JOURNEY THROUGH D.N.A. AND GENE
EDITING. DESIGNED BY A TEAM FROM
GEORGIA TECH AND PROVIDES
INNOVATIVES AND TECHNIQUES LIKE
CRISPR THAT ALLOW US TO MODIFY
THEM. THE NEXT IS ENGINEERING
DESIGN PROCESS AND SURGICAL
ROBOTS, DESIGNED BY KIERA QUINN.
ALSO AN ALUM AND GRADUATE
STUDENT. I THINK STILL GRADUATE
STUDENT AT JOHNS HOPKINS AND
INTRODUCES THE CONCEPT IN
SURGICAL ROBOTS AND GETS
STUDENTS GOING IN HANDS-ON IN
TEAMS TO DESIGN, CREATE AND TEST
THEIR OWN SURGICAL ROBOT
PROTOTYPES. FINALLY A BIONA
MATERIALS CURRICULUM DESIGNED BY
A THIRD-YEAR GRAD STUDENT AT
MAYO CLINIC, DESIGNED BY KATYL
IDEN, INTRODUCES OPPORTUNITIES
TO BIOMATERIALS AND POTENTIAL
APPLICATIONS IN MEDICINE
DESIGNED TO INSPIRE NEW IDEAS
FOR HOW TO IMPROVE MATERIALS AND
HAVE DIRECT IMPACT ON HEALTH
CARE. SHE IS PARTICULARLY
INTERESTED IN ORTHOPEDIC
MATERIALS AND FOCUS ON KNEES,
BONES THAT BREAK, JOINT
REPLACEMENTS AND SO FORTH. WE
ARE EXCITED TO ANNOUNCEMENT. AS
THESE WILL BE ROLLED OUT THROUGH
MANY DIFFERENT CHANNELS. IF YOU
ARE INTER TESTED IN
COLLABORATING IN THIS PROCESS
PLEASE CONTACT JESS. I WILL NOT
INTRODUCE RICK YET. THAT IS A
SIGN MY PRESENTATION IS OVER. I
THINK WE CAN TAKE SOME QUESTIONS
NOW.
I HAVE LULLED EVERYONE TO
SLEEP, DAVE.
>> DOCTOR, THIS IS RANU.
FIRST OF ALL I CONGRATULATE YOUR
ENTIRE GROUP OF PEOPLE AT NIBIB
FOR CONTINUING TO AMAZE US WITH
ALL THE ACCOMPLISHMENTS YOU HAVE
AND WHAT YOU ARE ABLE TO PUT
FORTH. IT IS REALLY INTERESTING
TO SEE THAT YOU HAVE GOT FROM
THE FAR END YOU ARE TALKING
ABOUT TECHNOLOGIES THAT ARE
GOING INTO MIDDLE SCHOOL. AND
OBVIOUSLY THE UNDERGRADUATE
PROGRAMS ARE DOING WELL. IF
THERE ARE WAYS IN WHICH NIBIB
MIGHT BE ABLE TO ENGAGE WITH
EVEN THOSE HBCUs YOU HAVE
BROUGHT IN TO THIS PROGRAM OF
MAKING SURE SOME OF THIS
CURRICULUM IS BEING ABLE TO BE
DISTRIBUTED TO SCHOOLS THAT MAY
NOT BE TRADITIONALLY BIOMEDICAL
ENGINEERING OR TRADITIONALLY
STRONG STEM SCHOOLS OR REGIONS
THAT HAVE THOSE CAPACITIES, THAT
WOULD BE FANTASTIC. IF WE CAN
GET MIDDLE SCHOOLERS TO LOOK. I
DON'T KNOW HOW THAT MIGHT BE
ABLE TO BE BROUGHT IN. MAYBE
ANOTHER COMPETITION FOR THESE
PEOPLE TO DO THAT, TO GET IT OUT
THERE. I DON'T KNOW ABOUT THAT.
FANTASTIC TO SEE THE MIDRI C
BEING ENGAGED AND CANCER PARTNER
BEING PUT -- YOU KNOW, ADDED ON
INTO THE RADAXIFICATION, SO TO
SPEAK. I LIKE THAT MATH WAY IS
MOVING FORWARD.
>> THANK YOU. THANK YOU. YAH,
SO WE RELY ON OUR PARTNERSHIP
WITH ALL OF YOU. YOU KNOW, WE
VIEW THIS AS A GROUP EFFORT. SO
PLEASE REACH OUT TO US WITH
IDEAS IF YOU HAVE WAYS THAT YOU
WOULD LIKE TO INTEGRATE THE
CURRICULUM OR PATHWAYS, PLEASE
LET US KNOW. WE ARE JUST KIND OF
-- IT IS OUR FIRST EFFORT IN
THAT AREA WITH MIDDLE SCHOOLERS
BUT I THINK AS YOU ALTHOUGH IT
IS CRITICAL TO GET KIDS EXCITED
EARLY, AND ACROSS A WIDE RANGE
OF PROGRAMS ACROSS THE COUNTRY.
JUST GREAT OPPORTUNITIES SO WE
LOOK FORWARD TO PARTNERING WITH
ALL OF YOU GUYS.
>> SO ONCE AGAIN, I WILL ECHO
THE AMAZEMENT OF EVERYTHING YOU
ARE DOING. FIVE YEARS. KEEP ON
INNOVATING. THERE IS NO SLOWING
DOWN. BUILDING ON RANU'S
COMMENT, I WANTED TO SEE WHETHER
THERE MIGHT BE A VEHICLE, A
WEBSITE OR SOME OTHER RESOURCE
PAGE THAT OTHERS ON THE OUTSIDE
WOULD BE ABLE TO ACCESS OR SEE
THESE TYPES OF CURRICULAR
RESOURCES. IN PARTICULAR A WAY
TO REALLY CONNECT WITH THE
TEACHERS BECAUSE, YOU KNOW, WE
CAN DEVELOP ALL THESE GREAT
THINGS AT THE STUDENT LEVEL BUT
THEY REALLY NEED TO BE
IMPLEMENTED BY THE TEACHERS.
JUST THINKING ALONG THAT LINE.
>> YAH, ABSOLUTELY. THAT IS
EXACTLY WHAT THE COMPS TEAM IS
WORKING ON AS A NEXT STEP. SO
THERE'S SOME LIKE CLOSED
CAPTIONING AND ADDITIONAL
OPTIMIZATION OF ALL THE
MATERIALS THAT WE WILL DO NOW.
AND ALL OF OUR KIND OF ON GOING
PARTNERSHIPS, TRADITIONAL ONES
LIKE WITH NSF, WE WILL GO
THROUGH THOSE AVENUES. AGAIN I
THINK THEY WILL BE WIDE BY
AVAILABLE FOR DISTRIBUTION. YOU
SHOULD TAKE THEM AND DISTRIBUTE
IN YOUR PARTICULAR NETWORKS.
LET'S KEEP THIS GOING. I MEAN, I
THINK THERE ARE A LOT OF
OPPORTUNITIES. WE JUST DID THIS
WITH A SORT OF, YOU KNOW, A CALL
OUT INTERNALLY INITIALLY FOR
GREAT IDEAS. OUR TEAM WON THIS.
BUT IT WAS REALLY JUST WITH
$25,000, YOU KNOW, OF DIRECTOR'S
FUNDS. SO THAT WAS SPLIT FOUR
WAYS EFFECTIVELY BETWEEN EACH
GROUP. AS YOU KNOW, OUR STUDENTS
AND GRADUATES ARE SO
ENTHUSIASTIC AND PASSIONATE.
MANY OF OUR COMMUNITY ARE DOING
THIS FOR FUN. SO THIS IS KIND OF
OPPORTUNITY TO TAP INTO THAT
ENERGY AND I'D LIKE TO SEE US DO
MORE OF IT. IT IS THERE. WE ALL
KNOW IT IS THERE. SO, YOU KNOW,
DEFINITELY A GREAT THING FOR US
TO DO, THANK YOU. LET'S SEE. I
THINK IT IS JENNIFER IS NEXT.
THEN SAM.
>> HI. SO I WANTED TO SAY
FIVE YEARS, WOW. YOU KNOW THSHGS
HAS BEEN A REALLY EXCITING FIVE
YEAR, SO CONGRATULATIONS AND
THANK YOU FOR LEADING FOR THESE
FIVE YEARS. YOU HAVE OBVIOUSLY
DONE A LOT OF AMAZING THINGS. A
LOT OF PROGRAMS. YOU JUST
PRESENTED NOW. WE HAVE HEARD YOU
TALK ABOUT IN THE PAST. I WANTED
TO ASK IF, YOU KNOW, YOU HAD A
VISION FOR FIVE YEARS FROM
TODAY. REALLY WHAT YOU THOUGHT
THE MOST IMPORTANT TOP IBS ARE
AND WHAT YOU'D LIKE TO HAVE
ACCOMPLISHED FIVE YEARS FROM
NOW.
>> WOW. OKAY. I'LL TRY TO
MAKE THIS VERY BRIEF BECAUSE I
WANT TO GET RICK IN. YOU KNOW,
PART OF THAT VISION IS REALLY
EMBEDDED IN A VARIETY OF
DIFFERENT LAYERS IN ALL OF THESE
ACTIVITIES IN THIS PRESENTATION.
YOU KNOW, WE ARE SEEING A
NATIONAL SHIFT IN PASSION FOR
THE AI OPPORTUNITY AND THREAT. I
THINK WE ARE IN A VERY IMPORTANT
POSITION TO BE ABLE -- YOU KNOW,
WE ARE ALWAYS WORRIED ABOUT THE
PROPER USE OF AI VERSUS
POTENTIAL DESTRUCTIVE POWER OF
AI. WE ARE UNIQUELY POSITIONED
TO MAINTAIN PROPER USAGE OF AI
AND NEED TO REALLY EXPAND OUR
VOICES AND EXPERTISE TO GET
INVOLVED IN THAT DISCUSSION. I
DO NOT WANT TO SEE A NATIONAL AI
RESEARCH RESOURCE EMERGE WITHOUT
STRONG ENGAGEMENT AND
PARTICIPATION FROM OUR
COMMUNITY. THIS REALLY SPEAKS TO
MANY OF THE RAPIDLY MOVING
TECHNOLOGIES YOU HAVE SEEN NOW.
OUR REFERENCE TO QUANTUM SENSES
AND QUANTUM TECHNOLOGIES. WE
KNOW THAT CAN DRAMATICALLY
CHANGE, POTENTIALLY
GAME-CHANGING OPPORTUNITIES FOR
A LOT OF WHAT WE DO. ULTIMATELY
LIMITED BY MATERIALS SO CONNECTS
INTO THE BUY BIOMATERIALS WORK.
IN A SENSE WE HAVE REALLY
ARTICULATED THE FOUNDATION OF
WHAT WE DO. IN THE NEXT FIVE
YEARS WE'LL CONTINUE TO EXPAND
THE CUTTING EDGE FROM A
DISCOVERY POINT OF VIEW. BUT
ALSO WITH ATTRIBUTION TO
MONICA'S ENTHUSIASM WE ARE NOT
DONE UNTIL WE CAN MOVE SOME OF
THESE CONCEPTS. THINGS THAT WE
ARE THE EXPERTS IN BUT DON'T
WANT TO LET CULTURE AND
STRUCTURE WHICH TENDS TO BE
CONSERVATIVE SLOW US DOWN FROM
MOVING THEM FORWARD TO BENEFIT
OUR HUMAN HEALTH. OUR COMMUNITY
I THINK IS ENGAGED AND EXCITED
BY DOING THAT SO WE CAN DRIVE
THAT FORWARD AND REFLECT THAT AS
WELL. I SEE RICK IS ON. HE IS
PART OF THAT FUTURE. HE WILL
TALK ABOUT THE EXPOSUM. THIS
WILL LIKELY BE PART OF OUR
ELECTRONIC HEALTH RECORDS.
EVERYONE'S ELECTRONIC HEALTH
RECORDS, AS WE MOVE FORWARD. HOW
DO WE DO THAT? HOW DO WE GET
THIS KIND OF INFORMATION BETTER
INTEGRATED. AT THE CORE IT IS
ABOUT TECHNOLOGIES. SO JENNIFER,
MAYBE A PLATONIC WEST WE'LL HAVE
MORE TIME. MAYBE NOT BECAUSE YOU
ARE PRESIDENT. BUT YOU WILL SORT
OF SEE THAT EMERGE ALSO IN THAT
CLINICAL TRANSLATION SESSION
MONDAY NIGHT.
>> THANK YOU.
>> WERE THERE ANY OTHER
HAND S?
>> YEAH SAM. YOU MAY BE ON
MUTE.
>> THANK YOU BRUCE FOR THE
EXCELLENT VIEW. I WAS GOING TO
FOLLOW UP ON THE QUESTION ABOUT
STRATEGIC PLAN FOR NIBIB MOVING
INTO THE NEXT FIVE YEARS. WE ARE
-- RELEASED THE RFI LAST YEAR
SOMETIME ABOUT IT. WHAT IS
STATUS OF THAT. SECONDLY, YOU
HAVE DONE AN AMAZING JOB FOR
RESOURCES FROM DIFFERENT AREAS
TO EXPAND OPPORTUNITIES FOR
NIBIB. THESE ARE FIRST. GIVEN
IMPORTANCE OF TECHNOLOGY AND
HEALTH CARE TODAY, HOW IT IS
GROWING AS WE SEE EVERY DAY,
WHAT SHOULD BE DONE INTO CREASE
THE BUDGET FOR NIBIB MOVING INTO
THE FUTURE?
>> WELL, OKAY SAM. FIRST ON
THE STRATEGIC PLAN, YOU SAW THE
ROLLOUT OF KEY ATTRIBUTES OF
THAT. THE VISION, THE MISSION,
THE DETAILS AND SO FORTH IN THE
LAST COUNCIL MEETING. WE HAVE
HAD LOTS OF GREAT FEEDBACK,
AFFIRMATIVE FEEDBACK, SO WE ARE
IN THE PROCESS OF TURN ING THAT
INTO A PRODUCT .
THE VARIOUS WAYS OF
DISSEMINATING. YOU CAN SEE MY
BACKGROUND. THE VISION AND SOME
OF THESE THINGS ARE BRANDED. I
HOPE THE NEXT COUNCIL WILL HAVE
THAT MORE COMPLETE ROLLOUT WITH
A VARIETY OF EXAMPLES. YOU KNOW,
KIND OF THING THAT WE CAN
DISTRIBUTE AND DISSEMINATE AMONG
COLLEAGUES AND BROADER
COMMUNITY. BUT THE ESSENTIAL
PRINCIPLES ARE UNCHANGED. THE
TECHNOLOGY ITSELF. OUR
PARTNERSHIPS IN INNOVATION. THE
IMPORTANCE OF TRAINING,
MULTI -LINGUAL WHO SPEAK THE
LANGUAGE OF TECHNOLOGY AS WELL
AS BIOLOGY AND MEDICINE. THOSE
ARE THREE GUIDING PRINCIPLES.
BECAUSE WE CAN'T REMEMBER THAT
MUCH MORE THAN THREE THINGS. SO
THAT IS KIND OF IT. OKAY. WHAT
WAS PART B.
>> BUDGET.
>> OH YAH. I CONVENIENTLY
FORGOT THAT ONE. YOU KNOW, WE
WILL NEVER GIVE UP ON THAT. BUT
YOU KNOW, WE PURSUE MULTIPLE
PATHS SIMULTANEOUSLY. CERTAINLY
WE NEVER PREDICTED THE
OPPORTUNITY TO CONTRIBUTE TO THE
NATIONAL TESTING INFRASTRUCTURE
DURING THE PANDEMIC AT SUCH
SCALE. NO MATTER EVEN IF I DID
SAY NAIVELY WHEN I CAME TO NIBIB
I'LL DOUBLE THE BUDGET. I DIDN'T
ACTUALLY THINK THAT WOULD
HAPPEN. SO WE REMAIN OPTIMISTIC
AND ENGAGED AND FORTUNATE TO
HAVE A CHAMPION LIKE MONICA --
NOT LIKE MONICA. MONICA IS A
CHAMPION FOR THE KINDS OF THINGS
WE DO AND BRINGING RIGHT TO THE
FOREFRONT AND EXPLAINING AND
ARTICULATING TO CONGRESS THE
IMPORTANCE OF TECHNOLOGIES,
DATA. SHE IS VERY VERY /*
FOCUSED ON THIS IN OUR TENURE AS
THE NIH DIRECTOR. WE WILL KEEP
DOING WHAT WE DO. PRACTICALLY
SPEAKING WE LOOK FORWARD TO ALL
YOU AND BROADER COMMUNITY BEING
ABLE TO USE THEIR VOICE TO BRING
ATTENTION TO THAT. CYNTHIA F
>> CONGRATULATION IN FIVE
YEARS, ACCOMPLISHING SO MUCH. I
THINK MIDRIC IS ONE OF THE
SHINING EXAMPLES OF WHAT YOU
HAVE ACCOMPLISHED. YOU AND I GO
BACK TO THOSE EARLY DISCUSSIONS
WHEN YOU WERE NEW AS A DIRECTOR
ABOUT WHAT WE COULD DO IN THE
DATA SCIENCE AREA. WHEN MIDRIC
WAS FORMED AROUND COVID WE HAD A
BLANK SLATE. THERE WERE NO COVID
DEPOSITORIES. I'M EXCITED TO SEE
IT MOVE INTO CANCER. THERE'S A
LOT OF OTHERS IN THAT DOMAIN.
WONDER ING IF YOU SEE POTENTIAL
BARRIERS THERE OR OTHER
COLLABORATIONS AND NOT RUN INTO
OTHER GROUPS LIKE THE CANCER
IMAGE ARCHIVE.
>> YAH THAT, IS SUCH A GREAT
QUESTION. AS I HAVE LOOKED,
PARTICULARLY IN CANCER AND MORE
TRADITIONAL DOMAINS, I THINK
THEY ARE MISSING WHAT MIDRC
BRINGS IS A UNIQUE SORT OF
PHYSICS TO MEDICINE PERSPECTIVE
WITH THAT KIND OF ATTENTION TO
SOURCE OF THE DATA. THERE ARE A
LOT OF PEOPLE WHO DRIVE BUT NOT
A LOT THAT CAN BUILD OR REPAIR
CARS. THAT HOW I FEEL ACROSS OUR
RESPECTIVE COMMUNITIES IN DATA
SCIENCE, WE HAVE A UNIQUE FEEL
FOR WHERE THE DATA COMES FROM.
YOU KNOW, WE ARE RIGHT AT THE
MACHINE LEVEL OF DATA
GENERATION. SO I THINK THAT IS
ONE OF THE THINGS THAT COMES
THROUGH VERY CLEARLY IN MANY
MIDRC, THAT SPIRIT. OF COURSE
CANCER WAS ON OPPORTUNISTIC,
WHERE THE OPPORTUNITY WAS. WE
KNEW WE HAD TO EXPAND BEYOND
COVID AND BIOMEDICAL FABRIC FROM
ARPAH WAS FOCUSED ON CANCER. SO
THAT HOPEFULLY WILL HAVE OTHER
OPPORTUNITIES AND OTHER AREAS.
BUT, YOU KNOW, STICKING WITH OUR
UNIQUE PERSPECTIVE IN EXPERTISE,
I THINK IT BRINGS SOMETHING
DIFFERENT TO MUCH OF THE WORK
THAT'S BEEN GOING ON IN AI. THEN
OF COURSE ALL THAT HAS CHANGED
JUST RECENTLY WITH THE EXPANSION
OF LARGE LARNGUAGE MODELS
GENERATIVE AI. WHAT WE WERE
DOING IS A LITTLE DIFFERENT AND
EVEN MORE CRITICALLY DEPENDENT
ON HAVING EXPERTS WHO UNDERSTAND
WHERE DID THE DATA COME FROM IN
THE FIRST PLACE. WHERE ARE
POTENTIAL BIASES. THERE ARE MANY
OF THOSE SOURCES. SO THAT IS
SORT OF THE GENERAL ROAD MAP.
RANU, MAYBE WE WILL MAKE THIS
THE LAST. I SEE RICK ON. I THINK
DAVE, WAS HE SUPPOSED TO START
15 MINUTES AGO?
>> NO, WE ARE QUITE PRECISELY
ALMOST SPOT-ON ON HIS 12:30.
WELL-DONE, BRUCE AND TEAM.
>> GOOD, GOOD.
>> IF YOU WANT ME TO GO ON I
CAN. I WAS CURIOUS YOU ARE DOING
THINGS WITH FETAL MONITORING.
BUT WHERE DO YOU THINK NIBIB
MIGHT GO WITH INITIATIVES FOR
MATERNAL HELP AS WELL AS
PEDIATRIC HELP.
>> YAH, THOSE ARE WONDERFUL
PARTNERSHIPS THAT WE'RE SO
EXCITED BY WORKING TOGETHER BY
THE NIBIB, NURSING INSTITUTE.
THE CLASSIC ROLE FOR US, WE
UNDERSTAND TECHNOLOGIES, WHERE
THEY COME FROM. THE COMMUNITY
THAT'S DEVELOPING THEM. THESE
ARE URGENT NEEDS THAT HAVE BEEN
ARTICULATED BY OUR COLLEAGUES.
SO WE ARE FORTUNATE TO GET THESE
PROGRAMS LAUNCHED AND TOGETHER.
THE RADAX MATERNAL HEALTH ARE IN
THE FINAL STAGES. THERE ARE TEN
SEMI FINALISTS. I BELIEVE AT THE
END O OF THE MONTH, THE PROGRAM
FOLKS, THERE WILL BE A DAY OF
PITCHES IN THOSE TECHNOLOGIES. I
MAY HAVE POINTED OUT IN ONE OF
THE PRESENTATIONS, AT LEAST FOUR
ARE QUITE PROMISING-LOOKING,
VIABLE TECHNOLOGIES FOR
CONTINUOUS BLOOD PRESSURE
MONITORING. NOT THE OCCASIONALLY
WORKING COMMERCIAL DEVICES THAT
WE ARE QUITE FAMILIAR WITH WUNLD
BE LESS OBTRUSIVE .ENTER NOT
REQUIRE, YOU KNOW, LIKE
CUFF LESS APPROACHES. SO WE HOPE
WE CAN SIMULATE REAL
TRANSFORMATIONAL TRANCE
INAUGU
TRANSFORMATIONAL TECHNOLOGIES.
FETAL TECHNOLOGIES ARE ABOUT THE
SAME AS THEY HAVE BEEN QUITE
SOMETIME. IN OUR CONVERSATIONS,
PARTICULARLY WITH EXPERTS THIS
SEEMS AN OPPORTUNITY TO JUMP
START THIS. THE GATES FOUNDATION
IS A CRITICAL PARTNER. THEY
ACTUALLY CONTRIBUTED A MILLION
TO THAT FETAL MONITORING TECH.
WE HAVE CONVERSATIONS WITH
MULTIPLE GATES FOUNDATION
GROUPS. THERE ARE ACTUALLY MANY
GROUPS WITHIN THE GATES
FOUNDATION INTERESTED IN
PARTNERING TO EXPAND
TECHNOLOGIES AND DIFFERENT FOCUS
AREAS FROM TB AND HIV AND
TECHNOLOGIES THAT INCLUDE
WEARABLE AS WELL AS VOLATILE
ORGANIC SENSING. SO I THINK WE
HAVE OPENED UP A WHOLE NEW WORLD
FOR THINKING ABOUT PARTNERSHIPS.
NOT JUST COME FROM NIH BUT
MULTIPLE INSTITUTES. WE CAN
REACH OUT TO FOUNDATIONS. WE
HAVE PATHWAYS. AGAIN, WE ARE
JUST REFLECTING ALL OF YOU. OUR
BIOENGINEERING COMMUNITY, OUR
ENGINEERING COMMUNITY IS AGILE
AND IS READY TO DEVELOP PROGRAMS
AND STRUCTURE TO SOLVE PROBLEMS.
NOT JUST RESIDE IN A PROGRAMMING
STRUCTURE. I THINK WE HAVE SOME
CAPACITY AND FLEXIBILITY TO DO
THAT. SO AM I ACTUALLY ON TIME?
THAT IS ALMOST UNHEARD OF.
>> DAVID GEORGE: NO COMMENT,
THIS IS GREAT. IMPRESSIVE. YOU
DO BETTER THAN DO I AT THE
COUNCIL MEETINGS.
>> I CAN'T SAY I'M BATTING A
THOUSAND AT BEING ON TIME, OR
CLOSE TO IT.
IF I COULD JUST SHARE MY SLIDES
FOR JUST A SECOND. IT IS SUCH A
COOL PICTURE. AND I'LL GO BACK
FROM THE HOLLYWOOD SQUARES. YOU
KNOW, I'M JUST SO DELIGHTED TO
INTRODUCE RICK. MY FEELING IS
SUMMARIZED BY LIKE THIS IMAGE.
THIS IS SUCH A GREAT IMAGE. AS
WE KNOW, IMAGES HAVE LOTS OF
INFORMATION CONTENT. THIS
CAPTURES SO MUCH OF RICK. BOTH
HIS KNOWLEDGE AND HIS JOY AND
HIS WONDERFUL SENSE OF HUMOR. SO
I WILL TAKE THAT DOWN NOW AND GO
BACK AND I'M GOING TO INTRODUCE
RICK MORE FORMALLY WITH A FEW
MORE WORDS. YOU KNOW, RICK THIS
IS AN IMAGING AND TECHNOLOGY
GROUPS. I HAD TO SHOW AN IMAGE
THAT SAYS MANY THINGS.
>> THAT IS GREAT. NEVER KNEW
IT WAS MAKING SUCH AN
IMPRESSION.
>> I ANALYZED IT INTENSIVELY.
IT IS ALL IN THE FREQUENCY
DOMAIN.
>> OKAY.
>> SO WE ARE REALLY LUCKY TO
HAVE RICK HERE. HE IS THE
DIRECTOR OF NATIONAL INSTITUTE
OF ENVIRONMENTAL HEALTH SCIENCES
AND DIRECTOR OF THE NATIONAL
TOXICOLOGY PROGRAM, WHICH I
DIDN'T QUITE KNOW. THAT IS A
THREE-AGENCY NATIONAL PROGRAM.
RICK LEADS THAT. PRIOR TO
BECOMING DIRECTOR OF NIEHS IN
JUNE OF 2020 HE SERVED AS DEPUTY
DIRECTOR OF NIEHS SO WAS ABLE TO
ABOUT TEN YEARS, NINE, TEN
YEARS, BUILD AND DIG IN AND GET
THOSE EXPERIENCES ABSOLUTELY
CRITICAL TO FORMULATION OF HIS
VISION. RICK, SCIENTIFICALLY IS
AMAZING. A MAMALIAN GENETICIST
AND HELPS IN OBESITY AND KIDNEY
DISEASE, HE'S MADE IMPORTANT
CONTRIBUTIONS TO UNDERSTANDING
MOLECULAR MECHANISMS OF HOW
ENVIRONMENTAL AGENTS INFLUENCE
THE EPIGENETIC EXPRESS OF GENES.
I FEEL LIKE I COULD TALK TO RICK
FOR HOURS. I'M HOPING YOU MAY
TOUCH A LITTLE IN YOUR
PRESENTATION. SOME OF RICK'S
REALLY QUITE IMPRESSIVE
EXPERIENCE, HE WAS THE PRESIDENT
AND CEO OF JACKSON LAB IN MAINE.
HE WAS ALSO THE DIRECTOR OF THE
LAB'S NCI DESIGNATED CENTER, ONE
OF THE FEW SCIENCE CANCER
CENTERS IN THE COUNTRY.
INCREDIBLY IMPORTANT ROLE. PRIOR
TO LEADING THE JACKSON LAB RICK
HAD MAJOR LEADERSHIP POSITIONS
IN ACADEMIA, GOVERNMENT AND
INDUSTRY, INCLUDING CSO AT LINKS
THERAPEUTIC, ALSO AT PARK DAVIS
SO SPENT SOME TIME IN
CALIFORNIA. PROFESSOR OF
PEDIATRICS, GENETICS AND
PHARMACOLOGY AT CASE. AT THE
TIME I DIDN'T QUITE REALIZE BUT
WE OVERLAPPED AT OAKRIDGE
NATIONAL LAB WHEN I WORKED FOR
BOTIM, DANNY NUTON. WE HAD
WONDERFUL CONVERSATIONS ABOUT
HIS TIME AND MY TIME AT OAKRIDGE
NATIONAL LAB. FINALLY, YOU KNOW,
VERY IMPORTANTLY, HE IS A
PASSION NATURAL AND INCREDIBLY
ARTICULATE ADVOCATE FOR
EXPANDING OUR UNDERSTANDING OF
THE EXPOSUM AND QUANTITATIVELY
MEASURING ITS ROLE IN HUMAN
HEALTH AND DISEASE. HE'S DONE
SIMPLY TRULY AN AMAZING JOB
EDUCATING ME AND COLLEAGUES
ACROSS THE NIH ON CRITICAL
IMPORTANCE. WE ARE ALWAYS
ARGUING FROM OUR PERSPECTIVE
THAT PRECISION MEDICINE HAS TO
BE LED BY PRECISION DIAGNOSTICS.
WHEN YOU LISTEN TO RICK IT IS
EASY TO MAKE THAT CONNECTION
THAT CRITICAL EXPOSUM
INFORMATION THAT CAN BE ACQUIRE
AND INTERPRETED USING SIMILAR
AND HIGHLY COMPATIBLE
METHODOLOGIES WE USE IN OUR
COMMUNITY, THEY HAVE TO MOVE
INTO THE EXPOSUM AS WELL. RICK,
I'M GOING TO HAND IT TO YOU TO
TAKE OFF AND EDUCATE US ON THESE
TOPICS THANK YOU FOR BEING HERE.
>> RICK WOYCHIK: TERRIFIC. WANT
TO DOUBLE-CHECK, YOU CAN HEAR
ME?
>> YES.
>> RICK WOYCHIK: ALWAYS GOOD TO
KNOW THE ZOOM IS WORKING. THANKS
SO MUCH FOR THE INVITATION TO BE
HERE. IT'S BEEN DELIGHTFUL
WORKING WITH YOU MANY IN SO MANY
WAYS. I MUST SAY I HAVE ENJOYED
ALL THE DISCUSSIONS WE HAVE HAD
ABOUT POTENTIAL PARTNERSHIPS
BETWEEN OUR INSTITUTES AND
CENTERS AT THE NIH. SO WHAT I
WILL TALK ABOUT IS SOME OF THE
RESEARCH PRIORITIES AT NIEHS. I
WILL TALK ABOUT EXPOSUM AND
THINGS WE ARE DOING AND
HOPEFULLY ANSWER QUESTIONS AND
EXPLORE ARE THERE THINGS
SPECIFICALLY GOING FORWARD WE
ARE NOT CURRENTLY DOING. LET ME
START BY TELLING YOU LITTLE
ABOUT NIEHS. SO WE GO TO THE
NEXT SLIDE. I WANT TO THANK --
WHERE IS HEATHER, TERRIFIC. THIS
IS ONE OF THE 26 CENTERS AT THE
NIEHS. WHY IT IS LOCATED IN
CENTRAL NORTH CAROLINA IN
RESEARCH TRIANGLE PARK? THERE IS
A GOOD SCIENTIFIC REASON AND
GOOD POLITICAL. THE GOOD
SCIENTIFIC IS THE WORK WE DO IS
FOCUSED ON ENVIRONMENT AND
PUBLIC HEALTH. IF THE NIEHS IS
GOING TO POSITION INSTITUTE
DEDICATED TO PUBLIC HEALTH AND
ENVIRONMENT, RTP IS JUST DOWN
THE STREET FROM UNIVERSITY OF
NORTH CAROLINA SCHOOL OF PUBLIC
HEALTH, ONE OF THE BEST SCHOOLS
IN THE COUNTRY. DUKE UNIVERSITY,
WHICH IS VERY CLOSE BY HAS A
VERY STRONG PROGRAM IN THE
ENVIRONMENT. NORTH CAROLINA
STATE HAS A FABULOUS AND VERY
STRONG PROGRAM, TOXICOLOGY
SCIENCE. IT JUST MAKES A LOT OF
SENSE. IF YOU ARE GOING TO
LOCATE INSTITUTE DEDICATED TO
THE ENVIRONMENT YOU'D PUT IN
CENTER OF NORTH CAROLINA. TURNS
OUT THE GOOD POLITICAL REASON IS
THE GOVERNOR OF NORTH CAROLINA
DELIVERS NORTH CAROLINA TO
KENNEDY IN THE ELECTION SO QUID
PRO QUO WAS WHEN THE GOVERNMENT
NEEDED ANCHOR TENANT FOR THIS
MODEL, KIND OF A SILICON VALLEY
HERE, HE NEED ED THIS , NIEHS IS
THAT ANCHOR TENANT. WE ARE PROUD
AND DELIGHTED TO BE HERE. IT IS
GREAT TO HAVE THIS OPPORTUNITY
TO INTERACT WITH THE STRONG
ACADEMIC ORGANIZATIONS IN
CENTRAL NORTH CAROLINA. SO WE
HAVE JUST LIKE MANY OF THE
OTHER, WE HAVE OUR INTRA
INTRAMURAL LABORATORIES AND THIS
LAB THIS COLLABORATED WITH THE
FDA AROUND TOXICOLOGY PROGRAM.
WE BRING INNOVATIVE NEW
TECHNOLOGIES AND APPROACHES TO
STUDY TOXICOLOGY, IN
COLLABORATION WITH OTHER FEDERAL
AGENCIES TO TAKE ON SOME OF THE
BIG CHALLENGES ON A NATIONAL
SCALE IN TOXICOLOGY SCIENCE. WE
HAVE THE EXTRA MURLAL FUNDING,
DRT, RESEARCH AND TRAINING AND A
SMALL PROGRAM HERE. IT IS AN
INSTITUTE DEDICATED -- THE NEXT
SLIDE.
IF YOU WANT TO KNOW WHAT WE DO,
LOOK AT THE MISSION AND
DIVISION. ONE OF MY FIRST JOBS
WAS WORK WITH OUR DIRECTOR,
LINDA BRAMBAUM, TO START THE
PROCESS. WE ARE GOING THROUGH
THE THIRD REVISION.LY TALK ABOUT
SOME OF THOSE AREAS IN A MINUTE.
THE MISSION OF NIEHS IS TO
DISCOVER HOW THE ENVIRONMENT
AFFECTS PEOPLE IN ORDER TO
PROMOTE HEALTHIER LIVES. AS
BRUCE AND I HAVE TALKED IN GREAT
DETAIL, I'M A GENETICIST BY
TRAINING BUT DOM REALIZE IF YOU
WANT TO IMPLEMENT ON POSITION
AND UNDERSTAND THE ETIOLOGY OF
HUMAN DISEASE IT HAS TO GO
BEYOND SEQUENCING GENOMES AND
THINGS THAT CONTRIBUTE TO
DISEASE. THAT IS CLEARLY
IMPORTANT BUT THE ENVIRONMENT
CAN MAKE PEOPLE SICK OR CAN HELP
PEOPLE STAY HEALTHY. WE HAVE TO
FACTOR THAT INTO THE EQUATION.
SO THE VISION OF NIEHS IS TO
PROVIDE GLOBAL LEADERSHIP FOR
INNOVATIVE RESEARCH THAT
IMPROVES PUBLIC HEALTH BY
PREVENTING DISEASE AND
DISABILITY. THE PREVENTING PART
IS A DIF REN S DIFFERENTIAL FOR
US. WE WORK WITH CANCER BUT LIKE
TO THINK WE CAN IDENTIFY
POTENTIALLY ENVIRONMENTAL
EXPOSURES THAT WOULD TRIGGER
CANCER TO PREVENT EXPOSURE TO
SOME OF THOSE ELEMENTS AND
PREVENT CANCER IN THE FIRST
PLACE. THAT IS A LITTLE ABOUT
NIEHS AND OUR MISSION AND
VISION. LET'S GO TO THE NEXT
SLIDE .
THE LIMITED TIME I HAVE, LET'S
DIG INTO SOME OF THE EMERGING
SCIENTIFIC PRIORITY AREAS. SO WE
ARE CURRENTLY IN OUR NEXT ROUND
OF STRATEGIC PLANNING. WE HAVE
REACHED OUT TO THE GLOBAL
ENVIRONMENTAL HEALTH SCIENCE AND
BIOMEDICAL COMMUNITIES AND
ASKING WHAT SHOULD WE FOCUS ON.
I TRY TO COVER SEVERAL. ONE, AS
BRUCE INDICATED, IS EXPOSUM. WE
HAVE LAUNCH ED THIS PROGRAM WE
CALL PRECISION ENVIRONMENTAL
HEALTH THAT. IS THE RECOGNITION
THAT PEOPLE RESPOND TO
ENVIRONMENTAL EXPOSURE. THE
POSITIVE OR NEGATIVE
ENVIRONMENTAL EXPOSURES
DIFFERENTLY BASED ON DIFFERENT
GENETICS AND BIOLOGY. WE ARE
TRYING TO FIGURE HOW DO WE
DEVELOP A PROGRAM THAT BUILDS ON
THE PRECISION MEDICINE PROGRAM
BUT FACTORS THE EXPOSUM AND
ENVIRONMENT SO I WILL TALK ABOUT
THE TRANSLATION OF TOXICOLOGY.
THERE IS A BIG NIEHS-WIDE EFFORT
THAT NIEHS IS PARTICIPATING IN
CLIMATE CHANGE AND HEALTH.LY
TALK BRIEFLY ABOUT THAT. VERY
BRIEFLY ABOUT ENVIRONMENTAL
JUSTICE, COMPUTATIONAL DATA AND
SCIENCE. FOCUSSING ON EXPOSUM,
THE TRANSLATION TO BIOMEDICINE
AND TOXICOLOGY. LET'S START WITH
THE EXPOSUM.ENTERTHIS IS A
CONCEPT ORIGINALLY PROMOTED IN
CRISIS WILDE IN 2005. HE
RECOGNIZED IF WE TRULY WANT TO
UNDERSTAND THE IMPACT OF THE
ENVIRONMENT WE HAVE TO GET
BEYOND STUDYING ONE EXPOSURE AT
A TIME. THIS WAS HAPPENING
SIMILAR TO GENOME PROJECT. IF WE
WANT TO UNDERSTAND THE PROJECT
WE HAVE TO UNDERSTAND ONE GENE
VARIANT AT A TIME. HE BUILD ON
THE GENOME CONCEPT AND PROPOSED
THIS EXPOSUM. SO THE EXPOSUM IN
THE LOWER PANEL IN BLUE HE IS
BASICALLY SAYING IF YOU WANT TO
UNDERSTAND THE IMPACT OF THE
ENVIRONMENT IT CAN'T JUST BE
ABOUT ONE FLAME RETARDANT OR ONE
PESTICIDE OR PM25 IN AIR
POLLUTION. WE ARE EXPOSED TO ALL
THESE THINGS IN THE WATER AND
SOIL. WE NEED TO BUILD A
FRAMEWORK , A RESEARCH FRAMEWORK
THAT ALLOWS US TO FACTOR ALL
THESE DIFFERENT ELEMENTS, THE
PHYSICAL AND CHEMICAL ELEMENTS
INTO THE EQUATION. THAT IS WHERE
BRUCE AND I WERE TALKING OF
THAT. WE NEED HELP IN NIBIB CAN
BE A VERY IMPORTANT PARTNER WITH
US IN DEVELOPING SOME OF THESE
TOOLS. BUT CAN'T BE ALSO JUST
ABOUT THE PHYSICAL AND CHEMICAL
ELEMENTS, AS SHOWN ON BANTIB BO
THIS IS A SCIENCE ARTICLE BY
SOME OF OUR GRANTEES. VERMILION
AND MILLER IN PARTICULAR.
PROMOTE ING THIS CONCEPT AND
DEVELOP THIS DIAGRAM. IT IS NOT
JUST ABOUT THE PHYSICAL CHEMICAL
BUT HOUSEHOLD INCOME, SOCIAL
CAPITAL, CULTURAL NORMAL,
PSYCHOSOCIAL STRESS. WE
RECOGNIZE THIS IS A MAJOR
FACTOR, MAJOR ENVIRONMENTAL
FACTOR THAT CAN BE INFLUENCING
HEALTH AND WELL-BEING BUT SHOULD
BE ABOUT PHYSICAL ACTIVITY,
SLEEP BEHAVIOR, SMOKING, DIET IS
A BIG ONE. WE ACTUALLY KNOW IN
ENVIRONMENTAL HEALTH SCIENCES
COMMUNITY THERE ARE MANY
ELEMENTS OF THE DIET CAN
POSITIVELY INFLUENCE HEALTH. IN
FACT, SOME CAN MITIGATE SOME OF
T
THESE IN THE PANEL. WE NEED TO
FACTOR ALL THESE THINGS INTO THE
EQUATION. SO THAT IS WHAT
EXPOSUM IS. I REMEMBER WHEN
TALKING WITH FRANCIS COLLINS, HE
SAID RICK THIS IS GREAT. I AGREE
WE NEED TO FACTOR THESE THINGS
INTO THE EQUATION. HOW DO WE DO
AN EXPERIMENT? WE NEED AN
OPERATIONAL DEFINITION. YOU
CAN'T DO EVERYTHING. THERE IS
ALSO THE RECOGNITION THAT
ACTUALLY WAS INTRIGUING TO TALK
ABOUT PEDIATRIC EXPOSURES
BECAUSE WE HAVE DATA -- ACTUALLY
DATA FROM MY OWN LAB TO INDICATE
EXPOSURE DURING PREGNANCY. NOW
BEGINNING TO UNDERSTAND
EXPOSURES TO THE PARENTS BEFORE
CONCEPTION CAN BE INFLUENCING
HOW GENES ARE OPERATING MUCH
LATER IN LIFE. WE NEED A
OPERATIONAL DEFINITION. THE
SECOND POINT IS KEY. THAT IS WHY
I'M SO HAPPY TO BE PRESENTING TO
ALL OF YOU. WE ARE GOING TO HAVE
TO BUILD NEW TECHNOLOGIES TO
STUDY THE EXPO SUM. THAT ARE
HIGH THROUGHPUT, LOW COST, THAT
WE CAN APPLY TO POTENTIALLY
MILLIONS OF DIFFERENT
INDIVIDUALS. CAPTURING THIS
DATA. AS BRUCE INDICATED WE LOVE
TO THINK THAT YOU EVENTUALLY AND
HOPEFULLY IN NEARER TERM THAN
LONGER TERM THAT PHYSICIANS
WOULD COME TO BEDSIDE WITH NOT
ONLY SEQUENCE AND BETTER
UNDERSTANDING OF GENETIC
PREDISPOSITION BUT WHAT ARE SOME
OF THE EXPOSURES THAT COULD BE
WORKING POTENTIALLY SIN
SYNERGYSTICALLY TO BIOLOGICAL
FUTURES TO UNDERSTAND THE
ETIOLOGY OF HUMAN DISEASE. THERE
IS THIS PRAGMATIC EXPOSUM. LIKE
THE GENOME PROJECT .
THE BOLD VISION IN THE 80s,
WHERE WE WILL SEQUENCE THE
GENOME AND DO THIS STUFF THAT
WILL TRANSFORM GENETICS BUT IN
THE EARLY DAYS I DON'T THINK
ANYONE KNEW HOW WE WERE GOING TO
ACTUALLY DO IT. SO WE STARTED
WITH TECHNOLOGIES WE HAD
AVAILABLE. MANY OF YOU MAY
REMEMBER SOME OF THOSE CDNA
CLONES SPOTTED MICRO ARRAYS ON
SLIDES, SO THAT WAS A STEP IN
THE RIGHT DIRECTION. OF COURSE
ULTIMATELY WE DIDN'T REALLY
UNDERSTAND HOW ULTIMATELY WE
COULD BE LOOKING AT WHOLE GENOME
SEQUENCES AND DOING RNA SEEK AND
TYPE THINGS WE CAN DO TODAY. SO
STARTING WITH THINGS WE CAN DO
WITH UNDERSTANDING THAT WE NEED
TO DEVELOP BOLD AND INNOVATIVE
HIGH THROUGHPUT, LOW COST
STRATEGIES TO CAPTURE THE
EXPOSUM. LET'S GO TO THE NEXT
SLIDE. HOW ARE WE GOING TO DO
THIS? WHAT WE HAVE TO DO IS GET
PEOPLE WORKING TOGETHER. UP
UNTIL THIS POINT SINCE 2005
PEOPLE HAVE BEEN THROWING OUT
THE TERM EXPOSUMN. REALITY THEY
ARE STUDYING ONE EXPOSURE. THE
OTHER QUESTION IS THE BIG
QUESTION IS WHERE DO THESE FIT?
CAN WE CAPTURE CHANGES THAT SAY
FOR EXAMPLE DURING PREGNANCY
THAT CAN PREDISPOSE CHANGES IN
THE WAY THE GENES ARE WORKING
LATER IN LIFE. SO WE NEED TO
DEVELOP THIS CONCEPTUAL
FRAMEWORK. SO WHAT WE HAVE DONE
IS WE HAVE MET AND TALKED ABOUT
DEVELOP ING THIS GLOBAL RESEARCH
COORDINATION TO ACCELERATE
PRECISION ENVIRONMENTAL HEALTH.
AGAIN I WILL TALK ABOUT THIS IN
A MINUTE. WE NEED TO DEVELOP A
COMMONLY AGREED FRAMEWORK FOR
THE ECONOMICS, PROMOTE BEST
PRACTICES, DATA SHARING AND
BUILD GLOBAL EXPOSUM COMMUNITY
TO FOSTER NATIONAL AND
INTERNATIONAL COLLABORATION.
THERE ARE THREE AND WE ARE
WORKING THROUGH DEVELOPING THEM.
THE KEY IS DEVELOP THAT GLEE
BALL COMMUNITY .
THE EUROPEAN UNION HAS BEEN
WORKING ON DEVELOPING RESEARCH
STRATEGIES FOR EXPOSOMICS FOR A
NUMBER OF YEARS. WE DON'T WANT
TO COMPETE WITH THEM. WE WANT TO
WORK COLLABORATIVELY WITH THEM.
THAT IS WHERE I THINK THE GENOME
PROJECT, INITIALLY WHEN
LAUNCHED, ONE GROUP AND ONE
COUNTRY COMPETING. ONCE WE
DEDECIDE TO FRANCIS COLLINS
CREDIT, ONCE WE STARTED
COLLABORATING THE JOB GOT DONE.
THE SPIRIT OF COLLABORATION
DECIDE WHAT THIS IS, WHAT DATA
DO WE COLLECT, WHERE DOES DA
SHARING AND DATA MANAGEMENT
PLANS AND THAT HAS TO BE AN
IMPORTANT PART BECAUSE ARE
COLLECTING ALL THESE DIFFERENT
TYPE OF DATA PART OF THE
FRAMEWORK. SO THAT IS WHAT WE
HOPE TO DO. NEXT SLIDE. THE GOOD
NEWS IS IN COLLABORATION, NOT ON
HERE. WE HAVE FULL SUPPORT FROM
BRUCE AND OTHERS. SO WE ARE
FUNDING A CENTER FOR RESEARCH
COORDINATION. WE RELEASED A NOFO
IN SEPTEMBER. REVIEWING
APPLICATIONS AND HOPE TO HAVE
THIS FUNDED IN THE SUMMER .
THE IDEA IS THIS IS GOING TO BE
DEDICATED TO WORKING WITH GLOBAL
COMMUNITY TO OPERATIONAL IZE
EXPOSUM SCIENCE SO TUNED AS WE
FLESH OUT DETAILS BRUCE AND I
WILL DISCUSS THESE THINGS. WE
ARE LOOKING FORWARD TO
COOPERATION AND COLLABORATION
WITH NIBIB. THE NEXT SLIDE, THAT
IS THE EXPOSUM. I HAVE LIMITED
TIME SO I CAN'T GO INTO GREAT
DETAIL IN ALL THESE SIX AREAS.
SO THIS IS ONE I'M INTERESTED IN
AND ADDRESSES THE RESPONSE. THE
FACT, JUST LIKE PRECISION
MEDICINE, WE ALL DON'T RESPOND
TO A BEGIN TREATMENT OR SAME
PREDISPOSITION TO DISEASE. IT IS
A FUNCTION OF OUR INDIVIDUAL
GENETICS. WE ARE ARGUING
POTENTIALLY PART OF YOUREN
EPIGENETIC HERITAGE. THIS IS
BUILDING ON PRECISION MEDICINE
BUT BRINGING GENE EFFECTS INTO
THE EQUATION. THE GOAL, AS MANY
GRANTEES HAVE DEFINED THIS, THE
GOAL IS GENETICS AND EPIGENETICS
DATA. G BY E BY D. ONE OF THE
CHALLENGES IN PRECISION
ENVIRONMENTAL HEALTH AS WE HAVE
WITH PRECISION MEDICINE IS THERE
IS NO SINGLE GEEN THAT HAS THE
VARIATION, NO GENE THAT IS
EPIGENETICALLY IDENTIFIED THAT
CAN BE INFLUENCING OUTCOMES AS A
CONSEQUENCE OF EXPOSURES. MOST
ARE FALLING INTO THE COMPLEX
TRAITS. THERE ARE POTENTIALLY
HUNDREDS OF THOUGHS OF THE GENES
THAT CAN BE INFLUENCING HOW AN
INDIVIDUAL RESPONDS TO THE
ENVIRONMENT. AGAIN THIS FALLS
INTO THIS CATEGORY OF COMPLEX
TRAITS. DO WE HAVE TO DO THIS?
BUILD ALL THE TOOLS TO MANAGE
COMPLEX TRAITS ON OUR OWN IN
ENVIRONMENTAL HEALTH SCIENCES
COMMUNITY OR LATCH ONTO OTHER
PROGRAMS THAT HAVE TAKE N ON
THIS CHALLENGE AND SO THAT IS
WHAT WE HAVE DECIDED TO DO. NEXT
SLIDE, I JUST WANT TO CALL YOUR
ATTENTION TO THE FACT THERE IS A
NEW COLLABORATION CALLED
INTERNATIONAL COMMON DISEASE
ALLIANCE. THIS WAS AN AN LINES
LAUNCHED IN SEPTEMBER OF 2019. I
WAS THE REPRESENTATIVE FROM
NIEHS WHO PARTICIPATED ON THIS.
ERIC LANDER AND FRANCIS COLLINS
CALLED TOGETHER THE GLOBAL
GENETICS COMMUNITY. BASICALLY
PRESENT ED A CHALLENGE. IF WE
TRULY WANT TO WORK OUT COMPLEX
TRAITS, WE ARE GOING TO NEED
LARGE COHORTS BECAUSE MAY
POTENTIALLY BE HUNDREDS OF
DIFFERENT GENES AND VARIANTS
THAT CAN CONTRIBUTE TO MEDICALLY
RELEVANT DISEASE PHENOTYPES. SO
DO WE ALL WORK IN COMPETITION
WITH EACH OTHER OR ON A GLOBAL
COMMUNITY KIND OF DEVELOP COMMON
COMPLEX TOOLS TO SEEM LESSLY
SHARE DATA. WE TALKED ABOUT THE
CHALLENGE, MAPPING TO MECHANISMS
TO MEDICINE. BUT THE BOTTOM LINE
IS WE NOW HAVE THIS COMMON --
INTERNATIONAL COMMON DISEASE
ALLIANCE. SO THE STRATEGY WE ARE
USING IS, LET'S BUILD ON THE
ICDA. LET'S BRING TO THE ICDA
THE NEED TO COLLECT THIS DATA
AND INTEGRATE THAT INTO THE
DATABASES DEVELOPED TO STUDY
COMPLEX TRAITS. HOPEFULLY THIS
WILL BE ENORMOUSLY HELPFUL AS
RELATES TO STUDYING THE
ENVIRONMENT EFFECTS. THE NEXT
SLIDE. THE TANGIBLE STEP WE HAVE
TAKEN IN THIS DIRECTION IS WE
CAN WORK IN OUR OWN BACKYARD.
MANY OF YOU ARE SURE ARE AWARE
OF THE ALL OF US, ONE MILLION
COHORT, THAT IS AT THE CORE OF
THE PRECISION MEDICINE PROGRAM
AT THE NIH. THIS IS ABOUT
TREATMENT AND CARE. IT IS REALLY
PROVIDES ACCESS TO EXPANSIVE
HEALTH DATA FROM DIVERSE
POPULATIONS. SO WE ARE LUCKY
ENOUGH THAT JOSH DEN DAI NY, THE
CEO AND JEFF GINSBURG, OF THE
PROGRAM THEY UNDERSTAND THE
ENVIRONMENT PLAYS A CRITICALLY
IMPORTANT ROLE. NEXT SLIDE. SO
WORKING TOGETHER WITH JEFF AND
WITH JOSH AND THEIR COLLEAGUES
-- MANY OF THEIR COLLEAGUES
ACROSS THE ALL OF US PROGRAM, WE
ARE NOW INCLUDING INTO THIS --
YOU KNOW, WE GOT THE PIECE OF
THE PIE. THE ENVIRONMENTAL DATA.
WE ARE INTEGRATING THAT INTO THE
DATASETS COLLECTED AS PART OF
THE ALL OF US PRECISION
MEDICINE. SO NEXT SLIDE. SO WE
ARE DOING INTEGRATING
ENVIRONMENT IN PHASES. SO THE
PHASE I IS INCREASING
RECOGNITION IF YOU KNOW WHERE
SOMEONE LIVES OR WHERE THEY HAVE
LIVED, SAY DURING PREGNANCY OR
WHERE THEY WORK OR WHETHER THEY
HAVE WORKED, KNOWING SOMETHING
ABOUT THE GIS COORDINATES CAN
HELP US TO UNDERSTAND WHAT ARE
THEIR LEVELS OF XING POE SURE TO
DIFFERENT ENVIRONMENTAL
TOXICANTS. FOR EXAMPLE, AIR
POLLUTIONF YOU LIVE NEXT TO THE
A MAJOR FREEWAY, THE
ENVIRONMENTAL HEALTH SCIENCES
COMMUNITY HAS DEVELOPED ROBUST
TOOLS TO HELP US CORRELATE THE
ENVIRONMENTAL EXPOSURES FROM
PM2.5, THE PARTICULATE MATTER TO
INDIVIDUALS. THE FIRST PHASE IS
GO BACK, AS THEY ARE DOING.
INTEGRATE THE GIS COORDINATES
INTO DATA SETS FOR ALL THE
INDIVIDUALS THAT ARE PART OF THE
ALL OF US PROGRAM. THE SECOND
PHASE, AND THIS IS WHERE I THINK
NIBIB CAN HEM US, DEVELOP THOSE
TOOLS. THE BIOINFORMATICS AND
COMPETITIONAL TOOLS TO CORRELATE
THE GIS LOCATION, WHERE YOU LIVE
AND WORK, WITH THE EXPOSURE TO
DIFFERENT TOXICANTS. PHASE 3 IS
MUCH MORE ELABORATE TO
INCORPORATE A MORE DETAILED
ANALYSIS LOOKING AT EPI GENETICS
AND MORE THOROUGH ANALYSIS OF
DIFFERENT CHEMICALS THAT MAY BE
PRESENT. I DON'T HAVE TIME TO GO
THROUGH THE DETAILS. THAT IS
WHAT WE ARE DOING IS ADVANCING
PHASE 3 TRIAL USING A SMALL
COHORT OF THE ALL OF US TO STUDY
TYPE 2 DIABETES. IN THE INTEREST
OF TIME LET'S GO TO THE NEXT
SLIDE. AS AN EXAMPLE IF YOU HAVE
GEOSPATIAL DATA YOU CAN CROSS
CONFERENCE THE AIR QUALITY
MODELS. YOU CAN FOR EXAMPLE GET
AN ESTIMATE WHAT PEOPLE WERE
BREATHING AS CONSEQUENCE OF THE
CANADIAN WILDFIRES THIS LAST
JULY. WE HAVE DAILY CLIMATE
DATA. WE HAVE THE CDC SOCIAL
VULNERABILITY INDEX. SO IF YOU
LIVE WHERE SOMEONE WORKS IT
GIVES YOU BETTER SENSE OF WHAT
TYPES OF EXPOSURE THEY HAVE BEEN
EXPERIENCING. ULTIMATELY WE
WOULD LIKE TO GO BEYOND USING
GIS DATA BUT LOCATING MORE
DETAIL AT SOME OF THE PARAMETERS
AND CORRELATING THAT WITH FULL
SACRUMS TO DO THE COMPLICATED
EXPERIMENTS. LET'S GO TO THE
NEXT SLIDE. SO I'M GOING TO JUST
ANOTHER AREA OF FOCUS IS, YOU
KNOW, THE TRADITIONALLY WE HAVE
DONE A LOT OF WORK IN
TOXICOLOGY. TRADITIONALLY YOU
TAKE SOME RATS OR GIVEN IM BRED
STRAIN OR BACKGROUND. DOSE THESE
MICE AT -- WITH DIFFERENT
CHEMICALS AT DIFFERENT DOSES AND
COUNT LUMPS AND BUMPS, CANCER
AND LOOK AT DEATHS OVER A PERIOD
OF TIME. THAT GAVE YOU SOME
ESTIMATE WHETHER SOMETHING IS
POTENTIALLY CANCER PROMOTING OR
CANCER CAUSING OR WHETHER CAUSES
NEUROLOGICAL DISEASE. SO WHAT WE
HAVE COME TO RECOGNIZE IS WE
TRULY WANT TO UNDERSTAND THE
IMPACT OF THE ENVIRONMENT, WE
HAVE TO GET BEYOND JUST THESE
EXPOSURE ASSESSMENTS. SO THERE
SAKE FOCUS IN GETTING AT THE
MOLECULAR MECHANISMS, DRUGS AND
ENVIRONMENTAL TOXICANTS AFFECT
BIOLOGY BY INTERFERING WITH THE
NORMAL PATTERNS OF GENE
EXPRESSION. WHAT ARE THOSE
IMPACTED BY DIFFERENT CHEMICAL
EXPOSURES OR BY EXPOSOMIC
EXPOSURES. SO FOR EXAMPLE HOW IS
THE EPIGENOME CHANGED AS
CONSEQUENCE OF EXPOSURE. SO THIS
IS A BIG FOCUS OF OUR SECOND
DIVISION CALLED DIVISION OF
TOXICOLOGY SO THAT WORK CLOSELY
WITH CDC AND FDA AS PART OF THE
PROGRAM. WE ARE VERY INTERESTED
IN DEVELOPING LARGE DATA SETS
USING AI AND ML. IT WAS A TREAT
TO HEAR A LITTLE ABOUT THE
INTEREST IN AI AND NML. SO DO IT
EFFECTIVELY YOU HAVE O ARE HAVE
GOOD DATA SETS THAT. IS WHY WE
ARE FOCUSSING. ALSO, PROBABLY
MOST IMPORTANTLY, IS WE ARE
INTERESTED IN DEVELOPING THE
MICRO PHYSIOLOGICAL 3D SYSTEMS
DERIVED FROM IPSCs AND
DEVELOPMENT OF THE NABS OR NEW
APPROACH METHODOLOGIES. AGAIN, I
DON'T HAVE TIME. I'M KIND OF
RUNNING OUT OF TIME ALREADY. I
WANT TO CALL YOUR ATTENTION.
BRUCE IS PROBABLY TALKED TO YOU
ABOUT THIS ALREADY. IT IS A NEW
EMERGING CONCEPT CALLED --
COMPLIMENTARY RI
EXPERIMENTATION. THIS IS ABOUT
DEVELOPING,
DEVELOPING, STANDARDIZING
METHODOLOGIES THAT CAN CHANGE
THE WAY WE DO BASIC AND CLINICAL
SCIENCE. IT IS ABOUT DEVELOPING
THESE NEW TOOLS SO YOU CAN TEST
YOUR DRUGS OR TEST DIFFERENT
CHEMICAL AGENTS. TO GET BETTER
SENSE OF WHAT SPECIFIC
BIOLOGICAL PROCESSES ARE YOU PER
TUSH G /* /* -- PERTURBING. WE
ARE NOT GOING TO SAY H IS GOING
TOAL LI TO ELIMINATE THE NEED O
MODELS BUT COMPLEMENT IT. AS
BRUCE INDICATED, THE FORMER
DIRECTOR OF JACKSON LABORATORY,
I CAN SAY THERE IS STILL A ROLE
FOR MICE IN BIOMEDICAL SCIENCE.
THIS IS A WAY TO COMPLEMENT AND
BRING SAY DIVERSE SET OF HUMAN
GENOMES IN FORM OF POPULATIONS
OF IPSLs TO BEAR ON BETTER
UNDERSTANDING INDIVIDUAL
VARIATION AS RELATES TO, YOU
KNOW -- AS RELATES TO
TOXILOGICAL OUTCOMES. LET ME --
ACTUALLY IN INTEREST OF TIME SO
CAN WE GO TO END TO LOOK AT WAYS
WE ARE COLLABORATING ALREADY?
I'M GOING TO SKIP OVER A FEW.
THERE ARE CURRENT COLLABORATIONS
BETWEEN NIEHS AND NIBIB. I DON'T
HAVE TIME TO GO THROUGH ALL OF
THEM. SO BRUCE THANK YOU FOR
YOUR WILLINGNESS TO WORK WITH
US. THERE IS THIS MACHINE
ENABLED TRACKING FOR
CROSS-SPECIES EXTRAPOLATION. I
DON'T KNOW ALL THE DETAILS BUT
OUR DBM -- HEAD OF OUR
VETERINARY SERVICES HERE IN OUR
-- VETERINARY RESEARCH PROGRAMS,
ANDRE COBBLE, EXCITED WORKING
WITH YOU. DEVELOPING NATIVE NEW
TOOLS FOR HOW DO WE WORK AT
THIS, HOW DO WE LOOK AT MICE AND
LOOK AT BEHAVIORS ASSOCIATED
CHANGES ASSOCIATED WITH
ENVIRONMENTAL EXPOSURE. NEXT
SLIDE. YOU PROBABLY ARE ALREADY
AWARE OF THIS BUT NIBIB HAS BEEN
WORKING WITH US AND OTHER
INSTITUTES AND CENTERS AROUND
DEVELOPING TISSUE CHAPS. SO
THERE IS A LOT OF FUTURE AND
DEVELOPING THESE TYPES OF
TISSUES SO WE CAN BETTER
UNDERSTAND ENVIRONMENTAL
EXPOSURES ONNED HOW THE PATH--
HOW THEY ARE DISRUPTED. MY
CHALLENGE AS GENETICS AND GENOME
MAKES PERSON WE HAVE PHENOMENAL
CAPABILITIES. WHO WOULD ARE
THOUGHT IN 80s WE WOULD SEQUENCE
THE ENTIRE GENOME LESS THAN A
THOUSAND, CAPTURE
METHYLATIOTION, PROTENOMICS. WE
NEED TO BRING INTEREST TO BEAR
ON TAPES TYPES OF CAPABILITIES
AND THE ENVIRONMENT. THAT IS WHY
WE NEED YOUR HELP. JUST GOING
THROUGH HERE, AS BRUCE INDICATED
I THINK WE ARE DESPERATELY IN
NEED OF INNOVATIVE THINKING ON
WHOLE AREA OF EXPOSUM AND
PRECISION ENVIRONMENTAL HEALTH,
BRING THE DATA SETS TO BETTER
UNDERSTAND HOW COMPLEX GENETIC
TRAITS WORK TOGETHER WITH
COMPLEXEN BY GENETIC TRAITS TO
ULTIMATELY TRIGGER DISEASE
PHENOTYPES. SO MAY BE DIFFERENT
NEUROLOGICAL DISORDERS THAT ARE
SAY THE GENETICS ORREN GENETICS
PRIMES THE INDIVIDUAL TO DEVELOP
THE DISEASE BUT EXPOSURE TO THAT
PESTICIDE THAT MAY TRIGGER THE
PHENOTYPE. IN THIS WHOLE AREA OF
PREDICTIVE TOXICOLOGY, NEW
APPROACH METHODOLOGIES ARE
CRITICALLY IMPORTANT. I THINK
THAT IS AN AREA RIPE FOR
OPPORTUNITIES COLLABORATION
BETWEEN NIBIB AND NIEHS. WE ARE
THE BIOLOGISTS SO WE NEED TO GET
WORKING TOGETHER WITH ALL OF YOU
AT NIBIB. LET'S GO TO THE NEXT
SLIDE. I THINK THAT IS IT. THANK
YOU ALL FOR THIS OPPORTUNITY.
HOPEFULLY THIS GIVES YOU A
LITTLE SENSE OF SOME OF THE
THINGS WE ARE DOING. MOST
IMPORTANTLY SOME OF THE HUGE
AREAS OF CHALLENGE. WE ARE THE
BIOLOGISTS. WE HAVE TO BE
WORKING WITH THE TECHNOLOGISTS
TO COME UP WITH INNOVATIVE NEW
STRATEGIES LIKE WE DID AT THE
OAK LABORATORY, RIGHT BRUCE? I
HAD MANY OPPORTUNITIES INTERFACE
WITH KWAN AND OTHERS. WHEN YOU
BRING PEOPLE WITH DIFFERENT
CAPABILITIES AND EXPERTISE
TOGETHER, MAGIC CAN HAPPEN. LET
ME STOP AT THIS POINT. HAPPY TO
ADDRESS COMMENTS OR QUESTIONS.
>> THANK YOU, RICK.
AGAIN THANKS FOR THE INVITE.
GREAT TO BE HERE. I SEE DAN'S
HAND IS UP. DAN, WHY DON'T YOU
LEAD US OFF.
>> ABSOLUTELY. SO THANK YOU,
DR. WOYCHIK FOR COMING AND TAKE
TIMING TO INTRODUCE US TO YOUR
INSTITUTE'S PRIORITIES. I
ACTUALLY WANTED TO FOLLOW UP ON
THE LAST FEW SLIDES THAT YOU
SHOWED, WHICH ARE SORT OF THE
PROVOCATIVE SLIDES FOR US TOOL
DEVELOPERS.
>> YEP.
>> I WANTED TO ASK MAYBE --
TO DIG IN A LITTLE MORE ABOUT
WHAT TYPES OF TECHNOLOGIES THAT
MIGHT FALL IN AN IB WHEEL HOUSE,
MOST NEEDED, IN YOUR VIEW NOW,
TO ASSESS ENVIRONMENTAL HEALTH.
WHICH NEED TO BE CONTINUOUS AS
OPPOSED TO SPORADIC. YOU SHOWED
GEE YOU KNOW -- GEOSPATIAL. IS
IT A CHIP OR IMAGING HAVE A ROLE
TO PLAY? OTHER TYPES OF SENSORS
YOU SEE AS PARTICULARLY KEY?
>> WELL, IT IS -- THERE ARE
MANY DIFFERENT OPPORTUNITIES
HERE. SO LONGITUDINAL -- THE
ABILITY TO DO LONGITUDINAL
TESTING IS IMPORTANT. ONE OF THE
OTHER THINGS PARENTS ARE EXPOSED
TO PRIOR TO CONCEIVING CHILD ONE
OF THE THINGS MOTHERS ARE
EXPOSED TO, THESE ARE CRITICALLY
IMPORTANT TIME FRAMES. WE CAN'T
JUST TAKE A SNAPSHOT AT SOMEONE
IN ADULTS AND PREDICT WHAT IS
LIKELY TO BE HAPPENING. WHAT ARE
THE HEALTH EFFECTS ASSOCIATED
WITH THAT EXPOSURE. BUT THERE
HAS TO BE A LONGITUDINAL
ELEMENT. SO I KNOW THERE IS A
GREAT DEAL OF INTEREST IN HIGH
RESOLUTION MASS SPECTROMETRY.
TAKE A MILLILITER OF BLOOD, BACK
TO THIS EXPOSUM, A LOT OF WORK
GOING ON IN DIFFERENT
LABORATORIES. TAKE LESS THAN A
ML OF BLOOD AND DO A THOROUGH
ANALYSIS. SO SOME OF THE
GRANTEES HAVE DONE THIS. WE KNOW
THERE ARE 600 CHEMICAL SPE SIS
THAT CAN BE IDENTIFIED IN A ML
THAT CAN HELP US BETTER
UNDERSTAND WHAT IS YOUR CURRENT
STATUS, WHAT IS YOUR LEVEL OF
LED, WHAT ABOUT CHLORINATED
SUBSTANCES OR TEFLON BUT OVER
THE COURSE OF TIME. SOME WILL
CLAIRE, SOME ARE NOT. I THINK
THINGS LIKE HI RESOLUTION MASS
SPEC. I WANT TO PUT IN A PLUG
FOR WE HAVE TO FIGURE OUT THE
EPIGENETIC CONSEQUENCES.
UNFORTUNATELY BRUCE I DIDN'T
HAVE TIME TO TALK ABOUT THIS IN
MY OWN LAB BUT WE DID AN
EXPERIMENT WHERE WE TREATED
PREGNANT FEMALE -- OF COURSE
FEMALE. MOTHERS WITH A SPECIFIC
PESTICIDE DURING PREGNANCY. WE
CAN GO IN AND SHOW EPIGENETIC
CHANGES THAT PERSIST. OO ANOTHER
AREA OF TECHNOLOGY DEVELOPMENT
IS TO BE ABLE TO DO A THOROUGH
INEXPENSIVE EN PIGENETIC
ACCESSMENT. DOING THESE WE CAN
CORRELATE THE EPIGENETIC CHANGES
DURING THE EXPOSUM. WE KNOW SOME
HAPPEN DURING SIGH SI
PSYCHOSOMATIC STRESS AND SOME
DURING SMOKING. IN FACT, IN MANY
WAYS EXPOSUM MAY BE THE
EPIGENOME SO MAY BE THINGS IN
EXPOSUM THAT WE DON'T KNOW WERE
THERE BUT WE ARE PAYING
ATTENTION TO CHANGES IN EXPOSUM
THAT CHANGE WAY GENES ARE
WORKING. DAN, I COULD GO ON.
DOES THAT GIVE YOU SENSE OF SOME
OF THE THINGS THAT WE COULD BE
DOING TOGETHER?
>> NO, THAT IS GREAT.
CERTAINLY THE EMPHASIS ON
LONGITUDINAL TESTING, THAT IS
SOMETHING I THINK IS AN ON GOING
THEME IN A LOT OF BIOMEDICAL
TECHNOLOGY DEVELOPMENT. I'M
GOING TO GO THINK ON IT MORE,
THANK YOU.
>> I HOPE ALL OF YOU , IN
FACT, I THINK BRUCE IS DOING A
LOT OF THINKING. THANKS FOR THIS
OPPORTUNITY. I HOPE COLLECTIVELY
WE CAN ALL BE THINKING ABOUT
TRANSFORM TIF TECHNOLOGIES WE
CAN BRING TO BEAR ON
EXPOSUMOMICS. SIMON?
>> THAT WAS A
THOUGHT-PROVOKING AND WONDERFUL
PRESENTATION. YOU MADE THE POINT
WE NEED TO GET BEYOND JUST
MEASURING ONE THING AT A TIME.
OBVIOUSLY THAT MAKES SENSE. AS I
THINK ABOUT THE EXPOSUM IT IS
INFINITE. SO MANY THINGS WE HAVE
TO FACTOR IN. YOU ALREADY MADE
THE POINT IN THE GENOMICS SPACE,
TRYING TO GET TO ANSWERS WHERE
WE HAVE HUNDREDS OF GENES OF
INTEREST REQUIRES COHORTS IN
TENS OF MILLION, HERE SEEMS WE
WILL BE AT HIGHER ORDER FOR
COHORTS. SO STRIKES ME WE WILL
HAVE TO FOCUS DOWN SOMEWHAT AND
BE IN BETWEEN MEASURING ONE
THING AND EVERYTHING. SO WHAT
ARE THE PRIORS? WHERE DO WE
FOCUS IN THE SHORTER TERM OUR
EFFORTS?
>> I THINK FOCUSSING ON THE
SHORTER TERM AND SOME OF THINGS
I JUST MENTIONED, THE EPIGENITIC
CHANGE, MASS SPEC, AND IT CAN'T
BE UNLIMITED. THAT IS
MEANINGLESS. FRANCIS EXPLAINED I
KNOW HOW TO DO THE EXPERIMENT,
SEQUENCE THE GENOME, BUT WHAT IS
IT? THAT IS WHY THERE IS A GREAT
DEAL OF FOCUS ON OPERATIONIZING
THE EXPOSUM. WHAT ARE THINGS WE
SHOULD BE COLLECTING THAT ARE
GOING TO TRULY BE INFORMATIVE OF
THE TYPES OF ENVIRONMENTAL
EXPOSURES LIKELY TO BE CAUSING
-- WELL, CAUSING DELETERIOUS
SIDE EFFECTS OR MOW MOATING
HEALTH? THAT IS THE CENTER I
DESCRIBE , THE BIG FOCUS. IS
BRINGING -- NOT JUST
ENVIRONMENTAL HEALTH SCIENCES
BUT THE BROADER BIOMEDICAL
COMMUNITY TOGETHER. WHAT ARE THE
CRITICAL THINGS WE NEED TO
MONITOR. WHAT CAN WE DO WITH A
SENSE OF LONGITUDINAL
CAPABILITIES THAT WILL TRULY BE
RELEVANT TO STUDYING THE
EXPOSUM. THERE IS ALSO THE VERY
IMPORTANT PART OF THE EXPOSUM IS
THE DATA MANAGEMENT TOOLS. THAT
IS SOMETHING I WANT YOU TO ALL
THINK ABOUT RIGHT NOW. SO
GETTING BEYOND ONE EXPOSURE AT A
TIME. FOR EXAMPLE HIGH
RESOLUTION MASS SPEC SO CAN BE
LOOKING AT EXPOSURE TO
POTENTIALLY 600 CHEMICALS. WHAT
IS DATA MANAGEMENT SYSTEM WE CAN
IMPLEMENT SO PEOPLE DOING ONE
EXPOSURE AT A TIME, WHY NOT
DEVELOP A DATA MANAGEMENT SO
THEIR SEAM LESSLY
INTEGRATE. ONE GROUP IS OZONE
BUT IS THERE A SYSTEM YOU CAN
INTEGRATE IT TOGETHER SO THE
EXPOSUM REALLY BECOMES YOUR DATA
MANAGEMENT. IT IS THE DATA
MANAGEMENT ARCHIVE IS REALLY THE
EXPOSUM. SO SIMON, DOES THAT
HELP?
>> YAH, I THINK, YOU KNOW,
THIS FIRST STEP OF DEFINING
OPERATIONALLY WHAT THE EXPOSUM
IS IS REALLY IMPORTANT FOR US
THEN TO SET STAGE FOR WHAT
TECHNOLOGIES NEED TO BE
DEVELOPED. SO I WANT TO
UNDERSTAND THAT. IT WOULD BE
EASIER TO FOCUS OUR EFFORTS.
>> I TOTALLY AGREE THAT. IS
WHY WE ARE FUND ING THIS CENTER
TO ESSENTIALLY TAKE ON THE
CHALLENGES OF WHAT IS IT WE ARE
GOING TO BE MEASURING? WHAT DO
WE HAVE THE CAPABILITIES OF
DOING? WHAT IS CRITICALLY
IMPORTANT? WHAT I BRING TO THE
WHOLE PICTURE IS RECOGNITION FOR
MY OWN LAB. IF YOU WANT TO
UNDERSTAND THE ETIOLOGY, IT HAS
TO GO BEYOND SEQUENCING GENOMES.
AS A GENETICIST I CAN SAY THAT
SO HOW DO WE ADD THE
ENVIRONMENT? WE HAVE TO
OPERATIONAL IZE THIS IN A WAY WE
KNOW WHAT DATA TO COLLECT. HOW
DO WE INTEGRATE THIS DATA
TOGETHER IN WAY WE CAN
ULTIMATELY KIND OF BRING TO BEAR
THAT VISION THAT I OUTLINED AT
BEGINNING. IS POSITION IS AT THE
PATIENT'S BED. YOU HAVE
KNOWLEDGE OF NOT JUST GENOME BUT
EXPOSED TO THE ENVIRONMENT. IT
IS SHOCKING RIGHT NOW.
PHYSICIANS DON'T ASK PEOPLE
WHERE DO YOU WORK. IF YOU ARE A
WELDER, GUESS WHAT? YOU ARE
EXPOSED TO HEAVY METALS IN A WAY
SOMEONE WORKING AT A DAYCARE
CENTER IS NOT. SO WE JUST NEED
TO BRING THAT RIGOR TO HOW DO WE
CAPTURE THAT DATA? ARE WE INTE
GRATED INTO ELECTRONIC HEALTH
RECORDS. WE NEED YOUR HELP. THE
THING YOU CAN BRING IS
REALISTICALLY WHAT CAN WE EXPECT
TO ACTUALLY DEVELOP TOOLS TO GET
BEYOND ONE EXPOSURE AT A TIME?
WHAT IS REALISTIC AND WHAT ARE
THINGS THAT ARE POTENTIALLY
SCALEABLE? RNA SEEK IS A GREAT
EXAMPLE. I WOULD HAVE NEVER
IMAGINED WE WOULD HAVE THE
CAPABILITY OF DOING RNA SEEK IN
EARLY 1980s WHEN WE FIRST
STARTED GENOME PROJECT. IT WAS
TRYING TO -- IT WAS REALLY THE
IDEA WE HAVE TO GET ONE GEEN AT
A TIME. CAPTURING THE ENTIRE
TRANSCRIPT. THAT WAS THE DRIVER.
STARTING WITH THE VISION WE CAN
DEVELOP TO ENABLE THIS. WE NEED
YOUR HELP.
>> THANK YOU.
>> OKAY. JOYCE, LOOKS LIKE
YOU WERE NEXT.
>> YES HI. THANK YOU VERY
MUCH. I THOUGHT THAT WAS
EXCITING. TO ME I THINK IT IS A
GREAT OPPORTUNITY BETWEEN NIEHS.
AS YOU SAID THERE IS A LOT OF
ENABLING TECHNOLOGIES. I THOUGHT
IT WAS EXCITING YOU SHOWING THE
ORGANS ON A CHIP AND FROM THE
BIOLOGY SIDE LOOKING AT
NON-TRADITIONAL MODELS,
DRASOPHOLI AND AS WELL. LIKE
WHEN THE DOCTOR ASKS WHERE
SOMEONE LIVES OR WORKS, THAT ALL
SPEAKS TO THE MONITORING. FROM A
DIAGNOSTIC VIEW, AS YOU PROBABLY
KNOW THAT, IS DIAGNOSTIC WITH
THERENOSTIC. WITH THERAPEUTIC, I
HAVEN'T SEEN THAT. I WASN'T ABLE
TO JOIN UNTIL YOUR TALK. I JUST
CAME BACK FROM TEACHING. SO I
I'M JUST CURIOUS WHAT YOUR
THOUGHTS ARE ON ONCE YOU HAVE
THAT INFORMATION. I THINK NIBIB
TYPE WORK CAN HELP FROM THE THER
PETE IK SIDE. IT IS NOT JUST A
DIAGNOSIS TO SAY WHAT? IS IT
BIOREMEDIATION. SO I'M CURES IF
YOU AND BRUCE HAVE HAD
DISCUSSIONS ON THAT.
>> I THINK THAT IS A GREAT
QUESTION. I GUESS FROM MY POINT
OF VIEW IS IF YOU WANT TO
DEVELOP A THERAPEUTIC, YOU HAVE
TO UNDERSTAND WHAT IS
MISBEHAVING IN AN INDIVIDUAL,
OKAY. SO WE ARE GETTING BETTER
AT UNDERSTANDING HOW GENE
VARIANTS CAN TRIGGER MISBEHAVIOR
OF GENES AND BIOLOGICAL
PATHWAYS. BUT I THINK WE ARE
REALIZE THERE YOU GO ARE CERTAIN
ENVIRONMENTAL EXPOSURES THAT CAN
TRIGGER SAY PARKINSON'S, CAN
TRIGGER IN FACT, WORKING
TOGETHER WITH YOUR GENETICS TO
TRIGGER ALZHEIMER'S. SO THAT IS
WHY I WILL OFTEN SAY IT IS
GETTING AT THE FUNDAMENTAL
UNDERSTANDING OF ETIOLOGY OF
HUMAN THE DISEASE. WHAT IS
MISBEHAVING AND HAPPENING AT
MOLECULAR LEVEL? IS THERE SAY
THE GENES OR SEGMENT INDIVIDUAL
UP TO DEVELOP PARKINSON'S AND AS
ENVIRONMENTAL TRIGGER THAT
TRIGGERS THE PHENOTYPE BUT WHAT
IT IS ABOUT THE ENVIRONMENTAL
TRIGGER? THERE NEEDS TO BE
CONTINUITY. WHERE DOES THAT FIT
INTO THE WHOLE ETIOLOGY OF HUMAN
DISEASE. ONCE YOU WANT TO
DEVELOP A THERAPY, YOU WILL LOOK
AT THE ENTIRE PATHWAY. WHERE ARE
POINTS OF POTENTIAL
INTERVENTION? ARE THERE
INTERVENTIONS THAT MAY BE
DIFFERENT IF SOMEONE IS
DEVELOPING PARKINSONS FOR
STRICTLY GENETIC REASONS VERSUS
INDIVIDUALS DEVELOPING
PARKINSONS FOR STRICTLY
ENVIRONMENTAL REASONS AND
DEVELOPING PARKINSON'S FOR GENE
REASONS. BASICALLY TO ANSWER
YOUR QUESTION IT IS ABOUT
FUNDAMENTALS, TOTALLY
UNDERSTANDING THE ETIOLOGY OF
HUMAN DISEASE. THAT ANSWER YOUR
QUESTION?
>> IT DOES BUT I THINK IT IS
ALSO PRESENTING A POTENTIAL
OPPORTUNITY WHERE IT IS THINKING
ABOUT LIKE YOU DON'T NECESSARILY
HAVE TO UNDERSTAND EVERYTHING
BUT LOWERING EXPOSURE. THAT WILL
BE DIFFERENT THAN WATER. SAY INI
HA
HAVEI I NVIVO BY REMEDIATION.
THAT HAS BEEN 30 YEARS IN THE
COMMUNITY. SO I'M CURIOUS
LEVERAGING THAT, AS THEY SAY.
>> I GUESS GETTING AT YOUR
QUESTION IS ABOUT THE PREVENTION
PART OF THIS.
>> RIGHT.
>> SO YOUR UNDERSTANDING
SOMETHING IS BAD FOR YOU.
>> YES.
>> WHAT ARE THE TYPES OF
TECHNOLOGIES -- IN FACT, THAT,
IS ANOTHER WHOLE ELEMENT,
COLLABORATION WITHIN NIBIB. WE
KNOW IN FACT, IN CENTRAL NIKE
NORTH CAROLINA, I THINK DUPONT
CONTAMINATED THE WATER SUPPLIES.
IN FACT, MY WIFE IS A REALTOR.
SO SHE ALWAYS -- WHEN TALKING
PEOPLE AROUND THEY DO THIS
TESTING AND THERE ARE A LOT OF
SURPRISES. SO ARE THERE
TECHNOLOGIES WE CAN BE DEVE
DEVELOPING TO BE CLEANING UP
INDIVIDUAL HOMES SUPPLY? I JUST
GO
GOT BACK FROM INDIA, JET LAG SO
HOPEFULLY THIS IS MAKING SENSE.
THE AIR POLLUTION IS CHOKING.
THE TWO WEEKS I WAS THERE THE
BEST IT GOT WAS SERIOUSLY
UNHEALTHY. 200 TO 300 PARTS PER
MILLION. ARE THERE TECHNOLOGIES
THAT PEOPLE THAT DO LOW-COST AIR
CLEANERS WITHIN A HOUSEHOLD? SO
I THINK THERE ARE A LOT OF
TECHNOLOGIES FOR MITIGATION
AAND
ADAPTING TO THAT ENVIRONMENT.
DOES THAT ANSWER THE OTHER PART?
>> YAH, THANK YOU. I'M JUST
SAYING ALSO TO THINK NOT
NECESSARILY JUST IN THE WATER
BUT IN THE PERSON TOO. SO ARE
THERE THINGS WITH LED. I LEARNED
WHEN I WAS IN INDIA STRIKINGLY
IT IS AMAZING WE KNOW HOW BAD
LED IS. THERE IS NO SAFE LEVEL
OF LED. THERE ARE PEOPLE DYING
OF LEAD POISONING ACROSS INDIA.
I THINK IT IS PARTLY BECAUSE
THERE ARE -- KIND OF GETS TO THE
SOCIAL DETERMINANTS OF HEALTH.
THERE ARE PEOPLE WHOSE BUSINESS
IS RECYCLE LED ACETATE
BATTERIES. SO SOME THINGS ARE
UNIMAGINE B
UNIMAGINABLE. CAN THERE BOTHE
THERAPEUTICS TO PROMOTE THIS?
>> THANK YOU.
>> BRUCE, LAST STOP. LOT OF
WORK WE HAVE TO BE DOING
TOGETHER. ZANE, LOOKS LIKE YOU
HAVE A QUESTION.
>> RICK, THANK YOU FOR THE
TALK. I WILL MAKE A QUICK
COMMENT ABOUT WHAT SOMETHING
JOYCE SAID. IF YOU CAN GET
PATIENTS TO TELL THE TRUTH IN
THE FIRST PLACE YOU'D PROBABLY
SEE A IMPROVEMENT IN HEALTH
CARE. BETTER OFF. THE OTHER
INFORMATION YOU ARE ASKING IN
REGARD TO THIS -- MY REAL
QUESTION BOILS DOWN TO WHERE
DOES THE NEW MICROBIOMICS OR THE
OTHER ASPECTS OF THE GUT
MICROBIOME FIT? THAT SEEMS LIKE
A FIRST STEP TO MANY. I MEAN
THAT, IS PROBABLY YOUR BIGGEST
EXPOSURE TO CHEMICALS, BIGGEST
EXPOSURE TO ANY KIND OF A
CHANGE. JUST CURIOUS ON YOUR
TAKE.
>> I GUESS YOUR QUESTION IS
WHERE DOES THE MICROBIOME?
>> YES.
>> EXACTLY. GREAT QUESTION.
ANSWER IS INDIGO HARVEST. WHAT
WE ARE DISCOVERING IS SOME OF
THE POTENTIALLY POWERFUL EFFECTS
OF DIFFERENT CHEMICAL AGENTS ON
HUMAN HEALTH MAY BE THROUGH
CHANGING COMPOSITION OF THE MY
CROWBIOME. TOMORROW I'M TALKING
TO DENTAL AND CRANIOFACIAL
GROUP. THERE IS EVIDENCE ORGANO
PHOSPHATES CAN BE CHANGING THE
ORAL MICROBIOME. THINGS WE NEED
TO PAY ATTENTION TO. THE GOOD
NEWS IS WE HAVE CONSCIOUSNESS OF
IMPORTANCE OF THE MICROBIOME.
AND WE JUST NEED TO BE DEVE
DEVELOPING STRATEGIES IN THE
ORAL AND GUT MICROBIOME. THESE
ARE CRITICALLY IMPORTANT FOR
MAINTAIN TRAINING GOOD HEALTH.
THAT ANSWER YOUR QUESTION?
>> THANK YOU.
>> SOUNDS GOOD. BRUCE.
>> BRUCE TROMBERG: I'M GOING TO
BE THE CLOSER. I'M GOING TO WRAP
THIS UP WITH A FEW COMMENTS.
MAYBE WE CAN GET ONE MORE ROUND
OF DISCUSSION. IT STRIKES ME A
LOT OF DISCUSSION IS PREDICATED
ON HAVING VALIDATED SYSTEMS,
SURROGATES FOR HUMANS. WE WOULD
LIKE TO SOLVE THE MYSTERY IN
HUMANS BUT THE MICROFIZZ LOGICS,
WE KEEP RETURNING TO NOVEL
METHODS. GETTING A FORM OF
STANDARDIZATION SO THEY CAN BE
REPRODUCED AND DISTRIBUTED
WIDELY. THE SOLUTION OF THE
PROBLEM -- THE PROBLEM APPEARS
QUIETEN FINISH IN IT WITH LOTS
OF VARIABLES. THE ONLY WAY TO
MAKE HEADWAY IS GET INFINITE OR
SEMI -INFINITE NUMBER OF PEOPLE
WORKING ON SAME PLATFORMS
APPROACHING PROBLEM FROM VARIETY
OF DIFFERENT ANGLES. I THINK IT
UNDERSCORES WHAT WE ALL KNOW,
SENSE OF URGENCY. I'M SPEAKING
IN PARTICULAR TO BIOMATERIALS
FOLKS ON COUNCIL. WE NEED TO GET
THE BIOECONOMY CRANKED UP AND
GETTING A AGREEMENT SO THESE CAN
BE MANUFACTURED. WE KNOW THEY
WORK BEAUTIFULLY IN INDIVIDUAL
LABORATORIES. WE CAN'T HAVE JUST
A BUNCH OF BOUTIQUES. WE NEED TO
GET THOSE VALIDATED AND
DISTRIBUTED. THAT IS ONE
INTERESTING THING. I THINK THE
SPIN-OFF ON THAT, RELATED TO
IMAGING TOO, IS HOW DO WE GET
THESE ALSO GENERATED IN SOMEWHAT
STANDARD AND PREDICTABLE WAYS
TOWARD AN INDIVIDUAL HUMAN. WE
WANT TO HAVE OUR PERSONAL
AVATARS TO UNDERSTAND WHAT'S
HAPPENED TO US. WE CAN IMAGE
THAT IN MI MICRO PHYSIOLOGY SYS
AND TEST OUT THE
APPROACHES.ENTERTHIS IS
SOMETHING THAT'S GONE ON A LOT.
BUT TO DEVELOP APPROACHES THAT
ARE RELIABLE AND WE HAVE
CONFIDENCE IN THE PLATFORM TO
HELP US UNDERSTAND WITHOUT DOING
EXPERIMENTS ON THE ENTIRE HUMAN
FIRST WHAT IS GOING ON. RICK
SENDS ME GREAT PAPERS. SEND ME
FROM END ENDOCRINE SOCIETY. SO
DEVELOPING FOR IMAGE SINGLE
CELLS, HE ADAPTED THAT TO LOOK
AT NANO PARTICLES, NANO PLASTICS
IN WATER THAT COMES FROM YOUR
PLASTIC WATER BOTTLE AND
IDENTIFIED TEN TO THE FIFTH
PRIMARILY NANO BUT SOME MICRO
PARTICLES PER LITER. YOU KNOW,
LIKE A SHOCKGLY HIGH NUMBER. SO
I THINK THERE IS SYNERGY AND
OVERLAP DEVELOPED BY OUR
COMMUNITY. MAYBE UNKNOWN-KNOWNS.
SO WE KNOW THESE ARE END
ENDOCRINE DISRUP TORS. 250
BILLION DUE TO THIS. OBVIOUSLY A
HUGE HEALTH CARE AND ECONOMIC
IMPACT. SO THERE WILL PROBABLY
BE PHENOTYPE SIGNATURES OF THESE
KNO
KNOWN DISRUPTORS YOU CAN TUNE
INTO. SO WE CAN LOOK AT
EXPOSURES THAT WAY. THERAPIES TO
REVERSE IN SOME SPECIFIC
TARGETED WAYS. JUST SOME RANDOM
THOUGHTS, TRYING TO TIE ALL THIS
STUFF TOGETHER. SOME OF THE
OPPORTUNITIES FOR OUR COMMUNITY,
RICK, WE ARE GRATEFUL FOR YOUR
PRESENTATION. THANK YOU FOR
SENDING ME A LOT OF THIS
INFORMATION. ENCOURAGING THIS
WONDERFUL, WONDERFUL DISCUSSION.
>> RICK WOYCHIK: BRUCE, THE KEY
IS WE NEED TO BE WORKING
TOGETHER .
THE BIOLOGISTS, THE THINGS WE
DO, WE WOULD NEVER IMAGINE HOW
WE CAN SOLVE SOME OF THESE
PROBLEMS. TAKES ME BACK TO
OAKRIDGE DAYS THERE WERE
DEVELOPING PARTNERSHIPS WITH
QUAN AND OTHERS. THESE WERE
INNOVATIVE SOLUTIONS I WOULD
HAVE NEVER THOUGHT OF DOING. SO
THAT IS THE KEY THING HERE.
DEFINED WHAT IS THE EXPOSUM AND
WHAT ARE CAPABILITIES WE CAN
BRING TO BEAR. CAN'T BE
EVERYTHING ABOUT EVERYTHING BUT
LET'S CARVE OUT WHAT CAN WE
MEASURE. THEN OPERATIONAL IZE
THIS IN WAY THAT POSITIONS AND
COLLECTS DATA AND CORRELATES
THIS WITH HUMAN HEALTH. THANKS
AGAIN FOR THIS INVITE. ALWAYS
EXCITING TO ENGAGE IN A
DISCUSSION WITH YOU.
>> YOU ARE NOT OFF THE HOOK
YET. I SEE SOHE HAS HAND UP.
>> QUICK COMMENT JUST ON
PLASTICS ALONE. I WANT TO FIRST
OF ALL SAY THIS IS A FANTASTIC
INITIATIVE. I REALLY LOOK
FORWARD TO GREAT OUTCOMES. I'M
AT THE NATIONAL SCIENCE
FOUNDATION. WE HAD A PROGRAM
CALLED ELIMINATION OF END OF
LIFE PLASTICS. WE HAVE A 40
MILLION, 20 PROJECTS, EACH OF
THEM 2 MILLION THAT ARE
INTERACTIVE, TRYING TO FIGURE
OUT TECHNOLOGIES TO RESOLVE
ISSUE OF PLASTICS AND ELIMINATE
FROM THE ENVIRONMENT THAT. IS A
DIFFERENT QUESTION. IN THE
COURSE OF PREPARING THE
SOLICITATION AND ALSO IN THE
COURSE OF -- IDEAS IN ITSELF, I
REMEMBER THE PANELIS THAT WOULD
COME, THEY WOULD ALWAYS ARGUE
THAT PALACE TIBS NOT THAT BAD.
WE DON'T -- PLASTICS NOT THAT
BAD. WE DON'T HAVE GOOD EVIDENCE
FROM BIG IMPACTS FROM PLASTICS.
SO WE HAD A HARD TIME SELLING
THE INITIATIVES AND HAVING A
GOOD SUBSTANTIAL INVESTMENT IN
ADDRESSING THE PLASTICS ISSUE.
SO I REALLY WOULD LOVE TO SEE
SOME GOOD EVIDENCE COME OUT OF
THIS INITIATIVE. ESPECIALLY IN
THAT AREA.
>> WE WOULD LOVE TO SEE THE
SAME THING. IN FACT, GETTING
BACK TO THAT ORIGINAL PICTURE
THAT BRUCE SHOWED, WHAT I DO IS
EVERY MONTH I INTERVIEW SOMEONE
DOING INNOVATIVE STUFF OR
WORKING IN AREA THAT IS A REAL
CHALLENGE. LAST YEAR I
INTERVIEWED DOUG WALKER, DOING A
LOT OF MASS SPEC WORK. SO THAT
WAS ALL ABOUT DISCUSSING
CHALLENGES ASSOCIATED WITH
ANALYZING PLASTICS. I ENCOURAGE
YOU TAKE A LOOK AT THE
DIRECTOR'S CORNER FROM LAST
YEAR. BUT THIS IS SOMETHING WE
HAVE TO SOLVE. THERE IS A LOT OF
DISCUSSION GOING ON WITH INCOME
TAX -- WITH THE NATIONAL
TOXICOLOGY PROGRAM. IT IS
SOCIALING AND THE ARTICLE WAS
STRIKING TO REALIZE WHAT WE ARE
BEING EXPOSED TO. IT IS
COMPLICATED BECAUSE IT IS NOT
JUST THE CHEMICAL COMPOSITION OF
SOME OF PLASTICS. USED TO BE
SIMPLE. BPA, PLASTICIZER. WE
DISCOVERED ORIGINALLY IN BABY
BOTTLES BUT IT IS NOW ABOUT A
WHOLE VARIETY OF THER TYPES OF
PLAS
PLASTICS. IT COULD BE THE
PHYSICAL TYPES. THINKING
ASBESTOS AND NANO PA PART CALLS
IT /* /* PARTICLES. IT IS
COMPLICATED. ONE WE NEED HELP.
ONE WE REALLY HAVE TO TACKLE THE
PROBLEM.
SAMUEL, LOOKS LIKE YOU HAVE
A QUESTION.
>> YES, DR. WOYCHIK, THANK
YOU FOR THIS EXCITING DISCU
DISCUSSION. THE PROBLEM HAS SO
MANY DIMENSIONS TO IT THAT MAKES
IT VERY CHALLENGING. DOES YOUR
INSTITUTE HAVE A KIND OF
PRIORITIZED DATABASE WHERE WE
CAN LOOK AND SEE WAYS OF
CREATING A MULTIPLEX ANALYSIS OF
SAMPLES AND COME UP WITH THE
APPROPRIATE TECHNOLOGIES TO
ADDRESS THEM IN FUTURE?
>> SO I GUESS MY RESPONSE TO
THE QUESTION IS THERE ARE MANY
DIFFERENT ELEMENTS SO THAT WAS
PART OF THE MOTIVATION FOR THE
CENTER. THE CENTER HAS TO BE
ABOUT OPERATIONALIZING IT. WHAT
ARE THE THINGS THAT WE SHOULD BE
FOCUSSING ON CAPTURING? NOW WE
HAVE LOTS OF DATABASES THAT
AREN'T TERRIBLY BE GRATED. THAT
IS ANOTHER ISSUE THAT BRUCE AND
I TALKED A LOT ABOUT. SO I THINK
PAYING ATTENTION TO WHERE IS THE
SCIENCE GOING. THAT HAS TO NOT
BE JUST ENVIRONMENTAL HEALTH
SCIENTIST BUT WORKING
REALISTICALLY WITH TECHNOLOGY.
WHAT CAN WE ACTUALLY
REALISTICALLY EXPECT TO DO SO I
MODEL THE THIS ON THE WORK
THAT'S BEEN DONE IN THE GENOME
PROJECT. SO WE STARTED OFF WITH
A BOLD VISION AND HAVE TO FIGURE
HOT HOW DO WE CHIZLE AWAY? JUST
LIKE GENOMICS. IT IS NOT ONE
THING. IT IS OTHER THINGS, CHIPS
AND ENVIRONMENT BUT EXPOSOMES,
SO NOT JUST ONE THING. TO ANSWER
YOUR QUESTION THERE ISN'T AN
AREA FOCUS NOW THAT I CAN POINT
TO THAT I WOULD SUGGEST YOU
FOCUS ON. LET'S FOLLOW THE
PROGRESS WE ARE MAKING IN
DEFINING WHAT IS THE EXPOSUM. WE
DO HAVE -- I DIDN'T HAVE TIME TO
COVER BUT WE HAVE CENTERS. ONE
IS AT MOUNT SINAI WHERE WE CHURP
THIS FROM HIGH RESOLUTION MASS
SPEC AND VARIETY OF THER TOOLS
SO THOSE ARE AVAILABLE. AT THIS
POINT AS THIS EMERGING LET'S NOT
LATCH ONTO SOMETHING. WE ARE AT
THE POINT OF LET'S THINK
CREATIVELY. THE TIMING IS GREAT.
I NEED YOUR HELP, BRUCE. LET'S
COME UP WITH THE INNOVATIVE
STRATEGIES I WOULDN'T HAVE
THOUGHT OF AND YOU WOULDN'T HAVE
THOUGHT OF. LET'S SEE IF WE CAN
DO THAT COLLABORATIVELY. SAMUEL,
DOES THAT ANSWER YOUR QUESTION?
>> YES, THANK YOU VERY MUCH.
>> OKAY. SO LET'S THANK RICK
AGAIN. I WILL TURN IT OVER TO
DAVE.
>> THANKS AGAIN FOR THIS
OPPORTUNITY TO BE HERE. I LOOK
FORWARD TO MORE INDEPTH
DISCUSSION.
>> THANK YOU SO MUCH.
>> TAKE CARE.
>> THANK YOU.
>> BYE.
>> THANK YOU, EVERYONE.
EXCELLENT DISCUSSION. THE
CHALLENGES FACED THERE, AS THE
COMMENTS SUGGESTED. VERY GOOD.
NOW WE ARE GOING TO MOVE INTO
TWO CONCEPT CLEARANCES FROM --
GIVEN BY TWO OF OUR NIBIB
COLLEAGUES. HIS BACKGROUND ON
THE NIB PROGRAM OFFICERS
RECOMMEND CONCEPTS WHICH YOU
DESCRIBE THE SCOPE AND OBJECTIVE
FOR NEINITIATIVES WE MIGHT WANTO
PURSUE. THE OTHER IS CLEARANCE
WHERE WE RECEIVE PUBLIC ADVICE
AND MERITS ON POTENTIAL
INITIATIVES FROM COUNCILMEMBERS.
SO DR. AFRUOZA ANDERSON.
>> AFROUZ ANDERSON: THANK YOU,
DAVID. I HOPE YOU CAN HEAR ME.
GOOD MORNING AND GOOD AFTERNOON
TO THE COUNCIL MEMBERS. TODAY
I'M PRESENTING A CONCEPT AND
HOPE TO RECEIVE COMMENTS. I'M
PROGRAM DIRECTOR AT THE
INSTITUTE OF TECHNOLOGY. WHY
SPECIFICALLY WORKING WITH THIS
CONCEPT IS BECAUSE THE GAP
WITHIN THE MEDICAL ADVISE
COMMUNITY. WE KNOW THERE IS GAP
IN TERMS OF REPEATABILITY,
PRODUCEABILITY AND KWAN FIING WE
CURRENTLY HAVE. ONE OF THE MOST
RECENT EXAMPLE IS RELATED TO THE
OPT TOM TRI DEVICES. WHEN THERE
IS A NEED, MENTAL CONDITION,
PHYSIOLOGICAL CONDITION AND
CONTENT. SO WE ARE TRYING TO
THINK ABOUT IN TERMS OF BRINGING
QUALITY CONTROL TO MARKET FOR
MEDICAL IMAGING. REDUCING THE
MEASUREMENT WITHIN AND BETWEEN
AND MAKING SURE DO NOT NEED TO
WORRY ABOUT ACCESSING THESE IN
ORDER TO HELP WITH COSTS. SO
OVER ARCHING GOAL WOULD BE
ACCELERATE PRODUCTION AND
FACILITATE REGULATORY APPROVE
FOR TRANSLATION OF MEDICAL
DEVICES FOR THE CLINICAL USE.
HERE I'M SHOWING EXAMPLES. SO WE
WOULD LIKE TO HAVE A PULL
MULTI -PRONGED APPROACH, THE
FIRST APPROACH WE STARTED
BUILDING IN 2021 IN RESPONSE TO
THE COUNCIL WAS NIBIB LIBRARY.
THAT WAS ONE APPROACH. FROM THAT
WE TRYING TO TAKE THREE
ADDITIONAL APPROACHES. ONE SEX
PANDA TO THE CENTER WE HAVE
HEARD ABOUT PREVIOUSLY AND
LEVERAGE WITHIN COMMUNITY. THE
LAST MORE -- LARGER SCALE WOULD
BE TO ADVANCE THE UNIVERSITY
PARTNERSHIP. I WILL GO THROUGH
SOME OF THESE EXAMPLE AND DETAIL
OF SOME FOR A CONCEPT. SO
EXISTING IN CREATION OF THE
MEDICAL PHANTOM WORKING GROUP
WAS TO CREATE RESOURCE SO THEY
COULD HAVE ACCESS TO STANDARD
AND BE ABLE TO DO THE ROUND
ROBIN. THESE ARE CALIBRATED,
TESTED AND CURATED AND HAS
ANALYSIS TOOLS RELATED. IN 2021
WHEN THE LIBRARY WAS ESTABLISHED
IT WAS STARTED WITH MOSTLY MRI
SUCH AS BREAST, DIFFUSION AND
TOWARD 2024 THE GOAL TO EXPAND
OR OTHER IMAGE MODALITIES AND MR
PHANTOM, IT HAS SOME OF THE MSK
PHANTOMS, BUT HOPE IS EXPAND
THESE IMAGING. SOME STATISTICS,
THERE ARE 12 IN LIBRARY. WE HAVE
HAD TWO -- FIRST TWO OF 28, LOTS
OF PUBLICATION RELATED. ONE
THING I WANT TO HIGHLIGHT IS
THAT THE VALUE OF THE LIBRARY
BEYOND JUST THE LENDING SIECHLT
I CAN HIGHLIGHT IT THROUGH THE
STORY THEY HAVE HAD. THIS IS
MULTI PARTNERSHIP STORY WHERE
THEY ARE DEVELOPED THROUGH NIHD
AND NIBIB AND QUANTITATIVE
PROFILED THE PLAN OF DESIGN.
FROM HERE THE PHANTOM LIBRARY
SPECIFICALLY IN THIS CASE
CALIBRATED AND TRACED OF
PHANTOMS, THEY HAVE THE PARTNER
HELPED. THIS NOT ONLY SUPPORTED
THE DEVELOPMENT O OF NEURAL AND
TISSUE BUT PROVIDED REFERENCE
DATA FOR CALIBRATION AND MOST
IMPORTANTLY ASSISTED WITH
CREATION OF NEW MODALITIES AND
HELPING TO BE DEVELOPING FOR THE
THERAPY AND MR. SO YOU CAN SEE
BROAD ASPECT TOWARD DEVELOPMENT
AND CREATING NEW PARTNERSHIP. SO
AS PART OF FIRST CONCEPT AND GET
TO EXPEND THE PHANTOM LIBRARY
AND WE ARE TRYING TO CONNECT THE
FEDERAL AGENCIES AND IMAGING
COMMUNITY IN ORDER TO SHARE AND
DISSIMILAR NATE THIS PHANTOM AND
RELATED RESOURCES. TO DO THIS WE
ARE THINKING ABOUT ESTABLISHMENT
OF PHANTOM LIBRARY WITHIN THE
DATA CENTER TO CREATE SECOND
SITE FOR CURRENT LIBRARY WE
HAVE. TO GET THIS STARTED WOULD
LIKE TO START WITH EXISTING
PHANTOM AT THE FCA AND TRANSFER
THIS INCLUDE THE OC PHANTOM. AS
I MENTIONED ONE EXAMPLE, MODULE
PHANTOM WITH MELAMINE WITH
TISSUE VARIABILITY AND WOULD
LIKE TO SEND TO SHARE WITH THE
COMMUNITY. AS PARTNER IN THIS
INITIATIVE WOULD LIKE TO
CHARACTERIZE AS NEEDED. OUR HOPE
IS DEVELOP BEST PRACTICES, CURE
RADIATION AND COMPREHENSIVE
DOCUMENTATION SO WE CAN HAVE
PHANTOMS DISSEMINATED TO PUBLIC.
OUR NEXT APPROACH IS TO SUPPORT
EXISTING PHANTOM WITHIN
COMMUNITY AND ALSO SUPPORT
OPTIMIZATION, CHARACTERIZATION
OF THIS WITHIN A COMMUNITY. WE
CAN LEVERAGE EXISTING
DEVELOPMENT AND SHARING. AGAIN
OUR HOPE IS DEVELOP REPRODUCIBLE
AND CALIBRATED PHANTOM FOR ALL
DIFFERENT MODALITIES. THIS
INCLUDE OPTICAL MRI AND ACOUSTIC
AND ULTRA ACCUSE TIM AND
CREATING THE BEST PRACTICES
RELEVANT DOCUMENTATION. OUR HOPE
IS INCORPORATE WITHIN BETA
CENTER AND HAVE THE PARTNER TO
CAPTURE PHANTOMS AS THEY COME IN
FROM THE COMMUNITY AND CURE RATE
THIS AS THEY COME THROUGH THE
LIBRARY. ON MORE LARGER SCALE
APPROACH IS TO ADVANCE THROUGH
INDUSTRY ACADEMIC PARTNERSHIP.
MORE OF FIRST OF ITS KIND
CONCEPT IN TERMS OF CREATING
MULTI SECTOR COLLABORATIVE
EFFORT. WE ARE STARTING WITH
OPTICAL PHANTOM BUT OUR HOPE IS
TO EXTEND BEYOND THAT. THIS IS
-- OUR HOPE IS ALSO FOR THIS
PARTNERSHIP TO BE ABLE TO
FACILITATE REGULATORY APPROVAL
AND ACCELERATE TRANSLATION OF
DEVICES. WE ARE TAKING WHOLE
HOLISTIC APPROACH HERE. MODEL
THINKING OF HAVING HEAD BASED ON
INTERAGENCY COLLABORATIVE MODEL
OF THE INDUSTRY UNIVERSITY
COLLABORATIVE CENTER , IRC
MODEL, BASED ON NSF. HERE IS
THAT UNIVERSITY PROVIDE CENTER
AND BUILDING AND PROVIDING THE
SUPPORT IN TERMS OF WHAT IS
NEEDED FOR THE INDUSTRIAL
MARKETS. GOVERNMENT AGENCIES CAN
SUPPORT RND USE OF THE FACILITY,
PROVIDE GUIDANCE. FOR EXAMPLE
TOWARD REGULATORY ASSISTANCE OF
PHANTOMS DEVELOPED. I HOPE FOR
THE IRC BASED MODEL IS CREATE A
NOVEL PHANTOM RELATED TO IMAGING
STANDARDS THAT CAN BE
INCORPORATED WITHIN CURRENT
EXISTING STANDARDS AND
INCORPORATED WITHIN BETA
CENTERS. SO AS ARE COMING IN AND
DEVELOPED THROUGH THE
MULTI AGENCY MODEL, WILL BE
DISSEMINATED THROUGH THE PHANTOM
LIBRARY. WITH THAT I WOULD LIKE
TO THANK MANY AMAZING
COLLABORATORS. DR. LU, ALICE
MOTH, DR. GOING, GILL AND BRUCE
AND NIB DR. FLAT MORGAN AND
WHITEMAN FOR THEIR SUPPORT AS
ARE THE FDA COLLEAGUES HERE
TODAY. NES COLLEAGUE HELP
IMMENSELY FOR THE LIBRARY. TRAP
MEDICAL IMAGING PHANTOM GROUP,
COMPROMISE DIFFERENT INSTITUTE
AS WELL AS VA HOSPITAL, NSF AND
OFFICE OF COMMUNICATION. WITH
THAT I WOULD LIKE TO END MY
PRESENTATION AND HAPPY TO ANSWER
QUESTION YOU MIGHT HAVE. I SEE
JENNIFER'S HAND IS UP.
>> THANK YOU. THAT IS EXCITED
AND NEEDED BY THE COMMUNITY.
WANTED TO MAKE A COMMENT ABOUT
THE DEVELOPMENT OF PHANTOMS FOR
OPTICAL IMAGING. I THINK THEY
ARE PARTICULARLY NEEDED THERE.
SO I REAL APPRECIATE THAT. ONE
OF THE OTHER CHALLENGES WITH
OPTICAL IMAGING IS IT IS LESS
ESTABLISHED FIELD, AT LEAST FOR
MOST OPTICAL MODALITIES. CT
THERE, IS A WHOLE VARIETY OF
SYSTEMS. WORK ON DIFFERPRINCIPL
HAVE DIFFERENT WAYS TO ACQUIRE
AND PROCESS SIGNAL. I HOPE THAT
AS PART THERE COULD BE GUIDANCE.
MAYBE NOT EVEN REALISTIC TO SAY
WHAT PARAMETERS YOU SHOULD USE
WHEN IMAGING BUT HOW TO DOCUMENT
WHICH PARAMETERS SHOULD BE
DOCUMENTED I THINK WOULD BE A
HUGE HELP.
>> THANK YOU. ABSOLUTELY.
THAT IS PART OF OUR HOPE FOR
THESE BEING DEVELOPED. THIS IS
BROAD. OUR HOPE IS START WITH
COUPLE OF THESE TO BRING THIS TO
POINT OF WHAT OTHER SIGNAL, HOW
LOOK LIKE, WHAT ARE SOME OF THE
BASIC TO BE INCLUDED. DEFINITELY
POINT WELL TAKEN. THANK YOU.
DOCTOR, SEE YOUR HAND UP.
>> YES. THANK YOU FOR THE
PRESENTATION. I UNDERSTAND THIS
IS A REALLY COMPLEX AREA, FOR
SURE. THE HEADWAY YOU ARE MAKING
IS WELCOME. FOR SURE. I WONDER
WHAT YOU MIGHT THINK ABOUT THE
ROLE OF OPEN SOURCE
DISSEMINATION IN SOME ASPECTS.
NOT NECESSARILY BY ALL THE
PHANTOM DEVELOPMENT. I THINK IF
I'M WONDERING IS THERE A
STRIPPED DOWN LOCALLY PRODUCED
WITH RAPID GUIDELINES, RAPID
TECHNOLOGY, PARTICULARLY WITH
NEED FOR VERIFICATION OR
CALIBRATION. JUST INTERESTED IN
YOUR THOUGHT, THANKS. WE ARE
HOPING ON A BROADER APPROACH.
AND FOCUSSING ON SPECIFIC AREAS
OF THE PHANTOM DEVELOPMENT. YOU
MENTIONED THE SPECIFIC WORDING.
IF YOU CAN REPEAT THAT AGAIN FOR
ME.
>> I WAS JUST CURIOUS ABOUT
ROLE THAT OPEN SOURCE MIGHT PLAY
AS A COMPLEMENT --
>> OPEN SOURCE, EVERYTHING
HAS GOOD AND BAD. WE ARE HOPING
THAT A COMMUNITY CAN USE THESE.
CAN GIVE FEEDBACK FROM PHANTOM
USERS. SO TENDING THESE TO THE
COMMUNITY AND FOR EXAMPLE AS
EXAMPLE. TRYING TO INTRODUCE
SOME. IT WILL COME BACK TO WHILE
THIS WORKED OR INTRACK TIF
MODEL. THEY CAN TELL US WHAT
SHOULD BE DONE. THIS PARTICULAR
PRACTICE. WORK BETTER FOR US IF
CAN INTEGRATE WITHIN OUR MODEL.
SO THAT IS ONE HOPE. KNOW FDA
HAS OPEN SOURCE. YOU CAN ALLUDE
TO THAT AS WELL. HOW GOING TO
INCORPORATE THAT WITHIN OUR
SYSTEM.
>> I WILL JUST ADD TO YOUR
ANSWER. THE FDA SIDE, ALL IS
OPEN SOURCE. WE HAVE A CATALOG.
HAD INSTRUCTIONS ON HOW TO BUILD
EVERY ONE WE ARE PUTTING INTO
THIS. THE ISSUE YOU ARE RUNNING
IT, 82% OF DEVICE COMPANIES ARE
SMALL. I DON'T HAVE A SPECIALIST
OR SOMEBODY THAT CAN BUILD IT
THAT. IS WHERE THE PHANTOM
LIBRARY COMES IN. IS THE ABILITY
TO AUGMENT, WHERE THEY DON'T
HAVE RESOURCES TO ACTUALLY
REPLICATE THAT PHANTOM. WE
ABSOLUTELY WOULD LOVE EVERYBODY
TAKE WHAT WE PUT AND BUILD IT.
BUT THEY DON'T HAVE THE
RESOURCES. ESPECIALLY LIKE THE
OCT PHANTOM -- WE HAVE OPTICS
FAN ON THE THAT REQUIRES A
NANOSCRIBE. THERE IS ONLY A FEW
IN COUNTRY AVAILABLE TO ANYBODY.
SO WE ARE TRYING TO AUGMENT THAT
OVERALL CAPABILITY. SO WE TRYING
TO MAKE THIS OPEN SOURCE SO THE
ENTIRE COMMUNITY CAN
BENEFIT .ENTER
>> I SEE YOUR HAND IS UP.
>> VERY EXCITING WORK. THANK
YOU FOR THE EFFORT. I KNOW
SITCOM MRI KATED, AS THEY
SAY .ENTER WE HAVE HAD INTEREST
IN TISSUE PHANTOM, ESPECIALLY
AFTER THE DISCUSSION OF WORKING
ON CHIP FOR IMAGING. HAS THAT
BEEN PART OF DISCUSSION OR I
APPRECIATE YOUR THOUGHTS, THANK
YOU.
>> ABSOLUTELY. I KNOW SOME OF
THE EXAMPLE WAS MOSTLY RELATED
TO OPTICAL BUT THIS IS JUST THE
START, BEGINNING. OUR HOPE IS WE
CAN HAVE A WIDE VARIETY OF
PHANTOMS FOR AS MENTIONED FOR
THOR TISSUE IMAGING PHANTOM. NOT
JUST OPTICAL IMAGING. WE HAVE A
WHOLE LIBRARY MR BUT AS
EXPANDING WILL DEFINITELY TAKE
THAT INTO CONSIDERATION AND
MAKING SURE. WE WOULD LOVE TO
HAVE YOUR INPUT. WE NEED INPUT
FROM THE COMMUNITY SO MAKE SURE
AS YOU ARE GOING THROUGH THIS
AND THINKING OF THE NEW PHANTOMS
OR TYPES, PLEASE LET US KNOW
THAT. WILL HELP US BUILD THIS
LIBRARY BETTER AND MORE USEFUL
FOR THE COMMUNITY AS WELL.
>> I WILL ADD IN AGAIN
BECAUSE FDA IS VERY INVOLVED. A
LOT IS TISSUE BOUND. LOT OF
THINGS YOU TRY TO PROVE IN
SAFETY AND EFFECTIVENESS WHEN
YOU COME TO AGENCY ARE DIFFICULT
TO PRO IF YOU DON'T HAVE A
TISSUE PHANTOM, SOMETHING THAT
REPLICATES WHAT YOU TRYING TO
OBSERVE. A LOT IS FISH YOU
PHANTOM BASED. OTHERS IS OPEN OF
COURSE TO WHATEVER IS MOST
IMPORTANT TO MEDICAL DEVICE
COMMUNITY AND THEIR NEEDS.
>> YOUR HAND IS UP.
>> YAH, THANK YOU. AS I WAS
LISTENING I WAS A LITTLE
CONFUSED HERE IN THAT THERE IS
AN INTRAMURAL AT BETA CENTER. IS
THIS A CONCEPT THAT WOULD SEEK
AT SOME POINT PROGRAMS THAT
WOULD BRING IN EXTRAMURAL PEOPLE
TO BUILD THESE PHANTOMS, THEN
GET DISTRIBUTED WITHIN THE
INTRAMURAL PROGRAM THROUGH BETA?
I DON'T BELIEVE THESE ARE BUILT
INTERNALLY IN INTERMURAL
PROGRAM. PERHAPS YOU COULD GIVE
CLARITY ABOUT WHAT IS THIS FOR
FOR SUPPORTING BURN BUILDING OF
THESE? IN WHICH CASE WITH WHICH
COMMUNITY? ASPECT DISTRIBUTING
THESE INTRAMURALLY OR
EXTRAMURALLY.
>> THANK YOU. SO BETA STERN
WAS CREATED AS A COMMUNITY TO
BRING ALL THE IC AND NIH TO WORK
ON COMMON PROBLEM AND BE ABLE TO
COMMUNICATE WITH OUTSIDE SUCH AS
UNIVERSITY, INDUSTRY OR WHOEVER
IS INTERESTED. THE CONCEPT OF
YOUR THINKING, AS I MENTIONED I
HAD THE LIBRARY PREVIOUSLY SO
CURRENTLY THE DECISIVENESS SO
TRYING TO REPLICATE EXACT SAME
MODEL THROUGH THE BETA CENTER.
SO BETA CENTER WILL BE RESOURCE
FOR OUTSIDE COMMUNITY AND
UNIVERSITIES FOR EXAMPLE SHARE
PHANTOM, RECEIVE FPHANTOM, LEAR
AND USE FOR DEVICES THEY
CURRENTLY HAVE. IT WOULD BE AS A
RESOURCE CENTER TO SHARE WITH
THE COMMUNITY. THAT WOULD BE THE
MAIN PURPOSE OF THE BETA STECEN.
>> IF I UNDERSTAND, BETA
CENTER WOULD BE SUPPORTED IN
THEIR EFFORT TO BE LIKING A
GATOR OF PHANTOM AND DISTRIBUTOR
BUT THEY ARE NOT MAKING THOSE?
>> NO.
>> THERE IS NO NEW PHANTOMS
CREATED IN THIS PROCESS? LIKE
NIV IS NOT SUPPORTING BUT
SUPPORTING INTRAMURAL BETA
CENTER TO BEING A THE
AGGREGATOR.
>> IT COULD GO BOTH WAYS. AS
YOU ARE ENVISIONING, AS THESE
ARE BEING DEVELOPED FROM THE
MODEL, WE ARE HOPING RESOURCE
SHARING PART THESE CAN BE
DISTRIBUTED, THEY CAN BE SENT TO
CENTER AND DISSEMINATED TO
PUBLIC AS GOVERNMENT RESOURCE SO
THE NEW PHANTOMS DEVELOPED BY
THE COMMUNITY OR CURRENTLY
EXISTING FOR EXAMPLE IN TERMS OF
FDA WHERE THEY ARE CURRENT AND
SHARED THROUGH BETA CENTER THAT
CAN BE SHARED TOWARD THE
COMMUNITY. AT THIS POINT NOT
ENVISIONS BUT DEFINITELY AGAIN
POINT WELL TAKEN. CAN GO AHEAD
AND THINK ABOUT THOSE. BUT I SAW
YOU CAME ONLINE. IF YOU HAVE ANY
OTHER COMMENTS I WOULD
APPRECIATE IT.
>> SURE. BRIEFLY, GREAT
THING, RANU. WE ARE THINKING
BETA CENTER WOULD BE MORE OF
ADMINISTRATIVE HOME FOR THIS AS
WE GET STARTED SO SOME OF THE
SUPPORT WE COULD PROVIDE,
STORAGE AREAS COULD BE
SUPPORTIVE TO PHANTOM LIBRARY.
>> THANK YOU FOR THE
CLARIFICATION, BOTH OF YOU.
>> DOCTOR, YOUR HAND IS UP.
>> YES, I APPLAUD YOU FOR
THIS EFFORT. DEVELOPING PHANTOMS
AND STANDARDIZING IS JUST
CRITICAL. WE WORKED IN THE SPACE
QUITE A BIT. I THINK ONE OF THIS
THINGS THAT MIGHT BE WORTH
VETTING, ONE OF THE CHALLENGES
IS CALIBRATION. PARTICULARLY
WITH THE IDEA OF OUTSOURCING,
PUTTING OUT PROTOCOLS FOR
DEVELOPING PHANTOMS WHEN PEOPLE
ARE DEVELOPING, THEY WANT TO
BUILD THE PHANTOM AND MIGHT PUT
A STUDENT ON IT OR SOMETHING.
THEY DON'T BE HAVE THE ABILITY
TO CALIBRATE AND CONFIDENCE THEY
HAVE DONE IT CORRECTLY. I DON'T
KNOW IF THERE IS A RULE OR MIGHT
BE WORTH DOING THINKING ABOUT
HOW TO PROVIDING CALIBRATION SO
THAT IF YOU OUTSOURCE THE
PHANTOMS OR RECIPES, SOMEONE
COULD SEND, HAVE KAL BAITED AND
COME BACK. A LOT DON'T HAVE THAT
CALIBRATION TOOL THEMSELVES.
THEY ARE COMING UP WITH A NEW
INNOVATED WAY TO DO THAT.
>> THANK YOU. THAT IS AN
IMPORTANT POINT. THAT IS WHERE
WE ARE HOPING PARTNERS BECAUSE
THEY HAVE METHODS FOR
CALIBRATION FOR LEVEL OF
MATERIAL AND AS A WHOLE PHANTOM
AND ALL DETAIL. FOR EXAMPLE IF
YOU DON'T HAVE ONE, CAN AFFECT
THE WAY YOUR PHANTOM IS BEING
MADE. WE ARE HOPING THAT IS WHAT
THEY ARE DOING, CALIBRATE.
PHANTOMS COME IN, CALIBRATE
AGAIN G
AGAIN AND AGAIN DEPENDING ON USE
CASE AND SAY THIS HAS BEEN
CALIBRATED. THIS IS OUR HOPE,
HAVE THE PARTNERSHIP OF NEST TO
HELP WITH CALIBRATION OF SOME OF
THESE AS WE MOVE FORWARD. GREAT
POINT, THANK YOU.
>> THANK YOU VERY MUCH,
BRUCE, FOR THAT. I'M LIKE HERE
MAYBE HE IS CLEARER THAN ME. IS
NIBIB GOING TO FUND THIS? WHAT
ARE WE-WORKING ON AS
COUNCILMEMBERS?
>> THIS IS JUST A CONCEPT. WE
ARE NOT SAYING THAT -- LIKE SO
WE ARE ALREADY HAVING THE BETA
CENTER SO WE ARE USING OUR
EXISTING CENTER AS RESOURCE TO
SHARE SOME OF THESE PHANTOMS.
FOR SOME OF CONCEPTS WE HAVE
THREE APPROACHES. AGAIN WE ARE
TRYING TO CLEAR THE CONCEPT,
HAPPY WITH CONCEPT OF THING
NEEDED FOR THE COMMUNITY. WHAT
ELSE CAN WE DO TO MAKE IT
BETTER. THE HOPE IS EXISTING
PHANTOM OR DEVELOPING THE
PHANTOM THEN WE HAVE TO THINK
ABOUT IF CONFERENCE GETS CLEARED
WE HAVE TO THINK ABOUT THE
BUDGET AND ALL DETAILS. AT THIS
POINT THEY ARE JUST PRESENTING
CONCEPT TO GET YOUR INPUT TOWARD
IF THIS IS A GOOD IDEA, SHOULD
MOVE FORWARD AND WHAT ARE
THOUGHTS AND DETAILS. STILL HAVE
TO SIT DOWN AND THINK ABOUT SOME
OF DETAILS OF THE PARTNERSHIP
AND BUDGET WE CURRENTLY DO NOT
HAVE IN HAND.
>> THIS IS AN EXCELLENT IDEA,
THANK YOU.
>> I THINK WE CAN SEE THE
VIDEO CAME ON. IF YOU HAVE
INPUT.
>> YAH, JUST WANTED TO FOLLOW
UP ON WHAT IS AFROUZ SAID. A
LIBRARY, FREE OF CHARGE TO
COMMUNITY TO GET TO LIBRARY? AND
NIBIB BETA CENTER, WHICH IS, YOU
KNOW, SUBSET OF THIS UPON FAP
TOM
TOM -- PHANTOM LIBRARY. BUT THE
REASON IS TO SHARE. BUT AT THE
NIBIB WE PROPOSE TO SUPPORT
PHANTOM DEVELOPMENTS AND PHANTOM
CALIBRATION, VALIDATION,
VERIFICATION AND SUPPORT OF THE
COMMUNITY TO ACTUALLY WITH OUR
PART
PARTNERS, FDA AND NSF, ET
CETERA, TO DO WHATEVER IS
NECESSARY. SOMETIMES IN SOME
CASES LEVERAGE EXISTING PHANTOMS
ALREADY SCATTERED IN LABORATORY.
SEVERAL NIH-FUNDED
INVESTIGATORS. WE NEED A LITTLE
SUPPORT TO CARRY THAT EXTRA
MILES TO BE ABLE TO HAVE IT
CALIBRATED AND VERIFIED SO
LIBRARY CAN TAKE AND THIS CAN
BECOME A RESOURCE TO LEND TO THE
COMMUNITY TO HELP THEM DO BETTER
WITH QUANTITATIVE IMAGING. TO
ANSWER YOUR QUESTION, RANU AND
SAM. YES, PROPOSING BOTH AS
RESOURCE SHARING BUT ALSO TO
EXPAND EXISTING LIBRARY FUNDING
WHEN NEEDED.
>> RHONDA, YOU SHOULD GO
AHEAD. I'M GOING TO HAVE LAST
WORDS, SUMMARY COMMENTS SO YOU
SHOULD GO AHEAD.
>> THANK YOU. SO I'M COMING
FROM LITTLE OUTSIDE THE FIELD
BUT TRYING TO LOOK THIS BECOMES
SUCCESSFUL. CLEARLY WE NEED
STANDARDIZED PHANTOMS THAT COULD
BE REALLY HELPFUL. THINK IT
MIGHT HELP A LOT, AT LEAST FOR
ME, MIGHT HELP TO UNDERSTAND
WHAT MAY BE INSPIRATIONAL
PROGRAMS LIKE THE MODEL THAT
BUILD NEW PHANTOMS OR COMMUNITY
ET CETERA, WHAT IMMEDIATE ACTION
APPROACHES WHERE YOU HAVE
EXISTING THAT JUST NEED
CALIBRATION AND MAYBE NIBIB
WOULD FUND THAT PART. THEN A
MODEL FOR DISTRIBUTION OF WHAT
WOULD BE MODEL FOR DISTRIBUTION
OF THESE PHANTOMS. ALSO LOOKING
INTO IT, SOMEBODY BORROWS THAT
PHANTOM, BREAK THAT PHANTOM. YOU
HAVE THIS SPECIALIZED PHANTOM.
WHAT WOULD BE PROCEDURES YOU
MIGHT USE. THOSE ARE DETAILS TO
BE WORKED OUT. FOR ME AS I'M
LOOKING AT WHOLE CONCEPT SAYING
OKAY, GREAT RESOURCE, DON'T KNOW
EXACTLY WHO IS GOING TO BUILD
THESE, HOW WE GOING TO MAKE SURE
FUTURE HAPPEN, MAKE ACCESS TO
THESE PHANTOMS. SO FEW MORE
DETAILS LIKE THAT, AS YOU ALL
ARE THINKING THROUGH THIS
CONCEPT. MAYBE TAKING SMALLER
CHUNK AND BREAKING IT DOWN IN A
PIECE. THAT MIGHT HELP THAT. IS
MY OVERALL SYSTEMS THINKING.
>> THANK YOU, RANU. YOU WANT
TO GO AHEAD?
>> YOU GO AHEAD.
>> SO I JUST WANT TO MAKE
SURE THAT YES, WE ARE DOING BOTH
APPROACHES YOU MENTIONED. WE ARE
TRYING TO SUPPORT THE COMMUNITY
TO BUILD NOVEL PHANTOM THAT CAN
BE SHARED THROUGH SHARED
RESOURCE. THEN ALL OF THESE WILL
GO THROUGH THE CAPTURIZATION AND
CALIBRATION. LET'S SAY EXISTING
CALIBRATION. WE NEED THIS. THAT
IS WHY THEY ARE WORKING WITH
NEST AND FDA TOWARD CURE
RADIATION, MA CURE ASIAN SHGS /
/* CURATION. THESE PHANTOMS THAT
ARE AVAILABLE THAT HAVE BEEN
CURATED, STANDARDIZED BY THE
NEST AND SENT OUT TO THE
COMMUNITY. EXPANDING THE SAME
MODEL. SO ONE OF THE APPROACHES
WAS WHAT YOU MENTIONED. EXISTING
PHANTOM HELPING THEM GET
THROUGH, CURATED, MAKE SENSE AND
DISSEMINA
DISSEMINATED.C THEN A LARGER
SCALE APPROACH. AT THE END OF
THE DAY THERE WILL BE A
CHARACTERIZATION AND CALIBRATION
WITHIN EACH OF THESE. WE JUST
DON'T WANT TO SEND A RANDOM
PHANTOM THAT MIGHT NOT WORK. WE
TRYING TO ACTUALLY MAKE THE
STANDARDS THAT ARE -- SO POINT
WELL TAKEN. YES, THIS WAS THE
CONCEPT. WE ARE DEFT WORKING ON
DETAILS TO MAKE IT BETTER AND
DEFINITELY APPRECIATE YOUR
INPUT, THANK YOU.
>> BRUCE.
>> BRUCE TROMBERG: OKAY. THANK
YOU, AFROUZ AND EVERYONE. I WANT
TO WRAP UP A LITTLE OF THIS IN
SORT OF WHAT IS THE ULTIMATE
THING. TOUGH LESSON, ALL OF US
WHO DEVELOP DEVICES HAVE LEARNED
THE FDA IS THE ULTIMATE ARGUED
ARBITOR OF PERFORMANCE. IF
ANYTHING WILL GET DISSEMINATED
IT WILL GO THROUGH THE FDA. THIS
IS BASED ON ALL OF US DWOOP
DEVELOPING AND SENSING DEVICE,
OUR COMMUNITY DEVELOPS THEIR
OWN. IF YOU ARE DOING THEIR
COMMERCIALIZATION YOU GO TO THE
FDA WITH OUR OWN. THANK GOODNESS
WE HAVE OSUL AT THE FDA,
BUILDING THESE TECHNOLOGIES.
THEY ARE MAKING PHANTOMS. SO
THEY HAVE KIND OF LIKE AN
APPROXIMATELY WAY BUT OSUL IS
THE SCIENCE PEOPLE, NOT THE
REGULATORY PEOPLE. WE WOULD --
OUR COMMUNITY NEEDS TO HAVE --
THE REGULATORY PEOPLE HAVE
CONFIDENCE THAT ME, FROM MY LAB
WITH MY PHANTOM, I SAW THIS IS
THE PERFORMANCE REALLY IS
PERFORMANCE THEY CAN UNDERSTAND
AND EXTRAPOLATE AND COMPARE TO
OTHER PLATFORMS. SO WHAT THIS
WOULD DO IS IT WOULD TAKE ALL
THAT EXPERTISE OF OSUL WHO MAKE
PHANTOMS, LIKE AMAZING ONES.
THEY CAN'T REALLY SEND THOSE
BACK TO THE MANUFACTURER WHO
SAYS I HAVE A NEW TECHNOLOGY AND
THEY SAY JUST MEASURE IT ON
THIS. BUT WE CAN THROUGH NIBIB.
IF WE CAN ADOPT THOSE AND GET
MYSELF TO AGR-- GET MIS TO AGRE
WE HAVE A GOLD STANDARD AND
ALLOWS THE CREATIVITY OF OPEN
SOURCE AND ENTIRE COMMUNITY.
EVERYBODY WILL HAVE SOMETHING TO
COMPARE TO. HOW CAN WE STIMULATE
VIBRANT ACTIVITY? LIKE THIS IS
IS AN AREA OF REGULATORY SCIENCE
PEOPLE SKIP OVER BUT THE
ULTIMATE BOTTLENECK TO GETTING
THINGS CLEARED AND AUTHORIZED.
SO THE WAY WE CAN DO THAT IS A
WAY WE DISCUSSED IN 2019 WITH
ZANE AND HIS BOSS, THERE IS THIS
WONDERFUL IUCRC MECHANISM THAT
NSF HAS. GETTING BACK TO RONU'S
COMMENT, WOULD WE PUT MONEY? IN
DEPENDS ON THE BUDGET. BUT COST
MODEL IS EFFECTIVE. SAYS TO THE
COMMUNITY PARTNERSHIPS, THE
GOVERNMENT WILL PROVIDE SOME
RESOURCES AND IN-KIND SUPPORT
BUT WITH NIBIB AND FDA AND
INDUSTRY KIND OF COMING TOGETHER
WE THINK IT WOULD BENEFIT
EVERYONE IN ACCELERATING
AUTHORIZATION PATHWAYS AND
GIVING PEOPLE REALLY CONCRETE
FOUNDATIONS FOR NEW
TECHNOLOGIES. IT VERY AMBITIOUS,
I KNOW. THE CENTER COMES IN
BECAUSE THE FDA IS NOT GOING TO
DISTRIBUTE THESE. NIST, WE
PROBABLY ALL WORK WITH NIST.
THEY ARE AMAZING AT
CHARACTERIZATIONING AND
VALIDATING MATERIALS BUT NOT
DEEPLY INTO SORT OF MEDICAL
APPLICATION AND LANGUAGE. SO
CULTURALLY IT IS OUR COMMUNITY
THAT NEEDS TO TAKE ON
RESPONSIBILITY OF BEING THAT
INTERFACE. I THINK IT IS AN
ENORMOUS OPPORTUNITY FOR GROWTH
AND MANY AREAS. WE LOOK FORWARD
TO MORE COMMENTS FROM ALL OF YOU
AND PARTICIPATION. ALL OF YOU
DEVELOPING TECHNOLOGIES IN THIS.
WE HOPE IT GETS OFF THE GROUND.
>> WE STILL HAVE MORE
COMMENTS.
>> THIS IS GREAT. THANK YOU,
BRUCE, FOR CLARIFYING. I THINK
IT IS WONDERFUL. I COMPLETELY
AGREE NEED FOR STANDARDIZATION
FOR PHANTOMS. I HAVE TWO KIND OF
QUESTIONS. ONE, HOW WILL DATA BE
SHARED? I GUESS ANOTHER PART IS
I GUESS INTELLECTUAL PROPERTY.
IS THIS CONSIDERED PRETTY
COMPETITIVE? HOW IS THAT GOING
TO BE DEALT WITH IF YOU ARE
DOING A NOVEL, YOU KNOW, PHANTOM
OR A NOVEL INSTRUMENT? I
UNDERSTAND HOW THE PHANTOM
ITSELF WILL BE SHARED. I THINK
THAT IS GREAT. THE OTHER
QUESTION IS THE KIND OF META --
ALL THE OTHER DATA ON TOP. HOW
IS THAT GOING TO BE DISTRIBUTED
OR CURATED? I'M CURIOUS THE DATA
AND INTELLECTUAL PROPERTY PART.
>> SURE. I CAN ANSWER TO DATA
THAN IP. THIS IS SOMETHING
WORKED ON WITH OUR OFFICES
INTERNALLY. DEFINITELY SOMETHING
WE ARE WORKING ON BECAUSE THIS
IS A IMPORTANT QUESTION. IN
TERMS OF DATA, WE DON'T JUST
ACCEPT THE PHYSICAL PHANTOM. HAS
TO COME WITH COMPREHENSIVE
DOCUMENTATION IN TERMS OF LIKE
HOW MANY MILLIGRAM OF SUPPOSED
MATERIAL THEY ARE USING.
PROCEDURE EXACT, THINKING OF
INCORPORATING VIDEO YES OF HOW
THESE ARE BEING MADE. INCLUSION
OF THE MOLD THESE PHANTOMS ARE
MADE OF. NOT JUST THE PHANTOM.
IF YOU ARE MAKING WITH A
SPECIFIC SHAPE AND IF THAT HAS
BEEN PD PRINTED. SHARE THE MOLD
WITH THE PHANTOM AS THOUGH THE
3D DATA USED BY THE GRANTEE OR
COMMUNITY TO REPLICATE THAT
PHANTOM, IF NEEDED. ALSO
COMPREHENSIVE MATERIAL OF WHERE
THE MATERIALS ARE PURCHASED. WE
THINK ONE THING IS LACKING AND
WANT TO MAKE SURE IT WILL BE
INCORPORATED WITH THE DATA, IF
THE ISSUE, IF YOU ARE USING A
SPECIFIC TUMOR, YOU HAVE TO BE
SPECIFIC ABOUT THE DIAMETER OF
THAT. ANY OTHER DATA IN TERMS OF
LIKE HOW YOU PRODUCE OR CREATED
THAT PHANTOM SHOULD BE INVOLVED.
SO I THINK THAT IS DATA PART. IN
TERMS OF THE IPS, THIS IS
SOMETHING WE NEED TO THINK
ABOUT. DEPENDING ON COMPLEXITY
OF PHANTOM WILL IMPACT THE ISSUE
BUT SOMETHING WE WILL WORK WITH
OUR TRANSFER OFFICE TO FURTHER
FIGURE OUT DETAILS OF IT. BUT SO
FAR BASED ON SERVICE WITH NIS
AND IP, PHANTOM LIBRARIES WE
DIDN'T HAVE A LOT OF ISSUE BUT
POINT IS WE NEED TO THINK ABOUT.
SO I APPRECIATE YOU BRINGING
THIS UP. TESTIFY %BACK
>> THANK YOU. I THINK WHAT YOU
SAID IS SO IMPORTANT. THE
TRANSFER OF KNOWLEDGE OF THE
PHANATOM MAKING. I WAS ALSO
THINKING ABOUT THE DATA YOU
ACTUALLY ACQUIRE FROM USING THE
PHANTOM. LIKE HOW IS THAT GOING
TO BE DISSEMINATE ED?ENTER DO
YOU THEN PUT A SPECIAL MARKER SO
PEOPLE CAN FIND IT SO YOU ARE
BASICALLY TRYING TO CHANGE THE
CULTURE AND SAY WE ARE TRYING TO
STANDARDIZE. I WAS CURIOUS. I
REALIZE IT IS A BIG PROJECT BUT
YOU HAVE THE OPPORTUNITY TO NAME
THEM A SPECIAL WAY SO THEN
BECOMES RECOGNIZED TO BE EASY TO
FIND THAT WAY. LIKE
DISSEMINATING THAT PART OF THE
DATA TO.
>> THAT IS A VERY VALID
POINT. LET'S SAY YOU HAVE
OPTICAL. SIMPLE CW YOU ARE
WORKING ON. IF YOU HAVE USED
YOUR DEVICE, LET'S SAY EXACT
WHAT IS IN ANOTHER LAB, YOU CAN
REPRODUCE THE DATA AND SHOW WHAT
ARE LEVEL OF INTENSITY YOU ARE
GETTING BASED ON THE SPECIFIC
USE PHANTOM, HOW MUCH IT HAS
IMPACTED CHANGES IN SCATTERED
AND INCLUDE THOSE. IF ANOTHER IS
USING IT FOR THE SAME DEVICE, AS
I MENTIONED LOOK AT BETWEEN AND
IN DEVICE VARIABILITY SO THEY
CAN SAY I PUT MY DEVICE THERE
UNDER SIMILAR CONDITIONS, SO THE
CONDITION HAS TO BE VARIABLE
WITHIN THE DOCUMENTATION. THESE
ARE THE VALUES -- THESE ARE IN
TERM OF THE PRIME. WHAT IF OTHER
LAB IS GETTING OR VALUES ARE
CLOSED. THAT WOULD BE ALSO
BUILDING BACKGROUND TWICE
INFORMATION RELATED TO PHANTOM
TESTED ON. I THINK THAT BECOMES
VERY IMPORTANT. YOU CAN HAVE
THIS SORT OF REFERENCE DATA. NOT
JUST FOR THE PHANTOM BUT ALSO
FOR THE DEVICE THAT SPECIFIC
DEVICE YOU ARE USING AND ALLOWS
ONCE ARE ES STAP DIED YOU CAN
VALIDATE DIFFERENT DEVICES TO BE
ABLE TO COMPARE THEM.
>> THAT IS FANTASTIC. CAN I
ADD ONE MORE THING, THAT IS
GREAT. I REALIZE IT IS OUT OF
SCOPE. BUT WHAT WOULD BE GREAT
IF IT IS FAN PHANATOM COMPARED
TO ACTUALLY TISSUE. LIBRARIES OR
DISEASE TISSUE. I KNOW IT IS OUT
OF SCOPE BUT I'M CURIOUS BECAUSE
OBVIOUSLY AT THE END OF THE DAY
IT HAS TO MIMIC THE CLINICAL. SO
I'M CURIOUS IF YOU ARE THINKING
ABOUT THAT. I KNOW IT IS A LOT.
>> NO, THAT IS OUR ULTIMATE
GOAL. MAKING THIS TISSUE
MIMICKING PHANATOM. EVERY TIME
YOU SAY THIS, IT HAS TO MIMIC
THAT. I THINK ALONG THE WAY
THERE HAS TO BE A LOT OF WORK
FOR PHANTOM IN TERMS OF MAKING
SURE THE MODEL IS MATCHING. BUT
ALSO TESTING SOME OF THESE EARLY
ON WITH LET'S SAY ANIMAL TISSUE
OR IN HUMAN MODEL TO MAKE SURE
VALUE S ARE WITHIN RANGE. OUR
HOPE IS AT END OF DAY THESE
STANDARDIZE AND COMPARE, REDUCE
NEED FOR USING HUMAN ANIMAL
MODEL AT EARLY STAGE TO ALLOW
THESE TO THEN MOVE TO HUMAN.
YES, INCLUDE DATA. GREAT POINT.
IT IS AMBITIOUS BUT THAT IS OUR
GOAL. WE TRYING TO INCLUDE AS
MUCH DATA AS POSSIBLE. ONCE TALK
ABOUT THIS, IT TAKES A WHOLE
VILLAGE TO PUT THAT TOGETHER.
APPRECIATE YOUR INPUT.
>> GREAT, IT IS VERY
EXCITING, THANK YOU.
>> IF I CAN JUST COMMENT ON
JOYCE'S -- SHE POSED AN
INTERESTING DILEMMA WITH RESPECT
TO INTELLECTUAL PROPERTY. OUR
STANDARD MODEL RIGHT NOW IS
THERE IS SOME COMMERCIALIZATION
THAT TAKES PLACE, TAKES CARE OF
DISSEMINATION SO A COMPANY WILL
DO THE JOB AND EVERYBODY WILL
BUY A PHANTOM BUT THAT IS NOT
WORKING WELL. SO COULD MOVE IN
THAT DIRECTION. LET'S SAY
EMERGING FROM THE IRCs WHICH
MOVE FORWARD WITH NON-EXCLUSIVE
ROYALTY-FREE LICENSES THAT SORT
OF COME OUT OF THEIR SYSTEM SO
CLASSICALLY COMPETITIVE OR COULD
JUST OPEN UP THE ENTIRE UNIVERSE
IF THE FDA GETS ON BOARD. AS
LONG AS YOU HAVE A COMMON
DENOMINATOR OR GOLD STANDARD
THAT IS BLESSED BY NIS AND FDA
SAYING WE WILL MAKE REGULATORY
DIVISIONS ON HOW YOUR DEVICE
MEASURE ED WITH YOUR OWN
PHANATOM PERFORMS WITH RESPECT
TO OUR PHANATOM AND FIVE
ATTRIBUTES, THEN THE FDA WILL
SET THE CRITERIA FOR
ACCEPTABI
ACCEPTABILITY. WE HAVE DONE THIS
IN RADAX WITH DEVELOPMENT OF
RAPID ANTIGEN TESTS MORE QUICKLY
THAN COMPARING TO EXISTING
BOOKEND TESTS THAT ARE
VALIDATED, BY LOOKING AT THEIR
PERFORMANCE. SO IT IS GETTING
REGULATORY TO NOT LOOK AT EVERY
THING AS IF IT IS A TOTALLY NEW
THING BUT TO COMPARE TO
VALIDATED ESTABLISHED BOOKENDS
OF PERFORMANCE AND
DIMENSIONALITY WILL DEPEND ON
CLAIMS SO MAY BE LIMITED IN
TERMS OF DIMENSION, MAY BE QUITE
COMPLEX. SO THIS WILL BE A
COMMUNITY EFFORT. WE ARE REALLY
GOING TO NEED OUR EXPERTS TO
WEIGH IN.
>> TO ADD TO WHAT BRUCE SAID,
REGULATORY IS ACTUALLY SIMPLE.
YOU TELL ME YOU CAN DO
SOMETHING, PROVE IT. THESE
PHANATOMS ARE THE WAY TO PROVE
IT. YOU HAVE TO DEMONSTRATE THE
PHANATOMS WORK. THAT THEY ARE
REPLICATING WHAT YOU SAY YOU ARE
TRYING TO MEASURE. YOU KNOW, IN
SOME INSTANCES THERE MAY NOT BE
A TISSUE EQUIVALENT. IF YOU TELL
ME YOU CAN MEASURE AT 80 MICRONS
AND SBO2 ON CANCER, HOW DO YOU
CUT IT OUT AND SHOW ME YOU CAN
DO THAT? AT 200 OR 400 MICRONS
OR 10 MILLIMETERS. YOU GET INTO
A BIND OF PROVING THAT WHAT YOU
ARE SAYING YOU CAN DO IS
ACTUALLY WHAT YOUR DEVICE DOES.
THAT IS WHERE THE PHANTOMS COME
IN. THEY CAN AGENDAMENT OR HELP.
YOU HAVE TO DEMONSTRATE THEY
WILL MY MAKE WHAT THEY SAY.
THERE HAS TO BE CLARIFICATION OF
THAT. WE ARE EASY, JUST PROVE
IT.
>> VERY GOOD. BRUCE, OKAY
WITH ALL THE INPUT? VERY GOOD.
THANK YOU SO MUCH, EVERYONE. I'M
HEARING VERY STRONG SUPPORT FOR
CONCEPT. LOT OF FANTASTIC INPUT
ON THE IMPLEMENTATION TO HELP US
ACHIEVE SUCCESS, SO THANK YOU
VERY MUCH. SO COUNCILMEMBER, WE
HAVE ONE MORE CONCEPT CLEARANCE.
YOU ARE AWARE OF WHAT WE HAVE
FOR CLOSED SESSION. WE HAVE
AMPLE TIME SO WE WILL BE ABLE TO
TAKE A 10, 15 MINUTE BREAK AND
COMPLETE BY 4:00 TODAY, SHOULD
BE NO PROBLEM, SO THANK YOU. SO
WITH THAT, IT IS A TIMLINESS
UPDATE I WILL TURN THE NEXT
CONCEPT CLEARANCE OVER TO DR.
TUBA FEHR FOR HER PRESENTATION.
>> ALL HEAR ME OKAY?
>> YES, VERY WELL.
>> GREAT.
>> THANK YOU, DAVID. MY NAME
IS TUBA FEHR, PROGRAM DIRECTOR
AND WITH DEPARTMENT OF TECH
TECHNOLOGY INAUGURALS AT NIB.
I'M EXCITED TO PRESENT A CONCEPT
CLEARANCE FOR BIOMEDICAL FOR
NEXTGEN TECHNOLOGIES BIOTECH.
SORRY, TRYING TO -- THE PURPOSE
OF THE INITIATIVE IS TO TURN
INNOVATIVE DISCOVE RIS INTO
HUMAN HEALTH THROUGH IMPROVED
COLLABORATION BY ADAPTING
EXISTING NIH FUNDING MECHANISMS.
NIH ALREADY HAS EXISTING
COLLABORATIONS WITH OUTSIDE
PARTNERS INCLUDING OTHER FEDERAL
AGENCIES. HOWEVER THESE -- THERE
ARE LIMITATIONS. NIH IS
PRIMARILY BIOMEDICAL RESEARCH
AGENCY. THOSE PARTNERS THAT
SUPPORT MORE FOUNDATIONAL SIGNS
TEND TO FALL ON OPPOSITE END OF
RESEARCH SPECTRUM.
IF DISTANCE BETWEEN TWO PARTNERS
RESEARCH DOMAINS IS TOO FAR THIS
INADVERTENTLY LEADS TO LIMITED
SPACE THAT FAVORS OVERLAPPING
INTERESTS, NAMELY MIDDLE OF
SPECTRUM WHERE PROJECT COULD BE
GOOD FIT FOR EITHER AGENCY'S
MISSION AND INTEREST. AS A
RESULT GRARNTEES ON FOUNDATIONA
SCIENCE ARE NOT NECESSARILY
TRANSITIONED TO NIH FUNDING .
THE U FURTHER ON THE SPECTRUM
THE LARGER THE EFFORT TO MAKE
THE JOURNEY TOWARD THE NIH.
THEREFORE THE BIGGEST LIMITATION
OF CURRENT COLLABORATIVE
APPROACH IS IT IS SUBOPTIMAL FOR
TRANSITIONING DISCOVERIES AT THE
FURTHER END OF THE RESEARCH
SPECTRUM TO APPLICATIONS
RELEVANT TO THE NIH MISSION. TO
TURN THESE DISCOVERIES INTO
BIOMEDICAL TECHNOLOGIES REQUIRES
ADDITIONAL APPLICATIONS, WHICH
RESULTS IN LOST TIME AND EFFORT.
TRANSITION OF FOUNDATIONAL
KNOWLEDGE TO BIOMEDICAL
TECHNOLOGYIES CAN BE INEFFICIENT
FOR THAT REASON. TRANSITION
HAPPENS OVER LONG TIME FRAME IF
AT ALL. FOUNDATIONAL KNOWLEDGE
CAN STAY SILOED. HERE WE PRESENT
PROPOSAL SOLUTION TO OVERCOME
LIMITATIONS. THE GOAL IS
ACCELERATE TRANSITION OF NOVEL
DISCOVERIES. THAT IS TWO EARLY
STAGE. TWO BIOMEDICAL
TECHNOLOGIES AT NIH THROUGH
INTERAGENCY COLLABORATION. WE
ARE PROPOSING TO ACCOMPLISH THIS
GOAL BY TAKING A FUNDING
MECHANISM WE USE INTERNALLY AT
THE NIH, THE AWARDING PROCESS
AND ADAPTING TO CAT LIES
EXTERNAL COLLABORATION WITH
PARTNERS. THIS APPROACH IS
MODELLED AFTER THE R21, R33
MECHANISM WHERE PROJECT IS
DIVIDED INTO TWO DISTINCT
PHASES. UP WITH INVOLVES
EXPLORATORY AND FEASIBILITY.
PHASE II FOCUSES ON EXPANDED
DEVELOPMENT OF PHASE 1
ACTIVITIES. TRANSITION TO PHASE
2 FOR ANY PROJECT IS NOT
GUARANTEED AS THERE IS A
MILESTONE-DRIVEN GO/NO GO POINT
IN BETWEEN THE TWO PHASES. THIS
IS NOT NEW TO NIH. WE ARE ONLY
TAKING OLD TOOL THAT EXISTS AND
TEACHING IT NEW TRICKS. THE
PROPOSED AWARDING PROCESS IS
MEANT TO EXPAND EXISTING
COLLABORATION WITH PARTNER
TOWARD FURTHER ENDS OF THE
SPECTRUM. UNDER THE MECHANISM A
SINGLE APPLICATION WITH IN
INTEGRATED PROJECT WILL ALLOW
DISCOVERIES DURING THE DOMAIN
INTO PHASE I INTO BIOMEDICAL
TECHNOLOGIES RELATIVE TO NIH
MISSION DURING PHASE TWO.
THAT SAID WE WANT TO ENSURE
SUCCESS THROUGH OVERSIGHT.
INCLUDING QUANTITATIVE
MILESTONES, METRICS OF SUCCESS,
WHERE ONLY THOSE PROJECTS THAT
DEMONSTRATE PROOF OF CONCEPT,
THEIR DISCOVERIES CAN BE
DEVELOPED INTO BIOMEDICAL
TECHNOLOGY WILL BE ALLOWED TO
TRANSITION TO PHASE 2 AT NIH.
THERE WILL BE A MIDPOINT REVIEW
BE PROGRAM STAFF TO ASSESS
REDNESS TO PHASE 2 AND GO
DECISION AT END OF PHASE 1.
WHILE PLAN PROPOSED BY
INVESTIGATORS FOR PHASES 1 AND 2
PROVIDES COLLECTIVE ROAD MAP FOR
LONG JOURNEY FROM PARTNER AGENCY
TO NIH, MILESTONES WILL PROVIDE
GOAL POSTS ALONG THIS JOURNEY
AND PROGRAMMATIC OVERSIGHT WILL
ENSURE PROJECT DOES NOT GET LOST
IN THIS UNCHARTED TERRITORY. WE
ENVISION MANY FIELDS COULD
BENEFIT FROM THE CONCEPT, WHERE
DISCOVERIES ARE TOO EARLY STAGE
FOR NIH TO BE PICKED UP BUT CAN
BE BROUGHT IN. FOR EXAMPLE
FOUNDATIONAL COST IN SYNTHETIC
BIOLOGY CAN BE TURNED INTO TOOLS
AND TECHNOLOGIES TO MODIFY CELL
AND TISSUE FUNCTION. QUANTUM
TECHNOLOGIES AND SENSES IN
PARTICULAR COULD BE TO NEW
TECHNOLOGIES TO AFFECT HEALTH
OUTCOMES. DISCOVERIES IN
CHEMICAL MATERIALS COULD BE
TURNED TO SCAFFOLDS TO MODIFY OR
ENHANCE TISSUE FUNCTION AND
MATERIALS WITH PROPERTYIES CAN
BE USED TO IMPROVE BIOMEDICAL
IMAGING. IN SUMMARY I HOPE I WAS
ABLE TO CONVINCE YOU THIS UNIQUE
APPROACH TO COLLABORATION WILL
USHER IN A NEW PHASE WHERE WE
ARE ABLE TO TAKE FOUNDATIONAL
KNOWLEDGE OUT OF ITS SILO AND
BRING TOWARDS APPLY 2
DEVELOPMENT FOR DIAGNOSIS,
THERAPY AND PREVENTION OF
DISEASE. THANK YOU, I'M HAPPY TO
ANSWER ANY QUESTIONS.
>> WOULD YOU LIKE TO CALL ON
HANDS?
>> YES, KATHY.
>> YES. I THINK THIS IS A
TERRIFIC IDEA TO LEVERAGE THIS
SUCCESSFUL TOOL TO FACILITATE
BRIDGING THIS GAP. I LOVE THIS
IDEA. I HAD A QUESTION ABOUT
KIND OF REVIEWS FOR THE PHASE 1
AND PHASE 2, SINCE IT WILL BE
INTERAGENCY. WOULD DIVISION BE
-- LET'S SAY PARTNER WITH NSF.
NIH AND NSF STAFF WOULD BOTH
REVIEW THE PROPOSALS FOR PHASE 1
AND 2 OR CLEAR TRANSITION
BETWEEN WHO IS MAKING THOSE
CALLS, WHICH AGENCY. HOW WOULD
THAT BE NAVIGATED?
>> THAN BES FOR THE QUESTION,
YES. SO THERE WILL BE ONE
REVIEW. IT WILL BE A JOINT
REVIEW. SAY NSF WE ARE
COLLABORATING WITH. THEY WOULD
COME TOGETHER AND DO REVIEW AND
DECIDE ON WHICH APPLICATIONS
WOULD BE FUNDED AT BOTH AGENCIES
BECAUSE PARTNER AGENCY WOULD
NEED TO AGREE TO PHASE 1 OF
PROJECT. N NIH WITH PHASE II.
WOULD BE SINGLE PACKAGE REVIEWED
IN JOINT COLLABORATION SO WE CAN
BOTH AGREE ON WHAT WE WANT TO
FUND JOINTLY.
>> THANK YOU.
>> CERTAINLY.
>> JENNIFER.
>> THANK YOU, I AGREE. THIS
IS A MARVELOUS IDEA. DOES SOLVE
A LONG-STANDING PROBLEM I SEE A
LOT. WHERE I SAID PEOPLE OVER IN
OUR BASIC SCIENCES OR PHYSICAL
SCIENCES WHO HAVE IDEAS WOULD
LOVE TO GET ENGAGED WITH NIH,
HAVE NO IDEA, NO TRACK RECORD,
ET CETERA, WE CAN TRY TO
COLLABORATION. THAT MAY HAVE
MIXED RESULTS. SO I UNDERSTAND
THIS IS A CONCEPT CLEARANCE.
PRETTY HIGH LEVEL BUT DO YOU
HAVE IDEA WHO PARTNERS WOULD BE
AND WOULD YOU EXPECT TO HAVE
CALLS FOR VERY SPECIFIC TYPES OF
TECHNOLOGIES YOU WANT THE FOCUS
ON TRANSLATE ING?ENTER
>> THANK YOU FOR THE
QUESTION, YES. SO AGAIN, THIS IS
A HIGH-LEVEL CONCEPT. WE CAN
ENVISION ANY FEDERAL AGENCY WHO
FOCUSES ON MORE BASIC SCIENCE
COULD BE A GOOD PARTNER FOR
THIS. KATHY BROUGHT UP NSF, THAT
WOULD BE A GOOD PARTNER, DOD,
DOE, ANY AGENCY THAT HAS
FOUNDATIONAL RESEARCH WOULD BE
GOOD PARTNER. THAT SAID THIS
EFFORT REQUIRES SOME LEGAL
FRAMEWORK SUCH AS PRESENCE OF
MOUs. WE DO HAVE ONE WITH NSF
CURRENTLY. AS LONG AS WE HAVE AN
EXISTING MOU WITH PARTNER
AGENCY, WE ARE -- WE CAN
IMPLEMENT IN JOINT
COLLABORATIONSN. TERMS OF
ANNOUNCEMENTS IT WOULD FOCUS ON
SPECIFIC ANNOUNCEMENTS. THE IDEA
OF THE BIPHASIC WOULD BE SAME
BUT CAN TAKE AND REPURPOSE FOR
-- TO FOCUS ON ANY SORT OF
EMERGING TECHNOLOGY OR ANY
SUBTOPIC UNDER EMERGING
TECHNOLOGY SO IT IS VERY
FLEXIBLE. THINK OF IT AS A
PARENT PARENT ANNOUNCEMENT. YOU
CAN REPURPOSE IT FOR ANY TOPIC,
IF YOU LIKE. I GUESS JUST SORT
OF GOING ALONG LINES OF THAT,
ONE OF THE THINGS I OFTEN SEE
THERE ARE FOUNDATIONAL
TECHNOLOGIES. BUT THOSE
INVESTIGATORS DON'T REALLY KNOW
WHERE THEY CAN BE APPLIED SO
SORT OF DEVELOPING TECHNOLOGY
WITHOUT AN APPLICATION. SO LIKE
I GUESS I WONDER WILL THERE BE
SOME WAY TO ALMOST -- MATCH OR
MARY TO HELP THEM FACILITATE
THAT APPLICATION SPACE WITHIN
THE NIH OR MAYBE IT WILL BE
BUILT INTO THE PROPOSALS. BUT IT
IS SOMETHING THAT I EVEN AS --
NAVIGATING AS ME TRYING TO
ALIGN, HEY THS, THIS COULD BE
APPLIED TO.ENTERTHIS SOMETHING I
SPENT A LOT OF TIME ON.
>> ABSOLUTELY, VALID POINT .
THE BURDEN FOR THIS IS ON THE
INVESTIGATOR BECAUSE THEY WILL
NEED TO PUT TOGETHER APPLICATION
FOR BOTH PHASE I AND PHASE II SO
REALLY NEED TO HAVE THOUGHT
ABOUT WHAT TECHNOLOGY DURING
PHASE I AND WHAT ARE SOME OF
POTENTIAL APPLICATIONS THEY
COULD PURSUE AT THE NIH. THAT
SAID AS YOU MENTIONED IT IS HARD
TO THINK THAT FAR AHEAD IN
FUTURE SO WE ENVISION WE WILL BE
HOLDING -- IF WE DECIDE TO GO
PURSUIT A SPECIFIC ANNOUNCEMENT
IN THIS MECHANISM IN FUTURE WE
WILL BE HOLDING WEBINARS AND
STOCKILY ENCOURAGE INVESTIGATORS
TO GET IN TOUCH WITH PARTNER
AGENCY STAFF AND NIH STAFF
BECAUSE IT IS HARD TO THINK IN
TERMS AND THAT LONG-TERM OF TIME
FRAME. WE WILL PROVIDE THE
NECESSARY GUIDANCE AND RESOURCES
FOR THEM TO MAKE THAT GAP.
AGAIN, THE PHASE 1 AND PHASE 2,
THEY WILL NEED TO CONCEIVE AS
WELL AS TRANSITION MILESTONE SO
SET UP THEIR OWN SUCCESS METRICS
TO TRANSITION TO PHASE 2 AS WELL
AS THINKING THAT FAR AHEAD
TOWARDS THE NIH FOR THOSE
INVESTIGATORS ESPECIALLY WHO
FALL UNDER THE BASIC SCIENCE
FOUNDATIONAL SCIENCE DOMAIN AT
THE AGENCY. I HOPE THAT ANSWERS
YOUR QUESTION.
>> YAH, THANKS.
>> DAN?
>> JUST TO FOLLOW UP ON WHAT
YOU WERE JUST DISCUSSING, I
WONDER WHETHER IT WOULD BE SORT
OF A NEAT ADDITION TO THIS
PROGRAM TO START COMPILING LISTS
OF PEOPLE WHO ARE ON THE MORE
TRANSLATIONAL SIDE OF SOME OF
THE EVERY YAS. YOU SAID YOU WERE
FOCUSSING ON SPECIFIC
ANNOUNCEMENTS SO WHY NOT GATHER
A LIST OF PEOPLE WHO HAVE SORT
OF A -- MORE OF A TRANSLATIONAL
HISTORY SO IF PEOPLE CALL YOU UP
AND SAY HEY, LISTEN, I HAVE THIS
GREAT IDEA BUT I'M NOT EXACTLY
SURE THE BEST PERSON TO WORK
WITH. YOU'VE GOT THAT CAPACITY.
I'M JUST PARROTING THE IDEA BUT
IT SEEMS TO ME SORT OF NEAT
OPPORTUNITY.
>> THANK YOU FOR THE
SUGGESTION, ABSOLUTELY.
>> I THINK ALSO ANOTHER NEAT
OPPORTUNITY FOR STORY TELLING
FOR SUCCESSES IN THIS PROGRAM, I
KNOW YOU HAVE TO ESTABLISH
BEFORE YOU HAVE SUCCESS T BUT
MAKES FOR A WONDERFUL STORY,
THIS HAND-OFF FACILITATED BY
MULTIPLE, YOU KNOW, MULTIPLE
INSTITUTES. AND PRESUMABLY
CULMINATING IN SOME DELIVERABLE
TECHNOLOGY. SO I THINK NIBIB --
IF IT PLAYS ROLE NOT AS FINAL
RECIPIENT BUT AS FACILITATOR
THAT IS A NICE PART OF THE STORY
FOR NIBIB.
>> YES, THANK YOU.
>> THANKS, BRUCE.
>> SO MAYBE IF ANYBODY HAS
ANY MORE COMMENTS, MAYBE YOU
SHOULD SPEAK. I JUST WAS GOING
TO WRAP SOME STUFF UP WITH A
PERSONAL PERSPECTIVE --
>> IF I MAY PICK YOU UP ON
YOUR HONOR, ON BE HALF OF NIBIB
THAT HAS BEEN QUITE THE GROUP
EFFORT TO ESTABLISH A UNIQUE
PATHWAY. IT INVOLVED US OF
COURSE HAVING TO DO A LOT OF
ADMINISTRATIVE RESEARCH AT NIH
TO FIGURE OUT IF IT IS ALLOWED,
CHIEF OF GRANTS MANAGEMENT AND
ONCALI WAS INVOLVED AND INVOLVED
THE NIH OFFICE DIRECTOR. WE
COULD REACH OUT TO COLLEAGUES
AND NEED TO FIGURE OUT IF IT IS
EVEN LEGAL. IT IS, OF COURSE.
THANK YOU SO MUCH. I JUST WANTED
TO MENTION THAT BRUCE, GIVE CUE
DOES TO THE WHOLE TEAM WORKING
ON THIS. YAH, NO. THIS IS
AMAZING. HOPEFULLY GAME
CHANGING. WHEN I WAS AN
INVESTIGATOR, LIKE ALL YOU, I
WOULD WRITE GRANTS TO NHS, DOD,
DOE AND I REALLY WISHED FOR SOME
INTEGRATION. I WOULDN'T HAVE TO
COMPARTMENT MENTAL IZE. MAYBE IT
IS GOOD TO HAVE THOSE
COMPARTMENTS SOMETIME BUT SO
MUCH SYNERGY ESPECIALLY THOSE
DEVELOPING FUNDAMENTAL
TECHNOLOGIES. IT WOULD BE NICE
TO SORT OF HAVE THAT ENTIRE
FUNDAMENTAL TO APPLIED SUPPORTED
IN A KNOWI INTEGRATED WEATAY AN
DIVIDING U US AND WE HAVE TO
SPEND THE TIME TO WRITE
PROPOSALS TO THE ALL THE
DIFFERENT AGENCIES. IF THIS CAN
GET GOING IT WOULD BE WONDERFUL.
I THINK IN THE BIOMATERIALS
SPACE AND OUR -- AS WE POINTED
OUT, AFFILIATED DEVICES RELATED
TO THOSE BIOMATERIALS THAT NEED
TO BE STANDARDIZED AND WIDELY
DISSEMINATED TO DRIVE DISCOVERY,
THIS COULD BE SO IMPACTFUL SO WE
ARE EAGERLY LOOKING FORWARD TO
SEEING HOW YOU NAVIGATE THIS,
THANK YOU.
>> THANK YOU, BRUCE.
>> THANK YOU, EVERYONE.
>> GREAT THANK YOU SO MUCH,
EVER. THANK YOU VERY MUCH, TUBA.
SO THAT CONCLUDES OUR OPEN
SESSION. BRUCE, BEFORE I
OFFICIALLY CLOSE OPEN SESSION
DID YOU HAVE ANY FINAL REMARKS
YOU MIGHT WANT TO MAKE?
>> BRUCE TROMBERG: SURE THANKS,
DAVE. AGAIN, I WOULD LIKE TO
THANK COUNCIL AND ALL OUR
SUPPORTERS FOR HANGING ON THE
LINE ON THE VIDEO CAST. I THINK
THIS WAS A REASONABLY GOOD
SNAPSHOT FOR YOU, WITH NOT TOO
MUCH INFORMATION CONTENT AND
SOME COHERENT THEMES EMERGING. I
LOOK FORWARD TO JOINING EVERYONE
LIVE, IN-PERSON IN MAY. EVEN IF
YOU ARE ROTATING OFF COUNCIL AND
WE HAVE SOME COUNCILMEMBERS WHO
ARE, WE ENCOURAGE YOU TO COME
VISIT. MY AMBITION AT SOME POINT
IS HAVE A COUNCIL REUNION. DAVE,
YOU WILL LET ME KNOW IF WE CAN
PUT THAT TOGETHER AND DO IT ON A
PERIODIC BASIC. WE HAVE SPECIFIC
MEETINGS BUT WE ARE INTERESTED
IN YOUR SUGGESTION FOR WAYS TO
CONVENE OUR COMMUNITY. AS WE
OPEN BACK UP MORE FOR IN-PERSON
MEETINGS. AGAIN, THANKS TO ALL
OF YOU AND EVERYBODY ON THE
CALL. THANKS TO OUR AMAZING
NIBIB TEAM FOR ALL OF THE WORK
YOU HAVE DONE IN PREPARATION FOR
COUNCIL. ALL RIGHT.
>> THANK YOU SO MUCH, BRUCE.
BEFORE WE -- THANK YOU SO MUCH.
BEFORE WE OFFICIALLY ADJOURN I
WOULD LIKE TO REMIND THE
COUNCILMEMBERS AND MY COLLEAGUES
ON THE NIBIB STAFF WHO ATTEND
THE CLOSED SESSION, IT IS A
SEPARATE MEETING REQUEST FROM
PAM WITH A SEPARATE LINK. SO WE
WILL BEGIN -- LET'S TAKE A
15-MINUTE BREAK. LET'S BEGIN
CLOSED SESSION AT 3:00 P.M.
EASTERN TIME, PLEASE. SO NOW
I'LL OFFICIALLY ADJOURN THE OPEN
SESSION. I'D LIKE TO THANK ALL
OF VISITORS TO ATTEND THE VIDEO
CAST, HOPEFULLY WE CAN SEE YOU
AT THE NEXT MEETING. THE THIS
OPEN MEETING OF THE 64TH MEETING
OF THE NIBIB NATIONAL ADVISORY
COUNCIL IS HEREBY ADJOURNED.
THANK YOU, EVERYONE.
[MEETING ADJOURNED AT 1:45 CS]